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With over 1 billion deaths in the last 200 years, tuberculosis (TB) is a bigger killer than any 
other infectious disease in history (1). TB is responsible for more casualties than the plague, 
malaria, AIDS, or cholera (1). Although TB is now considered a poverty-related illness, it 
may affect any susceptible individual, whether male or female, young or old, rich or poor. 
TB has also claimed many famous victims. Although many people know the famous victims 
of TB such as George Orwell, few know that Ghanaian highlife superstar Azongo “Captain 
Yaba” Nyaaba and Senegalese Mandinga musician Kaouding Cissoko also fell victim to TB. 
More recently, over 8 million people developed TB and approximately 1.3 million people 
died from the consequences of TB in 2012 (2). The incidence of TB is especially high in 
low-income countries. However, due to permanent and temporary immigration of migrants 
from high prevalence countries, TB is not only a low-income country problem, but affects 
countries worldwide (3). 
Mycobacterium tuberculosis
TB is a potentially deadly infectious disease caused by the aerobe Mycobacterium tuberculosis. 
The pathogen M. tuberculosis is a species of the family Mycobacteriaceae, together with other 
pathogens such as Mycobacterium leprae, Mycobacterium ulcerans, and Mycobacterium avium. 
In contrast to many bacteria encountered in common hospital infections, M. tuberculosis 
replicates with a minimum in vitro doubling time of approximately 15 hours (4). It requires 
a host to duplicate and has no known environmental reservoir (5).
Typically, TB is transmitted through droplets in the air. Droplets are generated by coughing 
or sneezing by patients suffering from pulmonary TB. With its lipid rich cell wall, M. 
tuberculosis is able to survive in air droplets, forming an infectious aerosol. When individuals 
inhale this aerosol containing the aerobe mycobacteria, the organisms may reach the lower 
respiratory tract and the pulmonary alveoli. The mycobacteria are engulfed by macrophages, 
such as alveolar macrophages and bronchial dendritic cells. In most cases, M. tuberculosis 
is cleared by these macrophages (6). However, mycobacteria may survive intracellularly (7, 
8). When the organism survives the host immune response, a ‘balance of terror’ may ensue: 
the organism persists in human macrophages, in a low metabolic, slowly replicating state, 
referred to as ‘latent TB infection’. Before this balance is established the organism may have 
spread through the body via the lymphatic and the circulatory system. In small children and 
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in adults with a failing immune system, infection may immediately become overwhelming, 
with miliary TB as a result. Most individuals however develop latent infection, and never 
develop active disease; some 10% of individuals develop active TB disease any time following 
infection. The pool of latently infected individuals represents the reservoir of the organism; 
as much as one third of the world population is considered carrier of TB (9). M. tuberculosis 
primarily infects the lungs, and established disease predominantly presents as pulmonary 
TB. As explained, TB may however affect virtually every organ and tissue. 
Symptoms and diagnosis
Patients with latent TB infection are infected with M. tuberculosis without displaying any 
symptoms; the bacilli have low metabolic and replicative activity, and the numbers are so low 
that the organisms cannot be detected by microbiological methods. Only immunological tests 
are able to confirm the diagnosis. When the immune system fails to control M. tuberculosis 
replication and metabolic activity, active disease may ensue with increased numbers of bacilli 
causing symptoms of cough, weight loss, fever, chest pain, weakness or fatigue, night sweats 
and coughing up of blood (10, 11). 
The clinical diagnosis of TB based on a combination of symptoms, history of prior 
TB infection, epidemiological factors and radiographic/laboratory findings can now 
be confirmed by microbiological methods. These microbiological methods comprises 
microscopy using acid- and alcohol-fast staining procedures, culture using specific culture 
media, and polymerase chain reactions demonstrating the presence of specific sequences 
of the DNA of M. tuberculosis. 
Multidrug-resistant tuberculosis
A worrisome fact is that an increasing proportion of TB patients happen to be infected with 
drug resistant M. tuberculosis strains. The World Health Organization (WHO) suggests that 
approximately 3.6% of new TB cases have multidrug-resistant strains, with much higher 
levels – up to 20% – in previously treated cases (12). In multidrug-resistant TB (MDR-TB) 
the organism is resistant to at least the classic anti-TB drugs rifampicin and isoniazid (13). 
For the individual patient, MDR-TB is bad news: the treatment duration required to obtain 
cure is increased more than three-fold, and outcome is less certain. Drug resistance is the 
result of selective pressure to resistant mutants in the microbial population causing the 
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infection; with inadequate therapy suppressing susceptible wild-type organisms, mutants 
may re-populate infection sites, and in the end all organisms are drug-resistant. It would 
help if fast molecular tests were available to timely detect and adequately target the offending 
organisms with a drug treatment combination that matches the susceptibility to the drug 
combination selected. Molecular testing using the Hain genotype MTBDRplus might give 
a swift preliminary result of the resistance of the isolate to rifampicin and isoniazid (14). 
The test is based on detecting the most common DNA mutations. As a proxy of MDR-TB, 
resistance to rifampicin only is now commonly used. The most widely used and studied 
test is probably GeneXpert-TB-RIF, a system that has been developed and validated in 
different settings (15, 16) and that can be used as a point-of-care test, also in settings with 
limited laboratory expertise available (17, 18). However, the gold standard to determine drug 
resistance is by analysing the minimal inhibitory concentration of a sample of mycobacteria 
isolated from the patient using the absolute concentration method (19).  
To treat MDR-TB, the WHO recommends to design treatment regimens containing at 
least four drugs that are probably effective (13). Therefore physicians are forced to design 
treatment regimens using less effective and less well-studied ‘second-line’ drugs. Some are 
prone to elicit adverse effects, further limiting the applicability to treatment regimens.
Treatment options are divided in several WHO groups (13). Group 2 – the second line 
parenteral drugs or ‘injectables’ – is composed of aminoglycosides, e.g. amikacin and 
kanamycin. Group 3 are the fluoroquinolones, with very active and widely used drugs 
such as moxifloxacin; and the group 4 drugs including oral bacteriostatic second-line anti-
tuberculosis drugs, e.g. prothionamide and cycloserine. 
As a last resort, physicians are often forced to prescribe WHO Group 5 drugs such as linezolid 
and clarithromycin. Both drugs are described in this thesis. Linezolid and clarithromycin are 
drugs with unclear efficacy and are therefore not recommended for routine use in treatment 
regimens for MDR-TB (20). However, more knowledge on the efficacy, toxicity, tolerability, 
i.e. the clinical pharmacology might unleash their untapped potential. 
Clinical pharmacology
New information on pharmacology in a clinical setting might contribute to the applicability 
of linezolid in the treatment of MDR-TB. The two main areas of pharmacology are 




of the drug through the body (absorption, distribution, metabolism and elimination): it 
addresses the question how the organism handles the drug. Pharmacodynamics describes 
the action of the drug in the human host – and in case of micro-organisms – how the 
offending organism is targeted.  
Therapeutic Drug Monitoring
These two principles, pharmacokinetics and pharmacodynamics, can be combined to 
perform therapeutic drug monitoring (TDM). TDM is defined by the International 
Association of Therapeutic Drug Monitoring and Clinical Toxicity as ‘a multi-disciplinary 
clinical specialty aimed at improving patient care by individually adjusting the dose of 
drugs for which clinical experience or clinical trials have shown it improved outcome in 
the general or specific populations (21)’.
TDM could perhaps improve the treatment of MDR-TB using the WHO group 5 drugs, 
such as linezolid. Therefore, we aimed to study the clinical pharmacology, with special 
focus on TDM of linezolid to optimize treatment of patients suffering from MDR-TB. More 
specific, we aimed to give a review of literature on pharmacokinetic drug interactions of anti-
mycobacterial drugs. Furthermore, we aimed to study a potentially new pharmacokinetic 
drug-drug interaction between linezolid and clarithromycin and to analytically and clinically 
validate two new methods to analyse linezolid in oral fluid and dried blood spots obtained 
from MDR-TB patients. Finally, we aimed to retrospectively study linezolid exposure in 
relation to efficacy, safety and tolerability in the treatment of MDR-TB. Besides the aim to 
study pharmacokinetics of linezolid, we aimed to investigate possible pharmacodynamic 
interaction between linezolid and clarithromycin in MDR-TB isolates.
Outline of the thesis
Chapter 2: In this chapter, we have reviewed the literature on pharmacokinetic drug 
interactions of anti-mycobacterial drugs. These drug interactions are important since 
impact efficacy and toxicity of drugs that are part of a treatment regimen in which very 
few treatment options are open, especially in case of MDR-TB. Drug-drug, food-drug, and 
herbal medicine-drug interactions are described focusing on the effect of the interaction 
on the antimicrobial drug itself (antimicrobial drugs as victim) or on the effect of the co-
prescribed drug (antimicrobial drugs as perpetrators). 
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Chapter 3: In the third chapter, we studied a pharmacokinetic drug-drug interaction 
between linezolid and clarithromycin based on a remarkable clinical finding from a patient 
admitted at the Tuberculosis Center Beatrixoord (University Medical Center Groningen, 
Haren, The Netherlands). As a part of routine therapeutic drug monitoring, linezolid blood 
concentrations were analysed. We discovered a considerable increase of the patient’s linezolid 
concentration after co-administration of clarithromycin. In this chapter we further explored 
the role of drug-drug interactions of linezolid with clarithromycin. 
Chapter 4: Therapeutic drug monitoring has gradually become a more widely accepted tool 
to optimize individual treatment regimens of anti-TB drugs. However, logistical problems 
with conventional drug sampling, and cold-transport of blood specimens to laboratories 
limit the use of TDM to research-oriented institutes. In this chapter, we aimed to develop 
and clinically validate a technique to overcome these problems: dried blood spot analysis 
of linezolid in patients with MDR-TB. 
Despite “lacking the drama of blood, sincerity of sweat, and the emotional appeal of tears 
(22)”, another potential advantageous matrix with non invasive sampling is oral fluid. In the 
second part of this chapter we developed and clinically validated the analysis of linezolid 
and clarithromycin in oral fluid of MDR-TB patients.
Chapter 5: In this chapter, we strived to get insight in linezolid efficacy, safety, and tolerability 
in patients with MDR-TB, focusing on pharmacokinetics and pharmacodynamics. Published 
data were lacking detailed information on pharmacokinetic / pharmacodynamic targets; 
several recently published studies did not incorporate TDM in their study designs. In two 
letters to the editor, we advocated the use of TDM in clinical trials in order to generate data 
on an anti-TB drug that is known to show inter-patient variability in pharmacokinetics and 
to display drug-interactions.  
This encouraged us to retrospectively analyse the data that was generated in the previous 
years in our TB Center. In order to enlarge our cohort, we included patients from both 
our Tuberculosis Center Beatrixoord (University Medical Center Groningen, Haren, The 
Netherlands) and from the Tuberculosis Reference Center for MDR-TB and HIV-TB E. 
Morelli Hospital (Sondalo, Italy). For this retrospective study, we planned to select patients 
that received linezolid as a part of their treatment regimen for MDR-TB and that underwent 
TDM. We aimed to relate linezolid efficacy, safety, and tolerability to linezolid drug exposure 




Chapter 6: As a rule, pharmacokinetic interactions are considered disadvantageous and 
potentially harmful. In this chapter, we study a potentially beneficial pharmacodynamic 
interaction between linezolid and clarithromycin. With a lack of new anti-TB drugs emerging 
from the pipeline, an effort should be made to optimize treatment regimens containing 
existing drugs with activity against M. tuberculosis. One of these drugs, clarithromycin, has 
a controversial role in treatment regimens due to the fact that blood levels of clarithromycin 
measured in patients are often below minimal inhibitory concentration as determined in 
vitro in clinical isolates. One reason to incorporate clarithromycin in treatment regimens is 
in vitro synergy between clarithromycin and isoniazid, rifampicin and/or ethambutol against 
M. tuberculosis (23). In this chapter, we investigated whether linezolid and clarithromycin 
display in vitro synergy in clinical isolates of Mycobacterium tuberculosis.
Chapter 7 and 8: In the seventh chapter, we present a summary of the findings of previous 
chapters. In the General Discussion of this thesis (chapter 8), we discussed the clinical 
impact of the studies presented on the role of linezolid in optimizing treatment for patients 
with MDR-TB. We discussed the clinical pharmacology, with especial focus on TDM, of 
linezolid in the context of MDR-TB, and present future perspectives.
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Like any other drug, antimicrobial drugs are prone to pharmacokinetic drug interactions. 
These drug interactions are a major concern in clinical practice as they may have an 
effect on efficacy and toxicity. The original article provides an overview of all published 
pharmacokinetic studies on drug interactions of the commonly prescribed antimicrobial 
drugs oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams, 
focusing on systematic research. However, in this chapter we present the data of the 
oxazolidinones. We describe drug-food and drug-drug interaction studies in humans, 
affecting antimicrobial drugs as well as concomitantly administered drugs. Since 
knowledge on mechanisms is of paramount importance for adequate management of 
drug interactions, the most plausible underlying mechanism of the drug interaction 
is provided when available. This overview can be used in daily practice to support 
management of pharmacokinetic drug interactions of antimicrobial drugs.
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INTRODUCTION
Antimicrobial drugs manifest a wide variety of drug interactions, which can differ greatly 
in extent of severity and clinical relevance. Not only co-medication, but also food and 
herbal medicine can interact with antimicrobial drugs and vice versa. The nature of these 
interactions can be of pharmacodynamic (PD) and/or pharmacokinetic (PK) origin. 
A PD interaction consists of an alteration of a pharmacological response, through either 
agonism or antagonism, without affecting the kinetics of the drug. In cases of PD interactions 
physicians are advised to re-evaluate the benefit-risk ratio of the co-prescribed drug for each 
individual patient (1). PK interactions result in an altered disposition of a drug within a 
patient and can take place at the level of each of four processes influencing drug exposure, i.e. 
absorption, distribution, metabolism, and excretion, commonly described by the acronym 
ADME. Historically the relevance of drug distribution, particularly of protein binding, has 
been over-emphasized in the assessment of drug interactions, and nowadays the main cause 
of drug-drug interactions has been recognized to be modulation of the activity, i.e. inhibition 
or induction, of cytochrome P450 (CYP) enzymes and transporters. 
Clinicians, prescribing the drug and pharmacists — often involved in medication review, 
therapeutic drug monitoring (TDM), or consultation on drug choice or dose — should be 
aware of clinically relevant interactions between antimicrobial drugs and co-medication, 
herbal medicine, and/or food in order to avoid toxicity, side effects, or inadequate treatment. 
PK interactions are in most cases manageable by adjusting the dose and by monitoring 
of drug levels (TDM) or vital signs. This review article will address PK interactions of 
antimicrobial drugs. The scope of the original article is to present an overview of PK studies 
on drug-drug and drug-food interactions of commonly prescribed antimicrobial drugs in 
daily clinical practice, i.e. oxazolidinones, rifamycines, macrolides, fluoroquinolones, and 
β-lactam antimicrobial drugs. In this chapter we present the data of the oxazolidinones.
EXPERIMENTAL SECTION
The Pubmed database was searched for PK interaction studies on drug-drug and drug-food 
interactions of antimicrobial drugs (Figure 1). The search was limited through the following 
selections: “Humans”, “Clinical Trial”, “Randomized Controlled Trial”, “Comparative Study”, 
and “Controlled Clinical Trial”. Only articles written in English were included. Per group of 
antimicrobial drugs, a separate search was conducted consisting of the name of the group, 
Chapter 2
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the name of the individual drugs, and the term “drug interaction”. When the Medical Subject 
Heading (MeSH) term “drug interaction” was used, indented terms such as “Herb-Drug 
Interaction” and “Food-Drug Interaction” were also searched. The search terms “NOT in 
vitro” and “NOT review” were added since this review focuses on original articles of studies 
with human subjects. Summaries of product characteristics or package leaflets were not 
consulted since these sources will only present a snapshot of the available information and 
will therefore not give a good overall impression of their use in clinical practice. 
When a search resulted in only a few results, the query was expanded with the criterion 
“Case Report” and explicitly marked as such in this review since its contents have to be 
interpreted carefully because of the limited level of evidence.
All searches were conducted in March and April 2011. The relevant results were described 
per group of antimicrobial drugs. For each group, the drug interactions are divided into 
interactions affecting the antimicrobial drugs and interactions effecting the co-medication. 
The drug that is affected is identified by the term ‘victim’ and the drug that causes the effect 
by ‘perpetrator’. A table summarizing the most important drug interactions is provided for 
each group of antimicrobial drugs.
Since the scope of the original article is broader than the scope of this thesis, an adapted 
version is included. In this chapter, we only presented the drug interactions with drugs of 
Figure 1 Scope of the original review and summary of the experimental section. 
The adapted version of the review, presented in Chapter 2, focuses on interactions with drugs of the 
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the oxazolidinone group. Both interactions where the drug is the victim or the perpetrator 
are included in this chapter.
RESULTS AND DISCUSSION
Oxazolidinones 
At this moment linezolid (LZD) is the only oxazolidinone authorized by the European 
Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The number 
of properly designed drug-interaction studies with oxazolidinones is limited and the 
underlying mechanisms of some drug interactions are not yet fully elucidated. Furthermore, 
there is a lack of reviewed publications on drug interactions of newer compounds such as 
PNU-100480, posizolid (AZD2563), radezolid (RX-1741), torezolid and others, several of 
which are still being studied in phase I, II or III clinical research. A summary of LZD PK 
interactions is provided in Table 1.
Oxazolidinones as victims
Antimicrobial drugs: In an open-label comparative study of 8 healthy volunteers receiving 
600 mg of both LZD and rifampicin (RIF) intravenously, a reduction of LZD plasma 
concentration was observed (2). An in vitro study demonstrated that LZD is not detectably 
metabolized by human CYP and did not inhibit the activities of human CYP isoforms 1A2, 
2C9, 2C19, 2D6, 2E1, or 3A4 (3). Based on these observations along with the fact that RIF 
is a well-known P-gp inducer, the authors suggest LZD to be a P-gp substrate (2). This 
hypothesis was further supported by a case report of a patient with MDR-TB. This patient 
Table 1 Summary of interactions of the oxazolidinone LZD with enzyme systems and/or food
Absorption Metabolism: Excretion:
Fat meal Antacids CYP P-gp Reactive Oxygen Species
LZD ↓ = - S* =
Downwards arrow (↓) indicates inhibition resulting in <50% decrease of AUC. “S” indicates the drug being a 
substrate, and “=” interaction is not relevant.
* Mostly based on case reports: in need of further research.
Note: Systematic research on newer compounds such as PNU-100480, posilozid (AZD2563), radezolid (RX-
1741), torezolid, and others is not available.
Since there were no interactions affecting displacement / distribution this process was not included in the table.
Chapter 2
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received LZD and clarithromycin (CLR), a potent inhibitor of P-gp and a well-known 
CYP3A4 inhibitor. It was shown that co-administration of CLR with LZD resulted in a 
markedly increased LZD AUC (4). 
The combination of aztreonam and LZD in an open-label cross-over study that included 
13 healthy volunteers resulted in a statistically significant, although probably not clinically 
relevant increase of LZD AUC of approximately 18% (5). The authors suggest that the 
mechanism for this interaction is partly explained by a common elimination pathway, i.e. 
renal excretion. However, the definite mechanism remains unknown.
Food and antacids: In a two-phase single-dose open-label cross-over study of 12 healthy 
volunteers, a fatty meal caused a small but statistically significant reduction of mean LZD 
plasma concentration (6). The Cmax decreased by 23% and tmax increased from 1.5 hours to 
2.2 hours, probably due to prolonged gastric residence time. An open-label cross-over study 
in 28 healthy volunteers tested the hypothesis that a disturbed balanced of reactive oxygen 
species might lower the in vivo clearance of LZD by supplementing dietary antioxidants, 
i.e. vitamin C and E, but concluded there was no significant effect on LZD Cmax and AUC 
(7). This is in line with current literature indicating that supplemented antioxidant vitamins 
have subtle effects on in vivo reactive oxygen species balance (7). A randomized open-label 
cross-over study of 17 healthy volunteers showed that the antacid Maalox has no effect 
on the PK of LZD (8).
Oxazolidinones as perpetrators
Serotonin reuptake inhibitors: A single randomized controlled trial (RCT) (9) and several 
case reports (10-23) describe LZD’s potential for drug interactions due to its reversible 
monoamine oxidase-A inhibitor activity. In case reports, serotonic toxicity was observed 
after co-administration of LZD with drugs that influence serotonin levels like selective 
serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, monoamine oxidase 
inhibitors, and other serotonergic agents such as citalopram, diphenhydramine, duloxetine, 
fluoxetine, paroxetine, sertraline, trazodone, and venlafaxine. However, one case report 
presented a depressed patient receiving co-administered mirtazepine and LZD being 
treated successfully without toxic signs (24). The RCT focused on the PK interaction of 
LZD with the over the counter (OTC) sympathomimetic drugs pseudoephedrine and 
phenylpropanolamine. A slight increase in blood pressure and a minimal effect on the PK of 
both co-administered drugs was found in 42 healthy individuals (9). The serotonin reuptake 
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inhibitor dextromethorphan was co-administered with LZD with no clinical effect: only a 
slight decrease of dextrorphan, the primary metabolite of dextromorphan, was observed (9).
CONCLUSIONS 
The original article, presenting an overview of PK studies on drug-drug and drug-food 
interactions of macrolides, fluoroquinolones, rifamycines, oxazolidinones, and β-lactam 
antimicrobial drugs, can be used by physicians and pharmacists in daily practice to assist in 
preventing and managing PK drug interactions of antimicrobial drugs. This chapter, adapted 
from the original article, provides an overview of drug-interactions of oxazolidinones. The 
interactions presented vary in extent of severity and clinical relevance. Potential clinical 
problems can range from therapeutic failure due to low drug exposure to adverse events due 
to toxic drug concentrations. PK interaction studies in both patients and healthy volunteers 
are included. It has been demonstrated that PK characteristics of drugs can differ between 
healthy volunteers and patients (25). As a result of an underlying disease, physiological 
changes can influence drug PK, although the mechanism remains to be elucidated. In 
many critically ill patients extracellular fluids have increased, possibly resulting in a higher 
volume of distribution that might affect PK (26). One should bear in mind that findings in 
PK interaction studies performed in healthy volunteers might not be observed in clinical 
practice in specific patient populations.
Furthermore, PK interaction studies administering both single doses and multiple doses to 
study subjects were used in this overview. It need hardly be mentioned that multiple-dose 
studies will reflect best clinical practice. This is particularly true for PK interaction studies 
with biotransformation as possible underlying mechanism since induction of enzyme systems 
might require days to 2 – 3 weeks to develop fully (27). The interaction may also persist at 
a similar length of time when the inducing agent is stopped. Unlike induction, inhibition 
of enzyme systems can occur within 2 – 3 days (27). 
Physicians and pharmacists should also be aware of the fact that some of the included studies 
used doses that are higher or lower than those used in daily clinical practice. Especially in 
non-linear PK, this makes PK interactions difficult to interpret.
Finally, drug interactions not only occur when two or more interacting drugs are administered, 
but can also surface when one of the interacting drugs is halted. Most electronic health 
record systems include a program that can routinely check for drug-drug interactions and 
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could assist in preventing drug interaction-related adverse events. However, these programs 
rarely check for interactions that can occur when one of the interacting drugs is halted. 
Multidisciplinary vigilance of physicians, pharmacists, and other health care professionals 
remains necessary for adequate management of drug-interactions of antimicrobial drugs.
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A 42-year-old male patient was admitted at our hospital for treatment of smear-positive 
pulmonary tuberculosis (TB). Drug Susceptibility Testing (DST) revealed extensively drug 
resistant tuberculosis (XDR-TB) and the isolate appeared only susceptible to cycloserin, 
linezolid, clarithromycin and clofazimine. According to the WHO treatment guidelines 
for TB the treatment regimen was composed of these four drugs as no other options were 
available (11). Linezolid was the cornerstone of this regimen because of the high in vitro 
activity against M. tuberculosis (MIC of 0.125 – 0.5 mg/L) (1, 8). Linezolid is a toxic drug and 
its labelled duration of administration is therefore limited to 28 days to prevent peripheral 
neuropathy and anaemia. Dose reduction has been evaluated in TB patients as an attempt 
to reduce toxicity to allow for prolonged treatment for 18 – 24 months (6, 7, 10). The target 
of linezolid serum concentrations in our hospital is to maintain an AUC (the area under 
the concentration-time curve over 24 h) / MIC ratio over 100 and time in excess of the 
MIC of 100%. These conditions are generally reached with a dosage of 300 mg twice daily 
(2). Serum concentrations are analysed using a validated liquid chromatography tandem 
mass-spectrophotometer method (5). In this patient, we measured a considerable increase 
in the AUC of linezolid from 29 mg*h/L to 108 mg*h/L (Figure 1). 
Figure 1 Linezolid serum concentrations over time before (solid circles) and after (open circles) 
addition of clarithromycin.
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This increase appeared to coincide with the start of clarithromycin (1000 mg once daily), 
a potent inhibitor of P-glycoproteins (3). We also found that the tmax of the absorption 
phase was delayed. Possible other drug-drug interactions were not expected as the patient 
received only clofazimine, domperidone, insulin, omeprazole, and vitamins. We did not 
observe any significant changes in his liver- or renal function to account for the sudden 
raise of linezolid serum concentrations. Based on the serum concentrations, the linezolid 
dose was decreased to 150 mg twice a day. After 6 months the sputum cultures and smear 
microscopy became negative. The patient was discharged from our Center in a good 
clinical condition. At follow-up his sputum cultures have remained negative for the last 
12 months of his 18 months treatment, and his clinical condition has remained excellent. 
The timely reduction of linezolid dosage might have prevented toxicity such as time- and 
dose dependant myelosuppression (9). This case further strengthens the suggestion that 
linezolid is a P-glycoprotein substrate. From an earlier case it is known that the addition of a 
potent P-glycoprotein inducer rifampicin, resulted in a reduction of linezolid concentration 
(4). In our case the administration of the P-glycoprotein inhibitor clarithromycin resulted 
in a clear increase of linezolid serum concentrations. Based on our observations, a dose 
reduction of linezolid and therapeutic drug monitoring should be considered if linezolid is 
co-administered with clarithromycin in order to prevent potential toxicity. A prospective 
pharmacokinetic study may help to quantify the interaction that we describe.
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The use of linezolid for the treatment of multidrug-resistant tuberculosis is limited by 
dose- and time-dependent toxicity. Recently, we reported a case of pharmacokinetic drug-
drug interaction between linezolid and clarithromycin resulting in increased linezolid 
exposure. The aim of this prospective pharmacokinetic study is to quantify the effect of 
clarithromycin on the exposure of linezolid.
Subjects were included in an open-label, single-center, 1-arm, fixed-order pharmacokinetic 
interaction study. All subjects received 300 mg linezolid twice daily during the entire 
study, consecutively co-administered with 250 mg and 500 mg clarithromycin once daily. 
Steady-state serum curves of linezolid and clarithromycin were analyzed using validated 
methods and differences between pharmacokinetic parameters were calculated. 
Linezolid exposure increased by a median of 44% (interquartile range: 23 – 102%, 
p=0.043) after co-administration of 500 mg clarithromycin (n=5) compared to baseline, 
whereas 250 mg clarithromycin had no statistically significant effect. Co-administration 
was well tolerated by most patients: none experienced severe adverse effects. One patient 
reported Common Toxicity Criteria Grade 2 gastro-intestinal adverse events. 
In this study, we showed that clarithromycin significantly increased linezolid serum 
exposure after combining clarithromycin with linezolid in multidrug-resistant 
tuberculosis patients. The drug-drug interaction is possibly P-glycoprotein mediated. Due 
to large inter-patient variability, therapeutic drug monitoring is advisable to determine 
individual effect size.
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INTRODUCTION
Multidrug-resistant tuberculosis (MDR-TB) is an infectious disease of major concern, 
especially in high TB burden countries (1-3). Treatment of MDR-TB poses challenges such 
as designing an effective second-line anti-tuberculosis regimen, entailing a combination of 
multiple drugs and a long duration of treatment (4). This translates in an intensive phase 
of at least 8 months and total treatment duration of at least 20 months as recommended by 
the WHO (5). In the intensive phase, treatment of MDR-TB should consist of at least four 
second-line anti-tuberculosis drugs likely to be effective. Additional drugs from Group 5, 
such as linezolid and clarithromycin, may be used, but their efficacy in the treatment of 
MDR-TB is unclear (5). Unfortunately, knowledge on the efficacy in the treatment of MDR-
TB with these drugs is scarce.
Linezolid is a promising antimicrobial agent for the treatment of MDR-TB. However, evidence 
on the treatment of MDR-TB with linezolid is limited. Efficacy against Mycobacterium 
tuberculosis has been shown in vitro (6), in animals (7), and in patients (8-10). A recent 
meta-analysis confirms this efficacy, but shows the necessity of caution in the prescription 
of linezolid due to toxicity; almost 60% of all analyzed patients experienced adverse events 
(11). Adverse events, such anemia (38%), peripheral neuropathy (47%), gastro-intestinal 
side effects/symptoms (17%), optic neuritis (13%), and thrombocytopenia (12%), have all 
been reported and limit the use of linezolid (11). Reducing the dose of linezolid has been 
evaluated in an attempt to reduce toxicity (12). A dose of ≤600 mg linezolid daily resulted in 
lower frequency of adverse events than a dose of >600 mg daily (respectively 47% vs 75%), 
thereby enabling longer treatment duration (11).
Clarithromycin has a less prominent place in the treatment of MDR-TB. The minimal 
inhibitory concentration (MIC) of Mycobacterium tuberculosis was thought to be well in 
excess of achievable serum concentrations based on 12 strains of Mycobacterium tuberculosis 
(13). However, lower MICs have been observed (<2 mg/L) and clarithromycin shows 
concentrations in epithelial lining fluid that are often higher than in serum, enabling 
clarithromycin to be added to treatment regimens (14). Several Group 5 drugs, e.g. linezolid 
and clarithromycin, may need to be combined in a single MDR-TB treatment regimen, albeit 
that little is known on drug-drug interactions of these agents. Drug-drug interactions could 
compromise the efficacy of treatment regimens or could increase toxicity through reduced 
or increased exposure respectively.  
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Recently, we reported a pharmacokinetic drug-drug interaction between linezolid and 
clarithromycin that resulted in increased linezolid exposure (15). Increased serum 
linezolid concentrations could lead to toxicity, such as time- and dose-dependent severe 
myelosuppression and polyneuropathy. In a meta-analysis comparing a cohort treated with 
>600 mg linezolid per day with a cohort treated with ≤600 mg, there was a higher probability 
of anemia (60% vs 23%), leucopenia (17% vs 2%) and gastrointestinal symptoms (29% vs 
8%) in the cohort that received >600 mg linezolid (11). Such toxicity could lead to the need 
to cease treatment with linezolid, severely limiting the treatment options left. Therefore, the 
aim of this prospective pharmacokinetic study was to quantify the effect of clarithromycin 
on the exposure of linezolid in adult MDR-TB patients hospitalized at the Tuberculosis 
Center Beatrixoord (Haren, the Netherlands).
METHOD
Study design 
This study was an open-label, prospective single-center, 1-arm, fixed-order, interventional 
pharmacokinetic interaction study. The study was performed at the Tuberculosis Centre 
Beatrixoord (University of Groningen, University Medical Center Groningen, Haren, The 
Netherlands). All study subjects received standard care for their MDR-TB and co-morbidities. 
Treatment of MDR-TB was based on the World Health Organization (WHO) guideline (5) 
individualized for each included patient. 
The primary objective was to quantify linezolid area under the concentration-time curve from 
0 to 12 hours (AUC0–12h) without clarithromycin and with 250 mg and 500 mg clarithromycin 
once daily. Secondary objectives were to compare pharmacokinetic parameters of linezolid 
and clarithromycin between different dosing combinations and to describe tolerability and 
safety of co-administration of clarithromycin and linezolid in MDR-TB patients.
All patients gave written informed consent. The study protocol was approved by the Medical 
Ethical Review Committee of the University Medical Center Groningen (University of 
Groningen, Groningen, the Netherlands). The study was registered at clinicaltrials.gov 
(NCT01521364). 
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Subjects 
All study subjects were aged ≥18 years and were diagnosed with MDR-TB, confirmed with 
standard microbiological culture methods. The criteria for exclusion were based on the 
contraindications and known drug-drug interactions as mentioned in the Summary of 
Product Characteristics of linezolid and clarithromycin (16, 17). Subjects were excluded 
from the study if they were pregnant or lactating; had previously shown hypersensitivity to 
linezolid, any macrolide antibiotics, or any of the excipients of linezolid or clarithromycin; had 
hypokalemia; or concomitantly received P-glycoprotein modulators. Drug sensitivity testing 
(DST) was performed at the Dutch National Mycobacterial Reference Laboratory (National 
Institute for Public Health and the Environment [RIVM], Bilthoven, The Netherlands) using 
the Middlebrook 7H10 agar dilution method.
Treatment
All patients received linezolid 300 mg every 12 hours. In previous studies, we showed that 
this dose resulted in seemingly effective serum concentrations with a median (interquartile 
range, IQR) AUC0–12h of 57.6 (38.5 – 64.2) mg*h/L and AUC0–24h/MIC ratios of 452 (343 
– 513) (12). Clarithromycin was added to therapy in a dose of 250 mg and 500 mg once 
daily consecutively during two weeks in a fixed order (Figure 1). From three cases at the 
Tuberculosis Center Beatrixoord, of which one case is published (15), it was expected that 500 
mg clarithromycin would result in an approximately doubled linezolid exposure, matching 
the exposure of linezolid resulting of labeled dose of 600 mg twice daily. 
Full linezolid pharmacokinetic curves were recorded at baseline (after one week of linezolid 
without clarithromycin), after receiving linezolid with 250 mg clarithromycin, and after 
First blood curve (baseline): AUCInformed Second bloodcurve: Third blood curve:  
LZD + 0 mg CLR
0-12h TroughConsent
 
LZD + 250 mg CLR
  
LZD + 500 mg CLR
CLR 250 mg (once daily)
CLR 500 mg (once daily)
LZD 300 mg (twice a day)   
0 1 2 3 4 5 6
Week
Figure 1 Study design, showing dosing and sampling schedules of linezolid (LZD) and clarithromycin 
(CLR).




linezolid with 500 mg clarithromycin for two weeks (Figure 1). A trough sample was obtained 
after a washout period of one week, during which the patients only received linezolid besides 
their standard treatment, but no clarithromycin.
Sample size was derived from AUCs in a previous study in MDR-TB patients (12) and from 
the relative large increase of exposure observed in three cases ((15); two cases unpublished). 
To reach a desired power of 80%, a sample size of at least 5 patients was calculated using 
G*Power 3.1 (Heinrich Heine Universität, Dusseldorf, Germany). A drop-out rate of 15% 
was estimated based on previous studies at the Tuberculosis Center Beatrixoord (Haren, 
the Netherlands). To compensate for this estimated drop-out, seven patients were included. 
Experimental procedures 
The baseline linezolid pharmacokinetic curve and the trough after a one-week washout 
period were obtained at steady state, which is reached after approximately three days (16). 
Pharmacokinetic curves after co-administration of linezolid and clarithromycin were 
assessed at steady state after two weeks, allowing the pharmacokinetic interaction to develop 
fully (18). Blood samples were collected before and 1, 2, 3, 4, 8, and 12 hours after intake of 
medication. The second dosage of linezolid was given directly after this last blood sample. 
The patients did not receive standardized meals, but were allowed to eat a regular breakfast, 
reflecting common clinical practice, since food does not influence the linezolid exposure 
(19). Adherence was ensured through a directly observed inpatient treatment program.
Serum concentrations
Blood samples were drawn and after centrifuging serum samples were stored at -20°C until 
analysis. Linezolid and clarithromycin serum concentrations were analyzed using validated 
high performance liquid chromatography tandem mass-spectrometry methods (20, 21).
Tolerability and safety 
The patients were clinically observed by nurses and attending physicians. Routine checks 
including blood tests were carried out at least weekly as part of continued standard 
care including monitoring for hyperlactatemia, haematological abnormalities such as 
thrombocytopenia and anemia. All patients received epoetine alpha (Eprex®) pre-emptively 
in a dose of 2000 IE twice a week to prevent anemia as part of standard care. Gastro-intestinal 
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side effects were determined using the Common Toxicity Criteria (CTC) and were scored 
Grade 0 to 4 (22). Routine testing of neurotoxic adverse events through electromyogram 
(EMG) or vibration sense monitoring are not carried out during the study of 6 weeks, since 
these effects have been reported to occur after a median (range) of 16 (10 – 111) weeks 
(23). In case of clinical suspicion of peripheral neuropathy, a neurologist was consulted as 
is common practice at the Tuberculosis Center Beatrixoord. Furthermore, patients receiving 
linezolid were examined by an ophthalmologist once monthly, which is also common 
practice in this Center.
Pharmacokinetic and statistical analysis 
The main study parameter, linezolid AUC0–12h and secondary study parameters clearance 
(CL), elimination constant (k) and elimination half life (t1/2) are calculated using trapezoidal 
rule in the Kinfit software (MWPharm 3.60; Mediware, Groningen, The Netherlands) (24). 
Pharmacokinetic parameters of linezolid and clarithromycin are described. Cmax was defined 
as the highest observed serum concentration and Cmin was defined as the concentration 
before intake of medication.
The hypothesis that the median of differences of AUC0–12h of linezolid at baseline compared 
to AUC0–12h after co-administration with either 250 mg or 500 mg clarithromycin equals zero 
was tested using the related-samples Wilcoxon Signed Rank test. Secondary pharmacokinetic 
parameters from the three curves were compared using the same related-samples Wilcoxon 
Signed Rank test. The non-parametric analysis of variances (ANOVA) Friedman test was used 
to test dose dependency of an effect of clarithromycin on linezolid exposure. All statistical 
evaluations were performed using SPSS 20 (SPSS, Chicago, IL, USA). 
RESULTS
Patient characteristics
From December 2011 to October 2012, 16 patients with possible MDR-TB were admitted to 
the Tuberculosis Center Beatrixoord (Haren, the Netherlands). Two of these 16 patients were 
<18 years old, one patient was pregnant, one patient was participating in another study, for 
one patient the planned period of admission was too short, leaving eleven patients for formal 
screening. Four patients were not included in the study for various reasons. In one patient 
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DST revealed normal sensitivity, in another patient venous blood samples were not obtained 
due to venous access problems, rendering the collection of three full pharmacokinetic 
curves impossible; a third patient was included in another study; and the last patient was 
deemed psychologically too unstable to comply with the study protocol. Seven hospitalized 
patients were included in the study five of whom were suitable for evaluation. One of the 
included patients dropped out of the study in the fourth week due to medical reasons. The 
patient had a fever and was nauseous, probably due to an infected venous access port and 
possibly combined with side effects of clarithromycin and other anti-TB medication such 
as moxifloxacin. Another patient could not be evaluated due to a logistical problem with 
the study medication. The two patients that dropped out of the study were excluded from 
all analyses.
Table 1 Baseline demographics (n=5) and results from drug susceptibility testing
Parameter Value
Age – year† 35.0 (23 – 65)
Male sex – no. (%) 4 (80%)
Bodyweight – kg† 66.8 (55.2 – 78.5)
Height – m† 1.74 (1.67 – 1.82)








HIV positive – no. 1 





























† Data presented as mean (range).
¥ Body-mass index is calculated by dividing weight in kilograms by the square of the height in meters.
∫ Drug susceptibility testing (DST) was not available for all isolates of the included patients.
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Patient baseline demographics and results from the drug susceptibility testing are presented 
in Table 1. The mean (range) age of included subjects was 35 (23 – 65) years and the mean 
(range) weight was 66.8 (55.2 – 78.5) kg. One of the patients was HIV positive and was treated 
with emtricitabin / tenofovir and raltegravir. Three patients originated from Somalia, one 
from Turkey, and one from the Netherlands.
Pharmacokinetic and statistical analysis 
From all patients suitable for evaluation (n=5), three full pharmacokinetic curves in serum 
were available. The mean plasma concentration-time curves are shown in Figure 2. The 
baseline median (IQR) AUC0–12h of linezolid of 36.3 (33.2 – 46.3) mg*h/L in patients with a 
mean (range) body weight of 66.8 (55.2 – 78.5) kg, is lower than the median (IQR) AUC0–12h 
of linezolid of 57.6 (38.5 – 64.2) mg*h/L from a previous study with patients with a median 
(IQR) body weight of 58.3 (52.7 – 62.8) kg (12). Linezolid concentrations in serum increased 
after co-administration of clarithromycin compared to baseline, but display a large standard 
deviation. There appears to be no effect on time of Cmax, i.e. tmax.
Figure 2 Mean linezolid concentration-time curves in serum (n=5) for linezolid without clarithromycin 
(solid circles with closed line), linezolid with 250 mg clarithromycin (open squares with dotted line), 
and linezolid with 500 mg clarithromycin (open triangle with dashed line).
Standard deviations are presented as error bars. For visual purposes, error bars for linezolid with 250 mg 
clarithromycin are left out.
Time (hours after dose)
































+ 0 mg clarithromycin
+ 250 mg clarithromycin
+ 500 mg clarithromycin
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Pharmacokinetic parameters of linezolid and clarithromycin are presented in Table 2. 
Compared to baseline, the median AUC0–12h of linezolid increased statistically significantly 
after co-administration with 500 mg clarithromycin (p=0.043), but not after co-administration 
with 250 mg clarithromycin (p=0.686). After co-administration of linezolid with 500 mg 
clarithromycin, the median (IQR) AUC0–12h of linezolid increased by 44% (23 – 102%) 
compared to baseline. Furthermore, administration of 500 mg clarithromycin statistically 
significantly increased the Cmax of linezolid by median (IQR) 48% (35 – 103%, p=0.043), but 
not the Cmin of linezolid by median (IQR) 50% (44 – 189%, p=0.080) compared to baseline. 
There was no statistically significant difference in linezolid half life after co-administration 
of 500 mg clarithromycin with linezolid compared to linezolid alone (p=0.138). Linezolid 
clearance and elimination constant decreased statistically non-significant when linezolid 
and 500 mg clarithromycin are co-administered compared to baseline (both p=0.08). No 
dose-dependent effect of clarithromycin on the linezolid exposure could be detected using 
the Friedman test (p=0.091). 
Safety / tolerability
Co-administration of linezolid and clarithromycin was well tolerated by most patients. None 
of the patients experienced severe adverse events, such as anemia, peripheral neuropathy, 
optic neuritis, or thrombocytopenia. One patient experienced CTC Grade 2 gastro-intestinal 
side effects three days after the start of administration of 500 mg clarithromycin once daily.





+ 250 mg 
clarithromycin p-value
Linezolid 









36.3 [33.2 – 46.3]
6.0 [5.1 – 6.4] 
1.2 [0.9 – 1.6]
7.0 [5.4 – 8.0]
0.17 [0.17 – 0.19]
4.1 [3.6 – 4.2]
61.0 [34.6 – 63.9]
8.0 [5.5 – 10.9] 
2.1 [0.9 – 2.2]
4.0 [3.5 – 7.8]
0.14 [0.12 – 0.18]







67.2 [66.9 – 76.0]
9.4 [8.9 – 10.5]
2.6 [2.4 – 3.9]
3.5 [2.7 – 3.5]
0.13 [0.11 – 0.13]








AUC0–12u (mg*h/L) N/A 8.2 [5.8 – 9.8] N/A 20.1 [14.0 – 23.6] 0.043
¥
Data are presented as median [interquartile range]. 
† p-values comparing parameters from co-administration of linezolid with 500 mg clarithromycin to baseline.
¥ p-value comparing AUC0–12h of 500 mg with 250 mg clarithromycin.
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DISCUSSION
In this study, we showed that clarithromycin significantly increased linezolid serum AUC0–12h 
after combining clarithromycin with linezolid in MDR-TB patients. After two weeks of 
co-administration of linezolid with clarithromycin 500 mg once daily, the Cmax of linezolid 
increased significantly by approximately 50%. Combining linezolid with clarithromycin 
in a dose of 500 mg once daily resulted in a significantly higher AUC0–12h of linezolid with 
a median of 44%. None of the patients experienced any severe adverse events. However, 
it should be noted that patients pre-emptively received epoetine alpha as part of standard 
care, potentially obscuring anemia as a side effect.
Besides our recent report on the interaction between clarithromycin and linezolid, there are 
no other reports on this pharmacokinetic drug-interaction. In fact, one of the few known 
drug interactions of linezolid to date is with rifampicin. Rifampicin, a well-known inducer 
of P-glycoprotein and cytochrome P 450 enzymes, decreases linezolid serum levels in 
critically ill patients (25). Another study confirmed this finding in healthy volunteers (26, 
27). Gebhart et al. suggest the interaction to be mediated by P-glycoprotein, since an in vitro 
study has shown that linezolid is not metabolized by cytochrome P450 enzymes (28). The 
interaction of linezolid and clarithromycin could also be mediated by P-glycoprotein, since 
clarithromycin is a well-known cytochrome P450 3A4 inhibitor and a potent inhibitor of 
P-glycoproteins (29). P-glycoprotein is a membrane efflux transporter enzyme that is highly 
expressed in a variety of tissues including the intestine, liver, and kidney (30). Inhibition 
of the P-glycoprotein efflux pump by clarithromycin could result in the increased levels of 
linezolid, possibly a P-glycoprotein substrate, through inhibition of P-glycoprotein at the 
intestinal site as well as the renal site. P-glycoprotein polymorphism could explain some of 
the inter-patient variation that we observed. However, in a recent study Gandelman et al. refer 
to unpublished data on file from Pfizer suggesting linezolid is not a P-glycoprotein substrate 
(27). Their hypothesis for the observed interaction between linezolid and rifampicin is that 
a large increase in expression of cytochrome P450 3A (CYP3A) that typically has a small 
contribution (0.7 – 10.5%) to linezolid clearance, could cause a small decrease in linezolid 
exposure (27). Further research on the exact mechanism of the drug-drug interaction is 
needed.
Co-administration of clarithromycin and linezolid resulted in a near statistically significant 
decrease of clearance and elimination constant of linezolid compared to baseline. This might 
suggest inhibition of CYP3A or renal or hepatic P-glycoprotein efflux transporter pumps. 
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However, decreased clearance might not solely explain the observed increase of linezolid 
exposure. Unfortunately, due to the limited number of samples during the absorption phase, 
it is impossible to adequately compare data on absorption constant and tmax. Since patients 
did not receive intravenous linezolid, data on bioavailability is not available. It is therefore 
difficult to draw conclusions on involvement of inhibition of intestinal P-glycoprotein efflux 
transporters, which could result in increased absorption. 
The increase of linezolid exposure after co-administration with clarithromycin has possible 
implications for clinical practice. The higher linezolid AUC0–12h could result in toxicity of 
linezolid, an agent that often causes adverse events, such as time- and dose-dependent 
severe myelosuppression and polyneuropathy. Severe adverse events often necessitate the 
cessation of effective anti-MDR-TB treatment, leaving few alternatives. Dose reduction of 
linezolid could prevent toxicity. However, care should be taken to assure adequate linezolid 
exposure and added information on whether linezolid exposure is too high, too low, or 
in the therapeutic range, could prove helpful. Therapeutic drug monitoring could help in 
assessing the linezolid dose after dose reduction (12), especially since the observed drug-drug 
interaction shows a large inter-patient variability. In limited resource settings, dried blood 
spot sampling could resolve logistical problems encountered with conventional therapeutic 
drug monitoring (31). 
After evaluation of the combination of clarithromycin and linezolid in a larger population 
and during a longer period of time, clarithromycin could eventually even be used as a booster 
for linezolid, comparable to the use of low-dose ritonavir as a booster to improve protease 
inhibitor exposure in combined anti-retroviral therapy. The relatively cheap clarithromycin 
could reduce the dose of the expensive linezolid while the same exposure is maintained, 
thereby leaving the risk of toxicity unaltered. Since the highest prevalence of MDR-TB is 
found in countries with limited resources, such a booster strategy could make treatment with 
linezolid feasible for a larger group of patients. Such a cost reduction could even contribute 
to the call for making global MDR-TB control affordable (32). Further research on WHO 
Group 5 drugs, such as linezolid besides evaluation of new drugs such as delaminid (33) or 
old drugs such as co-trimoxazole (34), is of great importance. 
In conclusion, we showed a 44% increase of linezolid AUC0–12h after co-administration 
of linezolid with clarithromycin in a dose of 500 mg daily in MDR-TB patients. The 
pharmacokinetic interaction between linezolid and clarithromycin is suggested to be P-gp 
mediated. Further research in a larger cohort is needed to provide insight in observed inter-
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patient variation, perhaps caused by P-gp polymorphism. Until effect size is predictable, 
possibly with help of P-gp polymorphism testing, therapeutic drug monitoring is advisable 
to determine individual effect size. The drug-drug interaction we showed in this study is an 
important step towards making the effective anti-TB drug linezolid available through cost 
reduction in less affluent settings where MDR-TB is highly prevalent. 
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Linezolid is a promising antimicrobial agent for the treatment of  multidrug-resistant 
tuberculosis (MDR-TB), but its use is limited by toxicity. Therapeutic drug monitoring 
(TDM) may help to minimize toxicity whilst adequate drug exposure is maintained. 
Conventional plasma sampling and monitoring might be hindered by logistic problems 
in most parts of the world that may be solved by dried blood sampling (DBS). The aim 
of this study is to develop and validate a novel method for TDM of linezolid in MDR-
TB patients using DBS.
Plasma, venous DBS and capillary DBS specimens were obtained simultaneously from 
eight patients receiving linezolid. A DBS method was developed and clinically validated 
by comparing DBS with plasma results using Passing-Bablok regression and Bland-
Altman analysis. 
This study showed that DBS analysis was reproducible and robust. Accuracy and between 
and within-day precision from three validation presented as bias and CV were less than 
17.2% for lower limit of quantification level and 7.8% for other levels. The method showed 
a high recovery of approximately 95% and a low matrix-effect of less than 8.7%. DBS 
specimens were stable at 37°C for 2 months and at 50°C for one week. The concentration 
ratio of DBS/plasma was 1.2 (95% CI: 1.12 – 1.27). Linezolid exposure calculated from 
DBS and plasma showed good agreement. 
In conclusion, DBS analysis of linezolid is a promising tool to optimize linezolid treatment 
in MDR-TB patients. Easy sampling procedure and high sample stability may facilitate 
TDM, even in underdeveloped countries with limited resources where conventional 
plasma sampling is not feasible.
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INTRODUCTION
Linezolid is used as a second line drug in the treatment of multidrug-resistant tuberculosis 
(MDR-TB) due to its efficacy in vitro (21), in vivo (9) and in patients (1, 2, 14, 17, 34) against 
Mycobacterium tuberculosis. The World Health Organization (WHO) classifies linezolid 
as a reserve anti-tuberculosis drug for the treatment of multidrug-resistant/extensively 
drug-resistant tuberculosis (MDR/XDR-TB) (33). Linezolid is usually added to a treatment 
regimen consisting of anti-tuberculosis drugs for which the Mycobacterium tuberculosis is 
still susceptible. However, treatment with linezolid may be limited by toxicity, such as time- 
and dose-dependent neuropathy or myelosuppression (17, 29), urging dose reduction or 
cessation of treatment with linezolid. Therapeutic drug monitoring (TDM) can be used to 
implement dose reductions to limit toxicity, whilst preventing inadequate exposure. Efficacy 
predicting pharmacokinetic / pharmacodynamic (PK/PD) parameters, such as the area under 
the concentration-time curve to MIC ratio (AUC0–24h/MIC), might be helpful in evaluating 
linezolid dosages (1, 7, 26, 32). The AUC0–24h/MIC has been shown to be the best predictive 
model in a murine model (32), but evidence from human data are lacking. Further PK/PD 
data from TB-programs or large studies are needed for the development of evidence based 
PK/PD parameters, such as an AUC0–24h/MIC ratio target.  
Linezolid treatment has been evaluated for TB treatment, in several case series (17, 23). 
However, neither drug susceptibility testing (DST) nor drug exposure assessment was 
performed for linezolid, making it difficult to draw conclusions on efficacy (5). For instance, 
drug-interactions with other antimicrobial agents might have occurred and may have had 
an impact on linezolid exposure (6, 15). In addition, conventional drug exposure evaluation 
for TB drugs using plasma samples might have been hindered in these studies by logistical 
challenges (30). The use of dried blood spot (DBS) sampling may provide a helpful alternative 
to conventional plasma sampling through simplified sampling procedure and increased 
sample stability. DBS sampling has been applied in the treatment of other infectious diseases 
like malaria and HIV (30). Other advantages may include a lower required blood sample 
volume and lower biohazard risk of DBS samples compared to conventional plasma samples 
(12, 18, 30). Compared to conventional sampling, DBS sampling may be hindered by inter 
and intra-patient hematocrit (Hct) variation causing different blood viscosity yielding a 
proportional analytical bias with Hct value. Furthermore, Hct may affect the drug blood /
plasma partition ratio complicating the comparison with conventional plasma samples. 
In the development of a bioanalytical method for linezolid using DBS analysis important 
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patient related factors like blood spot volume, Hct value (3, 24) and difference between 
capillary and venous blood, have to be assessed during validation (12, 18, 25, 30). To enable 
individualized linezolid treatment the aim of this study was to develop and validate a method 
for DBS analysis and evaluate it in MDR-TB and XDR-TB patients.
MATERIALS AND METHODS
Patients
From September 2010 to March 2012, MDR-TB patients (≥18 years) were recruited from 
the Tuberculosis Centre Beatrixoord, University Medical Center Groningen (Haren, The 
Netherlands). Eligible for inclusion were patients receiving treatment with anti-tuberculosis 
drugs for which routine therapeutic drug monitoring was scheduled. Patients with bleeding 
disorders were excluded from the study. The study procedures were reviewed and approved 
by the local Ethics Committee. Patients receiving linezolid were included after providing 
written informed consent.
Sampling was performed at least one week after the start of linezolid treatment to ensure the 
steady-state was achieved. Venous blood samples were obtained our before drug intake and 
at 1, 2, 3, 4 and 8 hours after dosing according to a previous study (2) and local procedures 
for TDM of TB drugs to be able to calculate drug exposure and other PK parameters. Venous 
dried blood spot (vDBS) specimens were prepared by pipetting 50 μL venous blood onto 
Whatman 31 ET CHR paper. The remaining venous blood was centrifuged at 3000 rpm for 
5 minutes at room temperature to attain plasma which was stored at -20°C until analysis. 
DBS specimens were obtained through a finger prick by dropping the blood directly on 
dried blood spot paper. DBS samples were obtained before drug intake, 2 and 8 hours after 
dosing, representing low, high and medium linezolid blood levels respectively. Both the 
vDBS and DBS samples were left to dry at room temperature and stored in sealed plastic 
bags with desiccant sachets at -20°C until analysis.
DBS analysis
To quantify DBS samples an 8 mm-diameter disc was punched out of each blood spot. 
Extraction of these discs was performed by sonication with a frequency of 47 kHz during 
a period of 20 minutes using 500 μL of extracting solvent consisting of cyanoimipramine 
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0.3 mg/L (internal standard) and EDTA 1 g/L in water. From this solution, a volume of 
200 μL was added to 750 μL of acetonitrile. The samples were vortexed for 1 minute and 
subsequently centrifuged at 11000 rpm for 5 minutes. An injection volume of 5 μL was 
analyzed using a validated LC-MS/MS analysis method (16). The plasma samples were 
prepared and analyzed using the same method.
DBS method validation
The DBS analytical method was validated in accordance with the recommendation of 
US Food and Drug Administration’s (FDA) Guidance for Industry Bioanalytical Method 
validation (27). For the validation, blood was prepared by mixing plasma, red blood cell 
and linezolid stock solution to achieve blood at desire concentration and Hct. Subsequently, 
the validation DBS samples were prepared by pipetting 50 μL of blood onto the paper. 
Linearity was assessed with 1/x2 weighting over a concentration range of 0.05 – 40 mg/L. 
Clinical relevant concentrations were well within the range of the assay standards (2). The 
within-day and between-day accuracy and precision were evaluated on four validation levels 
of LLOQ (lower limit of quantification), LOW, MED and HIGH at concentrations of 0.05, 
0.25, 15 and 30 mg/L, respectively. Each validation level was analyzed in fivefold on three 
consecutive days. The matrix effect and the recovery of linezolid from DBS were determined 
using a common method (18, 31). The stability of DBS specimens was assessed by storing 
validation DBS at ambient condition and 37°C after one week, two weeks and two months. As 
a worst case scenario the stability of DBS specimens was also assessed at 50°C after one day, 
two days and one week. The stability was evaluated at LOW and HIGH levels in fivefold by 
comparing the analytical result with the nominal concentrations. In addition to the criteria 
suggested in the FDA guideline (27), the impact on assay accuracy and precision due to 
the variations of Hct and blood spot volume were evaluated. For these purposes, Hct of 20, 
25, 30, 35, 40, 45 and 50%, and blood spot volumes of 30, 50, 70 and 90 μL were assessed. 
During the method validation, blood spot volume and Hct were standardized at 50 μL and 
35%, respectively. The set of Hct of 35% reflects the Hct in tuberculosis patients (3).
Pharmacokinetic and pharmacodynamic evaluation
Pharmacokinetic parameters were evaluated using a non-compartmental model of the 
KINFIT module of MW Pharm (version 3.9; Mediware, The Netherlands). The AUC0–12h was 
calculated using the trapezoidal rule from 0 up to 12 hours and the AUC0–24h by doubling the 
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AUC0–12h. The maximum concentration (Cmax) was defined as the highest observed linezolid 
concentration with tmax as corresponding time. The elimination half-life (t1/2) was calculated 
by dividing the natural logarithm of 2 (ln2) by the elimination constant (ke) as calculated 
by MW Pharm. The apparent clearance (Cl) of linezolid was calculated by dose/AUC0–12h. 
The volume of distribution (Vd) was calculated by dividing Cl with ke.
The drug susceptibility testing of the Mycobacterium tuberculosis isolates was performed 
at the Dutch National Mycobacteria Reference Laboratory (National Institute for Public 
Health and the Environment; RIVM) using the Middlebrook 7H10 agar dilution method 
(28). The AUC0–24h/MIC ratio, often used as a predictive pharmacodynamic parameter for 
efficacy, was calculated (32). 
Statistics
In the method validation, the bias was defined as the difference (in percentage) between 
analytical result and the nominal concentration. The method was clinically validated by 
comparing the concentrations of DBS and vDBS with plasma concentrations using Passing-
Bablok regressions and Bland-Altman analysis by applying the software tool Analyse-it 
2.20 (Analyse-it Software, Ltd). Conversion factors, calculated from geometric mean 
(v)DBS/plasma concentration ratios, were used to calculate conversed DBS and vDBS 
concentrations(4). Subsequently, the conversed concentrations were used to calculate the 
AUC0–12h of DBS and vDBS. The agreement between AUC0–12h value of conversed DBS and 
plasma was evaluated using Bland-Altman analysis. Spearman correlation and Wilcoxon 
signed-rank test was applied to other comparisons. 
RESULTS
Patients
Eight patients with a median (IQR) age of 29 (24 – 33) years were included in this study. The 
baseline characteristics are presented in Table 1. The median (IQR) of Hct was 37.4 (33.0 
– 41.4) %. At time of the study three of eight patients received linezolid 300 mg twice a day 
and five patients in a dose of 600 mg twice daily. Isolates of seven patients showed resistance 
to first-line drugs isoniazide, rifampicin, ethambutol, pyrazinamide, and streptomycin. The 
isolate of one patient showed resistance to all first-line drug except pyrazinamide. All DSTs 
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revealed resistance for rifabutin, whereas one isolate showed fluoroquinolone-resistance and 
three protionamide-resistance. None of the patients experienced significant discomfort from 
the finger pricks during DBS sampling which was supported by the fact that all completed 
the three consecutive samples in this study.
DBS method validation
The DBS assay method showed linearity over the analytical concentration range. The pooled 
correlation coefficient was r2 = 0.9947. The regression equation is: concentration = (0.1635 ± 
0.0025) × response + (0.0001 ± 0.0003). Within-day and between-day accuracy and precision 
showed CVs within accepted range. Within-day CVs ranged from 1.6% to 13.8% and 
between-day CVs from 3.5% to 10.2%. The mean measured concentration was within 98.7% 
Table 1 Baseline demographics of study patients (n=8)
Parameter Value 




Bodyweight (kg) (#) 60.5 [55.8 – 61.5]
Height (m) (#) 1.69 [1.67 – 1.76]







Hemoglobin (g/L) (#) 7.0 [6.4 – 8.8]
Hematocrit (v/v*100%) (#) 37.4 [33.0 – 41.4]








(#): median [interquartile range].
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to 106.3% of the nominal concentration. The bias caused by variable matrices, i.e. DBS and 
EDTA matrices, was less than 8.7%. The recovery of DBS extraction was between 94.1% and 
97.2%. No significant linezolid degradation was observed after storing DBS at 50°C for at least 
one week and at 37°C or ambient temperature for two months as biases were less than 15%. 
Variation of blood spot volume between 30 μL to 90 μL had a minor impact on the assay 
accuracy as the bias ranged from -11.6% to 7.1%. The variation of Hct from 20% to 50% 
yielded biases within -7.6% to 6.8% and -12.5% to 5.7% for MED and HIGH level. Larger 
biases of -17.8% to 11.9% were observed at the LOW concentration level (0.25 mg/L) (Table 2). 
Comparisons of DBS, vDBS and plasma analysis
Significant proportional biases were observed in Passing-Bablok regressions in which the 
slope of regression line between DBS and plasma was 1.28 (95% CI: 1.13 – 1.44) and vDBS 
and plasma was 1.46 (95% CI: 1.40 – 1.54). The intercepts were -0.42 (95% CI: -1.72 – 0.17) 
and -0.67 (95% CI: -1.36 – -0.09), respectively (Figure 1). In Bland-Altman analysis, the 
geometric mean concentration ratios of DBS and vDBS versus plasma were 1.20 (95% CI: 
Table 2 Summarized results of the validation of DBS analysis
Validation levels (n=5)
Validation criteria LLOQ LOW MED HIGH
Nominal concentrations (mg/L) 0.05 0.25 15 30
Reproducibility (#)
Accuracy (% Bias) 4.5 6.3 3.2 -1.3
Within-day precision (% CV) 13.8 4.0 4.1 1.6
Between-day precision (% CV) 10.2 3.5 6.1 7.7
Overall precision (% CV) 17.2 5.3 7.4 7.8
Matrix effect (%) 2.9 8.7 1.9
Recovery (%) 95.5 94.1 97.2
Effect of blood volume (range of % Bias) (¥) -2.9 – 4.1 -11.4 – 7.1 -11.6 – 9
Effect of hematocrit (range of % Bias) (£) -17.8 – 11.9 -7.6 – 6.8 -12.5 – 5.7
Stability (€)
1 week at 50°C (% Bias) 6.7 -3.4
2 months at 37°C (% Bias) -10 -5.9
2 months at ambient temperature (% Bias) -2.5 -2.0
(#): data from 3 separated validation days; (¥): comparison with samples of standardized hematocrit (35%); (£): 
comparison with sample of standardized blood spot volume (35 μL); (€): present data from the last time of the 
period only.
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1.12 – 1.27) and 1.36 (95% CI: 1.32 – 1.40), respectively. The ratio of vDBS/plasma was 
higher than that of DBS/Plasma (Wilcoxon signed-rank test, n=24, p<0.01). 95% limits of 
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Figure 1 Passing-Bablok regression between measurements in DBS/vDBS and plasma. 
– – – – : vDBS-plasma Passing-Bablok regression: slope = 1.46 (95% CI: 1.40 – 1.54), intercept = -0.67 (95% CI: 
-1.36 – -0.09);            : DBS-plasma Passing-Bablok regression: slope = 1.28 (95% CI: 1.13 – 1.44), intercept = 
-0.42 (95% CI: -1.72 – 0.17).
Figure 2 Bland-Altman plot of concentration ratios of DBS and vDBS vs. plasma. 
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Table 3 Steady state pharmacokinetic parameters of linezolid in plasma (n=8)
Parameter
300 mg linezolid
twice a day (n=3)
600 mg linezolid
twice a day (n=5)
AUC0-12h (mg*h/L) 50.9 [50.5 – 54.9] 126.9 [121.6 – 127.6]
Cmax (mg/L) 8.8 [7.8 – 8.9] 16.5 [14.4 – 16.5]
Tmax (h) 1.9 [1.9 – 4.8] 1.9 [1.7 – 3.0]
T1/2 (h) 4.6 [4.0 – 6.9] 7.5 [7.3 – 7.9]
Cl (L/h) 4.9 [3.8 – 5.1] 3.1 [3.0 – 3.1]
Vd (L) 32.6 [29.4 – 34.4] 34.8 [32.9 – 41.6]
Data are presented as median [interquartile range]. 
Pharmacokinetic and pharmacodynamic evaluation
A median (IQR) plasma AUC0–12h of 50.9 (50.5 – 54.9) mg*h/L was observed following 
a dose of 300 mg and 126 (121.6 – 127.6) mg*h/L following a dose of 600 mg. Linezolid 
pharmacokinetic parameters are shown in Table 3. The concentration-time curves of plasma, 
DBS and vDBS are presented in Figure 3. 
The AUC0–12h values of DBS and vDBS were calculated using the conversing factors 1.20 and 
1.36 for DBS and vDBS respectively. The subsequent result showed a good agreement with 
Figure 3 Concentration-time curves of linezolid in plasma, vBDS and DBS. 
Plasma and vDBS data are presented as mean and SD. For visual purposes, the DBS data are presented as 
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plasma. All the values were within the 95% limit of agreement (Figure 4). The individual data 
for each patient for AUC0–12h attained from plasma and conversed (v)DBS concentrations 
and the respective AUC0–24h/MIC values are presented in Table 4. Patients that received a 
linezolid dose of 300 mg twice daily (n=3) had a median (IQR) plasma AUC0–24h/MIC ratio 
of 236 (219 – 322) mg*h/L and patients that received 600 mg twice daily (n=5) had a median 
(IQR) plasma AUC0–24h/MIC ratio of 508 (486 – 1398) mg*h/L. 








Plasma vDBS(#) DBS(#) Plasma vDBS(#) DBS(#)
1 300 0.5 50.1 46.7 51.5 201 187 206
2 300 0.25 50.9 54.2 50.7 407 433 405
3 600 0.5 121.6 118.1 112.1 486 472 449
4 600 <0.125 127.6 130.9 114.2 >2042 >2094 >1827
5 600 0.5 126.9 132.0 140.2 508 528 561
6 600 0.5 66.6 69.4 64.2 266 278 257
7 300 0.5 58.9 46.1 42.4 236 184 170
8 600 0.25 174.7 183.1 189.6 1398 1465 1517
(#): relative AUC0–12h and AUC0–24h/MIC calculated using conversion factors (i.e. 1.20 for DBS and 1.36 for vDBS).
Figure 4 Bland-Altman plot of AUC0–12h from corrected DBS vs AUC0–12h plasma samples. 





























































This study showed that DBS analysis is an easy tool to individualize MDR-TB treatment with 
linezolid. In addition, this report presents a novel, validated method of analysis of linezolid 
in dried blood spots, with specimens that proved to be very stable over time. 
In previous studies on DBS analysis of other drugs, several technical factors were pointed out 
that have to be considered when interpreting DBS analysis, such as the effect of Hct and blood 
spot volume (12, 13, 18, 30). For the analysis of linezolid in DBS, the effect of Hct seemed 
to be of minor concern. In this study, biases fell within accepted ranges for Hcts between 
20 – 50%. These Hcts cover an even broader range than clinical Hcts found in TB patients 
in literature, i.e. 35.4 ± 6.7% (3), and in this study 37.4 ± 4.4%. Based on these findings, the 
standardization of Hct at 35% during DBS validation is acceptable. Furthermore, variation 
of blood spot volume between 30 – 90 μL had little effect as biases were within 15%.
Despite the minor influence of technical factors, i.e. Hct value and blood spot volume, 
physiological factors are also mentioned in literature to possibly limit the applicability and 
interpretation of DBS analysis (13). Such a factor might be differences between plasma 
concentration and whole blood concentration. This study shows that concentration of 
linezolid is higher in blood than in plasma. This is caused by different binding capacity to 
plasma proteins and blood cells. Furthermore, concentrations of linezolid were higher in 
vDBS than in DBS. This might be caused by differences between the capillary and venous 
blood (13, 25, 30). Nevertheless, the concentration of DBS and vDBS specimens, both 
showed good correlation with plasma concentration. To compensate for these differences, 
we propose conversion factors of 0.83 (1 / 1.20) for DBS and 0.74 (1 / 1.36) for vDBS to 
calculate corresponding plasma values. After the conversion, good agreement between 
AUC0–12h of DBS and plasma was observed. 
A meta-analysis showed that a ≤600 mg linezolid daily dose resulted in lower frequency 
of either adverse event or adverse events necessitating treatment discontinuation than the 
dose of >600 mg daily (8). Among the published data, the lowest rate of adverse effects was 
observed with a dose of 300 mg once daily (17). Nevertheless, lowering the dose clearly 
results in lower exposure to the drug (2, 19). In combination inter-patient variability and 
possible drug-drug interactions, under or overexposure may occur. Therefore, treatment 
with a fixed dose may be questionable (6, 11, 22, 26). The application of TDM for linezolid 
can help avoid under- or overexposure which may occur in 30 to 40% of the cases (20). 
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In this study, all patients had Mycobacterium tuberculosis isolates with a MIC ≤0.5 mg/L 
for linezolid. With a dose of 600 mg (n=5) twice daily, very high AUC0–24h/MIC ratios were 
reached (10), so dose reductions could be implemented to prevent time- and dose-dependent 
toxicity. Furthermore, a high correlation of AUC0–24h/MIC values between conversed DBS 
and plasma (Spearman’s rho = 0.976, n=8) was observed. This suggests that TDM using 
DBS may result in identical interventions compared with conventional plasma sampling. 
Therefore, adaptive dosing of linezolid to prevent potential toxicity and to assure therapeutic 
exposure is feasible using DBS.
The high stability of DBS specimens can minimize the logistic burden of conventional 
sampling in limited-resource areas. With a simple instruction, the DBS samples can be 
performed easily and sent to equipped facilities for analysis by mail (12, 30). This could 
enable the TDM in TB-programs worldwide including resource limited settings where MDR/
XDR-TB epidemic is a growing problem. TDM using DBS for MDR/XDR-TB should be 
especially considered in areas where HIV or malaria co-infections are highly prevalent as 
DBS has been successfully applied to monitor the treatment of such diseases (30).
Since treatment of MDR/XDR-TB is long and complicated by adverse drug reactions, 
TDM of linezolid with DBS could be used to optimize drug exposure during treatment. In 
conclusion, this study presents a novel, validated analysis of linezolid in DBS specimens 
that is suitable for optimization of linezolid treatment of MDR-TB. Advantages include a 
very simple, low biohazard risk sampling method using a finger prick, easy logistics and 
very good stability of DBS specimens.
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Clinical validation of the 
analysis of linezolid and 
clarithromycin in oral fluid 
of multidrug-resistant 
tuberculosis patients
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Linezolid plays an increasingly important role in the treatment of multidrug-resistant 
tuberculosis. However, patients should be carefully monitored due to time- and 
dose-dependent toxicity. Clarithromycin plays a more modest role. Therapeutic drug 
monitoring may contribute to assessing treatment regimens, helping to reduce toxicity 
whilst maintaining adequate drug exposure. Oral fluid sampling could provide a 
welcome alternative in cases where conventional plasma sampling is not possible or 
desirable. The aim of this study was to clinically validate the analysis of linezolid and 
clarithromycin and its metabolite hydroxyclarithromycin in oral fluid of patients with 
multidrug-resistant tuberculosis. 
Serum and oral fluid samples were simultaneously obtained and analyzed using validated 
methods, after extensive cross-validation between the two matrices. Passing-Bablok 
regressions and Bland-Altman analysis showed that oral fluid analysis of linezolid and 
clarithromycin appeared suitable for therapeutic drug monitoring in MDR-TB patients. 
No correction factor is needed for the interpretation of linezolid oral fluid concentration 
with a linezolid serum / oral fluid ratio of 0.97 (95% CI, 0.92 – 1.02). However, the 
clarithromycin serum / oral fluid concentration ratio is 3.07 (95% CI, 2.45 – 3.69). 
Analysis of hydroxyclarithromycin in oral fluid was not possible in this study due to a 
non linear relationship between concentration in serum and oral fluid. In conclusion, 
the analysis of linezolid (no correction factor) and clarithromycin (correction factor 
*3) in oral fluid is applicable for therapeutic drug monitoring in multidrug-resistant 
tuberculosis as an alternative to conventional serum sampling. Easy sampling, using a 
non-invasive technique may facilitate therapeutic drug monitoring in specific patient 
categories.
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INTRODUCTION
Tuberculosis is a mostly curable and preventable infectious disease caused by Mycobacterium 
tuberculosis. Approximately 3.7% of new tuberculosis patients and 20% of previously treated 
patients are infected with multidrug-resistant strains that are resistant to at least rifampicin 
and isoniazid (1). Treatment regimens of multidrug-resistant tuberculosis (MDR-TB) should 
consist of at least four anti-TB drugs for which the bacterium is susceptible (2). 
The oxazolidinone linezolid is effective against M. tuberculosis and is increasingly used as a 
part of treatment regimens in patients with multidrug-resistant or extensively drug-resistant 
tuberculosis (3). However, patients should be carefully monitored due to time- and dose-
dependent serious toxicity of linezolid, such as myelosuppression and polyneuropathy (4). 
Clarithromycin has a less pronounced place in MDR-TB treatment regimens due to serum 
concentrations that usually do not reach minimal inhibitory concentrations (5). Nevertheless, 
sufficiently high local clarithromycin concentrations are reached in epithelial lining fluid 
and alveolar cells (6, 7). Furthermore, occasionally observed lower MICs [unpublished data], 
synergistic activity of clarithromycin against MDR-TB strains (8) and absence of severe 
adverse events (9) contribute to its place in anti-TB therapy. 
Serum concentrations of linezolid have shown large inter-patient variability (10). 
Drug-drug interactions might further contribute to the observed variability in linezolid 
pharmacokinetics. For instance, clarithromycin has been observed to increase linezolid 
serum concentrations significantly (11). Therapeutic drug monitoring could potentially assist 
in identifying MDR-TB patients with too low or too high linezolid exposure. Conventional 
serum sampling is not always possible or desirable due to lack of venous access, complicated 
logistics, or due to the invasive character of the technique. Previously, we developed a dried 
blood spot analysis of linezolid (12) and clarithromycin (unpublished data) as an alternative 
to conventional serum sampling. A clinically validated method could be useful in patients 
that do not accept or tolerate an indwelling venous catheter, or who have difficult venous 
access. We therefore aimed to clinically validate the analysis of linezolid, clarithromycin, 




From December 2011 to October 2012, patients were included from the Tuberculosis Center 
Beatrixoord (Haren, The Netherlands). Patients were ≥18 years old, were diagnosed with 
MDR-TB and provided written informed consent. The study protocol was approved by 
the local Medical Ethical Review Committee, as part of a previously published study. The 
prospective pharmacokinetic study is registered at www.clinicaltrials.org (NCT01521364). 
All patients received oral dosages of linezolid 300 mg twice daily and clarithromycin 250 
mg once daily. Full pharmacokinetic curves were obtained at steady state, after at least 
two weeks of administration of both drugs, using a practically feasible sampling schedule 
which resulted in adequate area under the time-concentration curves (AUC) in previous 
studies in our Center. Blood and oral fluid samples were collected simultaneously before 
and 1, 2, 3, 4, 8, and 12 hours after medication intake. Blood samples were drawn and after 
centrifuging serum samples were stored at -20°C until analysis. Oral fluid samples were 
collected using a small cotton roll on which the patients chewed for approximately two 
minutes (Salivette®, Sarstedt, Leicester, UK). Oral fluid samples were centrifuged and then 
stored at -20°C until analysis.
Linezolid and clarithromycin serum and oral fluid concentrations were analyzed using 
validated high performance liquid chromatography tandem mass-spectrometry methods 
(13, 14). Cross-validation between two matrices was performed by comparing calibration 
samples in pooled serum and non-stimulated, pooled oral fluid from six batches. 
Pharmacokinetic parameters such as, most importantly, AUC were calculated using Kinfit 
software (MWPharm 3.60; Mediware, Groningen, the Netherlands) as described in a previous 
study using non-compartmental, trapezoidal calculations (10). Other pharmacokinetic 
parameters that were calculated using Kinfit software were Cmax, Cmin, apparent clearance 
(CL), elimination rate constant (kel) and half-life (t1/2). Of these parameters, CL, kel, and 
t1/2were determined using log-linear regression of the concentrations in the terminal period. 
The method was clinically validated by comparing the linezolid, clarithromycin and 
hydroxyclarithromycin concentrations in serum samples with the concentration in oral fluid 
using Passing-Bablok regressions and Bland-Altman analysis (Analyze-it Software, Ltd.). The 
Pearson’s correlation and Wilcoxon signed-rank test were applied to other comparisons. 
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RESULTS
Baseline patient demographics are presented in Table 1. Seven patients with MDR-TB, four 
male and three female, were included in the study. The isolates that were obtained from 
all patients displayed resistance for at least rifampicin and isoniazid. The patients had a 
median (interquartile range, IQR) age of 31 (25.5 – 33.5) years and weighed in at median 
(IQR) 71.5 (56.0 – 75.3) kg. Five patients were from Somalia, one from Turkey and one 
from the Netherlands. At the time of sampling, patients were on MDR-TB treatment for a 
mean (range) of 61.4 (33 – 149) days. One patient was HIV positive for which the patient 
was on cART with adequate virological and immunological response (before admission 
CD4 count: 380 cells/mm3).  
Table 1 Baseline demographics (n=7) and results from drug susceptibility testing
Parameter Value
Age – year† 31.0 (25.5 – 33.5)
Male sex – no. (%) 4 (57%)
Bodyweight – kg‡ 71.5 (56.0 – 75.3)
Height – m‡ 1.73 (1.64 – 1.74)







HIV positive – no. (%) 1 (14%)





























† Data presented as mean (range), ‡ Data presented as median (interquartile range), ∫ Drug susceptibility testing 
(DST) was not available for all isolates of the included patients.
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Figure 1 Scatter plot with Passing-Bablok fit of serum and oral fluid concentration in mg/L. 
Identity lines are presented as dashed lines and regression lines as solid lines. A. linezolid (n=49): regression 
line of linezolid serum-oral fluid concentration has a slope of 1.05 (95% CI, 0.94 – 1.11) and intercept of -0.26 
(95% CI, -0.52 – 0.05). B. clarithromycin (n=42): regression line of clarithromycin serum-oral fluid concentration 
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Comparison oral fluid and serum analysis method
Comparison of analysis in two matrices showed that linezolid, clarithromycin, and 
hydroxyclarithromycin had no significant differences of intercept and slope in serum and in 
oral fluid. The calibration curves in oral fluid were analyzed three times with all coefficients 
of variation (CVs) below 15%. All biases in concentration were <12% for linezolid and <8% 
for clarithromycin and its metabolite. 
Passing-Bablok regression (n=49) of linezolid concentration in serum and oral fluid showed 
a proportional bias of 1.05 (95% confidence interval [CI], 0.94 – 1.11) and a constant bias 
of -0.26 (95% CI, -0.52 – 0.05) (Figure 1A). For clarithromycin, the Passing-Bablok scatter 
plot (n=42) showed a proportional bias of 2.67 (95% CI, 1.95 – 3.75) and a constant bias of 
-0.06 (95% CI, -0.18 – 0.21) (Figure 1B). There were 7 missing clarithromycin and 8 missing 
hydroxyclarithromycin values due to concentrations below limit of quantitation of the applied 
method of 0.2 mg/L. A linear relationship was detected using Cusum linearity test (p>0.1) 
between oral fluid and serum concentrations of both linezolid and clarithromycin. However, 
the Cusum linearity test detected a non-linear relationship (0.05<p<0.1) between serum and 
oral fluid hydroxyclarithromycin concentration, with Passing-Bablok showing a constant 
bias of 0.02 (95% CI, -0.20 – 0.24) and proportional bias of 2.00 (95% CI, 1.14 – 3.00). 
Bland-Altman assessment showed good agreement between analyses of linezolid and 
clarithromycin in serum and oral fluid; 4.1% (2/49) of observations falling outside 95% limits 
of agreement for linezolid, and 7.1% (3/42) for clarithromycin; see Figure 2. The observed bias 
for linezolid (n=49) was 0.97 with 95% confidence intervals below and above one (95% CI, 
0.92 – 1.02) (Figure 2A). For clarithromycin, the observed bias was 3.07 (95% CI, 2.45 – 3.69) 
(Figure 2B). Pearson’s test revealed that the analyses of linezolid and clarithromycin in serum 
and in oral fluid were correlated with r = 0.95 (p<0.01) and r = 0.80 (p<0.01) respectively. 
Pharmacokinetic and pharmacodynamic evaluation
Pharmacokinetic parameters of linezolid and clarithromycin in serum and oral fluid are 
displayed in Table 2. Paired sample Wilcoxon Signed rank test showed no statistically significant 
difference between medians of all pharmacokinetic parameters in serum and oral fluid, except 
for linezolid kel and t1/2 (p=0.018). However, the clinical significance of this observed difference 
is little since the AUC is the most important pharmacokinetic parameter for therapeutic drug 
monitoring of linezolid and clarithromycin in multidrug-resistant tuberculosis patients.
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Figure 2 Bland-Altman plot of serum/oral fluid concentration ratio compared to average serum and 
oral fluid concentration. 
The line representing the bias is presented as a solid line and the 95% limits of agreement as dashed lines. A. 
linezolid (n=49): bias is 0.97 (95% CI, 0.92 – 1.02), the lower and upper 95% limits of agreement are respectively 0.64 
(95% CI, 0.56 – 0.73) and 1.30 (95% CI, 1.22 – 1.38). B. clarithromycin (n=42): bias is 3.07 (95% CI, 2.45 – 3.69), the 
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Pharmacokinetic and pharmacodynamic parameters of linezolid from all patients are 
displayed in Table 3. Isolates from all patients were susceptible for linezolid with a MIC of 
median 0.25 mg/L. Patients had a linezolid AUC0–12h of median (IQR) 63.9 (47.8 – 83.8) 
mg*h/L in serum and 62.1 (50.5 – 59.2) mg*h/L in oral fluid. All patients had an AUC0–24/
MIC ratio of >100 in both serum and oral fluid. For patient 2, AUC0–24h/MIC ratio reached 
approximately 1000. Median (IQR) linezolid AUC0–24h/MIC ratio in serum was 277 (260 
– 517) mg*h/L and in oral fluid 288 (262 – 594) mg*h/L. Paired sample Wilcoxon Signed 
rank test showed no statistically significant difference between AUC0–12h or AUC0–24h/MIC 
ratio in serum or oral fluid (p=0.296).
Table 2 Pharmacokinetic parameters of linezolid and clarithromycin in serum and in oral fluid (n=7)
Serum Oral fluid p-value†
Linezolid






63.9 [47.8 – 83.8]
10.9 [6.8 – 11.5]
2.2 [1.5 – 4.2]
3.5 [2.4 – 5.9]
0.14 [0.10 – 0.17]
4.9 [4.2 – 7.9]
62.1 [50.5 – 89.2]
10.1 [8.2 – 10.7]
2.3 [1.7 – 4.2]
3.6 [2.2 – 5.0]
0.13 [0.08 – 0.16]













t1/2 (h)  
8.2 [6.2 – 12.2]
1.7 [1.3 – 2.7]
0.01 [0.01 – 0.04]
28.5 [19.3 – 39.1]
0.21 [0.19 – 0.23]
3.3 [3.1 – 3.6]
10.7 [9.4 – 12.1]
2.8 [2.0 – 3.4]
0.03 [0.03 – 0.06]
62.2 [52.8 – 81.0]
0.64 [0.49 – 1.06]







Data are presented as median [interquartile range]. † p-values comparing pharmacokinetic parameters between 
serum and oral fluid. ¥ Statistical significant difference between median of the parameter in serum and in oral fluid.
Table 3 Pharmacokinetic and pharmacodynamic parameters of linezolid
AUC0–12h (mg*h/L) AUC0–24h/MIC ratio
Patient MIC (mg/L) Serum Oral fluid Serum Oral fluid
1 0.25 34.6 42.1 277 337
2 0.25 120.1 126.4 961 1011
3 0.5 61.0 62.1 244 248
4 0.5 63.9 58.8 256 235
5 0.25 33.0 34.5 264 276
6 0.5 76.6 72.0 306 288
7 0.25 90.9 106.3 727 850
Total¥ 63.9 [47.8 – 83.8] 62.1 [50.5 – 89.2]± 277 [260 – 517] 288 [262 – 594]±
¥ Median [interquartile range], ± no statistically significant difference between serum and oral fluid (p=0.296).
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Patients had a clarithromycin AUC0–12h of median (IQR) 8.2 (6.2 – 12.2) mg*h/L in serum 
and 3.5 (3.1 – 4.0) mg*h/L in oral fluid. One patient was inadvertently administered 500 mg, 
instead of 250 mg clarithromycin at the day of sampling. The samples obtained from this 
patient were included in the evaluation. The clarithromycin AUC0–12h after administration of 
500 mg clarithromycin was 29.1 mg*h/L in serum and 15.7 mg*h/L in oral fluid, well above 
the AUCs of the patients receiving 250mg clarithromycin. After applying the correction 
factor of 3.07 as determined using the Bland-Altman assessment, patients had an adjusted 
clarithromycin AUC0–12h of median (IQR) 10.7 (9.4 – 12.1) mg*h/L in oral fluid. Paired 
sample Wilcoxon Signed rank test showed no statistically significant difference, but did 
show a trend towards difference between clarithromycin AUC0–12h in serum and in oral fluid 
after applying a correction factor of 3.07 (p=0.091).
DISCUSSION
The clinical validation performed in this study showed that oral fluid analysis of linezolid 
and clarithromycin are suitable for TDM in MDR-TB patients. No correction factor is 
needed for the interpretation of linezolid oral fluid concentration. However, clarithromycin 
oral fluid concentration should be corrected by multiplying by three to enable comparison 
to clarithromycin serum levels. After applying a correction factor of three in case of 
clarithromycin or no correction factor in case of linezolid, the pharmacokinetic parameter 
AUC0–12h as calculated from oral fluid samples are applicable for TDM and could assist in 
identifying patients with too high or too low exposure.
Unfortunately, analysis of hydroxyclarithromycin in oral fluid is not possible due 
to a non-linear relation with concentrations in serum. Nevertheless, the analysis of 
hydroxyclarithromycin shows good linearity over a range of 0.2 – 10 mg/L in both serum 
and oral fluid. A possible explanation for the observed non-linear relation between analysis 
of hydroxyclarithromycin in serum and in oral fluid might be the low hydroxyclarithromycin 
concentrations that were observed. In this concentration range, around the limit of 
quantitation, CVs are relatively high although within acceptable limits of <20%. This 
could explain a non-linear relationship between analysis of hydroxyclarithromycin in 
serum and oral fluid in this low concentration range. Possibly, analysis of a larger cohort 
or higher clarithromycin doses with corresponding higher hydroxyclarithromycin 
concentrations would reveal a linear relationship. Furthermore, this could confirm that 
there is no significant difference between clarithromycin exposure in serum and oral fluid 
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(after correction), despite a trend towards statistical significance that was observed in 
our cohort. 
The kel and t1/2 of linezolid showed a statistical significant difference of medians in oral 
fluid compared to serum. The parameters kel and t1/2 are calculated from concentrations 
obtained in the terminal period, i.e. in the last 3 – 4 samples in a relatively small cohort. The 
relevance should be confirmed in a larger cohort or using curves with more samples in the 
terminal period. In clinical practice, not the paramater kel or t1/2, but the pharmacokinetic/
pharmacodynamic parameter, AUC/MIC ratio of linezolid, is used for therapeutic drug 
monitoring (10–11).
To date, there has been no comparison in the literature of the analysis of clarithromycin and 
linezolid between serum and oral fluid in patients with MDR-TB. However, there are several 
studies describing pharmacokinetics of clarithromycin and hydroxyclarithromycin in saliva 
(15, 16), but none describing pharmacokinetics of linezolid in oral fluid. Clarithromycin 
administered to 12 healthy volunteers in a dose of 500 mg twice daily, resulted in an AUC0–12h 
of 18.0±5.0 mg*h/L (15). We observed a similar AUC0–12h of 15.7 mg*h/L in the one patient 
that was administered 500 mg clarithromycin. Saliva-serum ratios of around two were 
reported, lower than the ratio of three observed in our study. However, no data were presented 
comparing results from the analysis of clarithromycin in serum and oral fluid, since the 
study aimed to describe kinetics, not to clinically validate the analysis in oral fluid (15). 
Another study, described pharmacokinetics of clarithromycin in saliva and serum after a 
single dose of 500 mg clarithromycin (16). However, the aim was to describe the penetration 
of clarithromycin into saliva, not to clinically validate the analysis of clarithromycin in 
saliva. The Summary of Product Characteristics (SmPC) of linezolid describes a linezolid 
oral fluid – plasma concentration ratio of 1.2, comparable with the bias of 0.97 that was 
observed in the Bland-Altman assessment (17). Our current study describes the method 
of analysis of clarithromycin and linezolid, cross-validation between serum and oral fluid, 
and most importantly clinical validation in MDR-TB patients. No statistically significant 
differences were found between AUC0–12h or AUC0–24h/MIC ratio of serum and oral fluid.
TDM could potentially assist in identifying MDR-TB patients with too low or too high 
linezolid exposure. Analysis of anti-TB drugs in oral fluid may be advantageous in patients 
without readily accessible venous access, hindering blood sampling. Furthermore, the 
non-invasive sampling could be suitable in children with MDR-TB, in whom indwelling 
intravenous catheters are no option, and in whom no study data on pharmacokinetics 
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are available to guide therapy. Oral fluid sampling in pediatric patients is preferred over 
conventional serum sampling by a majority of children and their parents (18). Oral fluid 
sampling might even reduce costs due to the higher level of trained personnel needed for 
blood sampling and since less time is needed (18). Oral fluid sampling might even take 
place at home. No children were included in this study. A clinical validation of oral fluid 
sampling in pediatric MDR-TB patients is urgently needed. Furthermore, the applicability 
of saliva and/or other collection devices than the Salivette® (Sarstedt, Leicester, UK) for 
pharmacokinetic analysis and therapeutic drug monitoring in MDR-TB patients should 
be clinically validated. 
In conclusion, the clinically validated analysis of clarithromycin and linezolid in oral 
fluid could provide a helpful alternative if conventional blood sampling is not possible or 
desirable. Using a correction factor of 3.07 for clarithromycin oral fluid concentrations and 
no correction factor for linezolid makes the oral fluid sampling readily applicable in clinical 
practice and allows for easy interpretation.
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We read with great interest the article “Daily 300 mg dose of linezolid for multidrug-resistant 
and extensively drug-resistant tuberculosis: updated analysis of 51 patients” by Koh et al. 
in which they describe retrospectively examined records of one of the largest case series 
of patients treated with linezolid for multidrug-resistant and extensively drug-resistant 
tuberculosis (MDR/XDR-TB) (1). They describe long-term outcomes of 51 patients, whereas 
the previous study only described the short-term outcomes of 17 patients (2). Their objective 
was to evaluate efficacy, tolerability and adverse events of a 300 mg daily dose of linezolid in 
the treatment of MDR/XDR-TB. Based on a favorable treatment outcome of 78%, compared 
to 60 – 100% in literature albeit in smaller case series, they suggest that linezolid is effective 
against intractable MDR/XDR-TB at a daily dose of 300 mg. In our opinion it is difficult to 
draw this conclusion from the presented data. The lack of a control group makes it impossible 
to attribute favorable outcome in patients to a single drug such as linezolid as it is only a 
part of an expanded treatment regimen. Favorable treatment outcomes could very well be 
caused by other drugs of the expanded regimen the patients received.
To implicate efficacy of their linezolid containing regimen, Koh et al. make assumptions 
on the minimum inhibitory concentration (MIC) for linezolid for their population and 
the linearity of linezolid pharmacokinetics. They assume their patients are infected with 
Mycobacterium tuberculosis with a MIC of 0.25 mg/L for linezolid. Koh et al. base this on a 
recent study that described wild-type MIC distributions for linezolid and 6 other second-line 
drugs in 78 consecutive susceptible clinical isolates (3). Although most isolates had a MIC 
of 0.25 mg/L for linezolid, the wild-type MIC distribution ranged from 0.125 to 0.5 mg/L 
and an epidemiological cut-off value of 0.5 mg/L was suggested (3). The fact that we found 
the MIC to be 0.5 mg/L in eight isolates, 1 mg/L in eight isolates and even greater than 1 
mg/L in one isolate in a previous study in 23 isolates (4), may raise some doubt about the 
assumption that all clinical isolates have a MIC value of 0.25 mg/L.
Koh et al. assume the pharmacokinetics of linezolid to be linear. Unfortunately, the pharma-
cokinetics of linezolid are not linear in TB patients as we have demonstrated in a previous 
study (5). Besides, substantial intra- and interpatient variability of linezolid in TB patients 
can be observed. We found the AUC0–12h of 300 mg twice daily to be 56 mg*h/L but with an 
interquartile range (IQR) of 38.5 – 64.2 mg*h/L. 
We agree with Koh et al. that for linezolid, the in vitro MIC to area under the free concentration 
time curve (fAUC0–24h/MIC ratio) is often used as a predictive model for efficacy (5). Based 
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on the data of Schon et al. they suggest that a daily dose of 600 mg linezolid would lead to 
an fAUC of 56 mg*h/L, resulting in an fAUC/MIC ratio of approximately 100 for a wild-
type MICECOFF of 0.5 mg/L and of approximately 200 for the more common MIC of 0.25 
mg/L. In both cases, the pharmacodynamic target of fAUC/MIC >100 is met. However, 
during the study period, DST as well as plasma concentration monitoring (therapeutic drug 
monitoring; TDM) were not performed for linezolid. This is very unfortunate since linezolid 
is the drug of interest in their study. As a consequence, it is unknown if the pharmacokinetic/
pharmacodynamic target of fAUC0–24h/MIC >100 is met. Therefore, in our opinion it is not 
correct to assume linezolid to be effective without DST and TDM for linezolid or without 
a control group. 
Finally, we also do not support the conclusion that Koh et al. draw from the presented data 
being that a daily dose of 300 mg linezolid may be associated with fewer neuropathic side 
effects than a daily dose of 600 or 1200 mg linezolid. It was necessary to cease linezolid 
therapy in 14 patients (27%) due to neurotoxicity, which is within the range of the highly 
variable incidence of neurotoxicity of 4 – 89% at daily doses of 600 or 1200 mg as presented 
by Koh et al. in an overview of literature (1). Despite the daily dose of linezolid being low, the 
duration of administration of linezolid is long with a median of 278 days. This concurs with 
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We read with interest the article “Linezolid, an effective and cheap drug in MDR-TB treatment 
failure patients in India” by Singla et al. (1), which described the treatment outcome of 29 
(pre-)extensively drug-resistant (XDR) tuberculosis (TB) patients from Delhi, India. All 
patients received linezolid as part of their anti-TB regimen. The high percentage favorable 
treatment outcome in the study led Singla et al. (1) to conclude that “linezolid could have 
played a key role”. However, in our opinion, conclusions on the role of a single agent, such as 
linezolid, are difficult to draw from a series of cases without controls, in which every patient 
received linezolid in addition to an injectable and a fluoroquinolone. Indeed, the important 
role of later-generation fluoroquinolones is addressed, but neither drug susceptibility testing 
(DST) nor drug concentration monitoring for linezolid, is performed. Therefore linezolid 
treatment itself could even be sub-therapeutic (2). 
Singla et al. (1) conclude that “an aggressive, comprehensive management program using 
linezolid along with other drugs can favorably treat significant number of patients”. Although 
we concur with this statement, a closer look at the management program applied in this 
study suggests that the program might not be too aggressive or comprehensive. For instance, 
no Directly Observed Therapy (DOT) is applied, nor did the patients receive nutritional 
or good psychosocial support. Compliance was only assessed indirectly by checking empty 
blisters. Since non-compliance could lead to treatment failure and increase of resistance 
against the few drugs that are still effective in (pre-)XDR-TB treatment, we would strongly 
advise to abandon DOT only in exceptional cases where compliance is highly probable 
(3). Therapeutic drug monitoring (TDM) can be recommended to ensure adequate drug 
exposure during treatment. In rural areas dried blood spot analysis may enable TDM by 
offering an affordable tool for drug concentration measurement in a centralized laboratory 
using stable easy-to-obtain samples (4).
The very low incidence of major adverse events (AEs) of 10.3% as reported by Singla et 
al. (1) is in contrast with findings in literature where 41.2% of 85 MDR/XDR-TB patients 
treated with linezolid experienced major AEs (5). The authors provided no explanation for 
low AE incidence found in their study. Perhaps the fact that temporary discontinuation of 
linezolid is scored as a minor adverse event along with the absence of DOT resulted into 
a lower score of AEs in the study of Singla et al. Unfortunately, the authors provided no 
information on the manufacturer of the linezolid. Only the low cost of linezolid of less than 
$1 per tablet is mentioned, compared to approximately $80 per tablet in The Netherlands. It 
is well established that counterfeit drugs pose a great threat and counterfeit drugs sometimes 
contain little to none of the claimed drug (6). Although there is no evidence that the 
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administered drugs in this study are counterfeit, it can also not be excluded based on the 
information as provided by Singla et al. (1). This, combined with the absence of DOT and 
TDM, could very well be a reason for the low incidence of major adverse events as observed 
in the study by Singla et al. (1). 
In our opinion, only a randomized controlled trial of linezolid vs. placebo as add on to an 
adequate background regimen using DST and TDM will provide comprehensive results 
on efficacy and safety of linezolid as potential drug for (pre-)XDR-TB treatment regimen. 
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Linezolid, known for its toxicity, is a promising drug for the treatment of multidrug-
resistant tuberculosis (MDR-TB). Dose reduction has been studied attempting to limit 
toxicity, but concerns exist that dose reduction could result in inadequate linezolid 
exposure. 
Methods
We aimed to investigate linezolid safety and tolerability in relation to linezolid exposure 
in a retrospective study at two tuberculosis centers in the Netherlands and Italy.
Results
A total of 58 MDR-TB patients was included. No correlation was observed between 
microscopy or culture conversion and the area under the time concentration curve / 
minimal inhibitory concentration ratio. Patients that experienced peripheral neuropathy 
had received a higher median cumulative dose or received linezolid for a longer median 
period of time, compared to patients without peripheral neuropathy.
Conclusions
Treatment regimens containing linezolid were effective and well tolerated. Peripheral 
neuropathy seemed to be mediated by cumulative linezolid dose and number of days 
of exposure to linezolid.
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INTRODUCTION
The prevalence and incidence of multidrug-resistant tuberculosis (MDR-TB) cases, caused 
by M. tuberculosis strains resistant to at least rifampicin and isoniazid, is increasing in high 
tuberculosis burden countries and is expected to keep rising in the next three years (1). The 
World Health Organization (WHO) recommends to prescribe an MDR-TB therapeutic 
regimen consisting of at least four in vitro active anti-tuberculosis drugs (2-6). 
Linezolid is a promising anti-tuberculosis drug for the treatment of MDR-TB (7, 8) and may 
be added to anti-tuberculosis regimens requiring a Group 5 drug. Recently, two systematic 
reviews and meta-analyses pointed out its excellent efficacy (9, 10). However, linezolid 
toxicity may outweigh its potential benefits. Indeed, adverse events were notified in almost 
60% of the treated cases, with a high incidence of severe events such as anemia, peripheral 
neuropathy, optic neuritis, and thrombocytopenia. Dose reduction has been studied in an 
attempt to limit the toxicity. Decreased doses were associated with significantly lowered 
toxicity (11). Nevertheless, concerns might exist about the loss of efficacy or the emergence 
of acquired resistance, since dose reduction might result in inadequate linezolid exposure. 
Therapeutic drug monitoring (TDM) has increasingly been recognized as an asset in the 
field of tuberculosis treatment several years ago (12-14). TDM may be adjunct in assessing 
individual linezolid exposure, especially since linezolid pharmacokinetics show a large 
inter-individual variability (15) and important drug-drug interactions have been observed 
(16, 17). Defining predictors for inter- or intra-patient variability might help in identifying 
patients at risk for deviating exposure. Preliminary data show that area under the time 
concentration curve (AUC)/minimal inhibitory concentration (MIC) ratio may be the 
pharmacokinetic / pharmacodynamic (PK/PD) target for Mycobacterium tuberculosis in 
order to adjust dosages based on TDM results (18). Furthermore, the evidence on correlation 
between reduced linezolid exposure and lowered toxicity is limited. Therefore, we aimed to 
retrospectively investigate linezolid safety and tolerability in relation to linezolid exposure.
METHODS
Study setting and participants
A retrospective study was conducted at two tuberculosis reference hospitals: the Tuberculosis 
Center Beatrixoord (University Medical Center Groningen, Haren, The Netherlands) and 
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the Tuberculosis Reference Center for MDR-TB and HIV-TB E. Morelli Hospital (Sondalo, 
Italy). We selected multi- and extensively-drug resistant tuberculosis (XDR-TB) patients 
that received linezolid as a part of their treatment regimen from 2010 – 2012 in Sondalo 
and from 2007 – 2012 in Haren (4). Patients had been diagnosed by means of standard 
microbiological culture tests. Patients younger than 18 years, patients lacking data due 
to recent admission to either reference hospital, and patients of whom no TDM data was 
available were excluded from the study.
Drug susceptibility testing and sample analysis
Data from drug susceptibility testing (DST) and pharmacokinetic analyses was collected 
retrospectively. DST was performed by the National Mycobacteria Reference Laboratory 
(National Institute for Public Health and the Environment, Bilthoven, the Netherlands) for 
patients in Haren or by the WHO Supranational Reference Laboratory (Milan, Italy) for 
patients in Sondalo. Exact MICs were determined for linezolid (19). 
In Haren, linezolid samples were analyzed using a liquid chromatography tandem mass-
spectrometric method (20). Samples obtained from patients in Sondalo were analyzed at 
the Luigi Sacco hospital (Milan, Italy) using a high performance liquid chromatography 
method (21). 
Data collection
Anonymous retrospective data were retrieved by two researchers. The Institutional Review 
Board of the University Medical Center Groningen waived the requirement for research 
subjects to give informed consent (METc 2013/492). Date of admission, gender, country 
of birth, WHO Region of birth were collected. We calculated body mass index (kg/m2) at 
time of admission. In case of diabetes mellitus type II co-morbidity and HIV co-infection, 
clinical information including treatment was recorded. Besides these variables, detailed 
information on the DST and the location of infection (extra-pulmonary and/or pulmonary, 
including radiographic findings) based on findings of the attending physician were noted. 
Treatment information consisted of treatment outcome, duration of treatment in months, 
and cumulative composition of the administered treatment regimen. 
Pharmacokinetic data consisted of AUC0–12/24, the highest and the lowest measured 
concentration (Cmax, and Cmin, respectively). AUCs were calculated using trapezoidal, non-
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compartmental, no lag-time calculations. Date of sampling, number of days after starting 
linezolid, linezolid dose at time of sampling, co-medication during linezolid sampling were 
noted in regard to linezolid pharmacokinetics. In Haren, dose reduction was considered if 
the calculated AUC0–24h/MIC ratio exceeds 100 (12, 15, 18). After dose reduction, linezolid 
TDM was repeated at steady state. If full pharmacokinetic curves were available for different 
doses, the curve of the dose that was administered during the longest period of time was 
used for the analysis. 
Treatment outcome was assessed besides interim status through collecting data on days 
to sputum smear (SS) or culture conversion, i.e. time in number of days between the first 
positive and first of two consecutive negative samples. To assess safety and tolerability, 
adverse events, e.g. leucopenia, peripheral neuropathy, and optic neuritis, were collected 
from the hospital records or laboratory data using local reference values. Patients in Haren, 
as opposed to patients in Sondalo, received prophylactic erythropoietine. Information on 
hemoglobin (Hb in mmol/L) was recorded at respectively day 0, 30, 60, 90, 120, and 150 
after the first dose of linezolid, regardless of treatment duration of linezolid. 
Statistical analysis
Statistical evaluation was performed using SPSS 20 (SPSS, Chicago, IL, USA). Baseline data 
of patients from both hospitals were compared using Student’s t test was performed for 
parameters that were normally distributed. Levene’s test for equality of variances was used to 
determine whether equal variances may or may not be assumed. Independent sample Mann-
Whitney U tests were used for parameters that were not normally distributed. Frequency 
distributions were compared using Pearson Chi-square test for categorical parameters; in 
case the necessary assumptions were not met, Fisher’s Exact test was used. 
RESULTS
In both centers, a combined number of 58 MDR/XDR-TB patients that had received 
linezolid and underwent TDM were included. Figure 1 depicts a schematic summary of 
the selection process of the patients at both centers. From 54 enrolled patients in Sondalo, 
36 were excluded: 6 due to insufficient data due to recent admission and 27 due to absence 
of pharmacokinetic data of linezolid. Demographic and clinical characteristics of the 
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setting and different policy concerning migrants of both countries and, thus, the influx of 
migrants, the WHO Region of origin of patients differed for both hospitals. In Sondalo, 
most patients were from Europe (n=14, 77.8%), whereas in Haren, most patients were from 
Europe (n=13, 32.5%) and the Eastern Mediterranean (n=12, 30.0%). In one case from 
Sondalo, radiology revealed extra-pulmonary tuberculosis. The referral center in Sondalo 
mostly received complicated infectious cases and does not admit extra-pulmonary TB cases 
for a long period of time.
Table 1 Socio-demographic and clinical characteristics in 58 patients with multidrug-resistant 
tuberculosis treated at Sondalo (Italy) and Haren (the Netherlands)
All patients (n=58) Sondalo (n=18) Haren (n=40) p-value


















































Weight (kg; median, IQR) 62.2 (55.6 – 69.9) 64.0 (58.0 – 70.0) 60.9 (55.5 – 69.4) 0.550
BMI (kg/m2; median, IQR) 21.2 (19.3 – 23.7) 21.4 (18.4 – 23.2) 21.0 (19.5 – 23.8) 0.455
Radiology findings
Cavitary lesions
Bilateral pulmonary involvement 
with cavitary lesions




















IQR: interquartile range; HIV: human immunodeficiency virus; ART: antiretroviral therapy; WHO: World Health 
Organization; BMI: body mass index; *Fisher’s Exact Test. 
The t-test for equality of means between Sondalo and Haren was used for normally distributed parameters, i.e. 
age, weight and BMI. Normality was confirmed using Shapiro-Wilk test. Frequency distribution of sex between 
patients in Sondalo and Haren is calculated using the Pearson Chi-square test.
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Table 2 Treatment regimen composition in 58 patients with multidrug-resistant tuberculosis treated 
at Sondalo (Italy) and Haren (the Netherlands)
All patients (n=58) Sondalo (n=18) Haren (n=40) p-value
Drug susceptibility of Mtb 
(Number of drugs; median, IQR)
Susceptible 6.0 (4.0 – 8.0) 7.0 (5.8 – 8.3) 5.0 (4.0 – 7.8) 0.071
Resistant 8.0 (7.0 –10.0) 8.5 (6.8 – 9.3) 8.0 (7.0 – 10.0) 0.534
Drugs used:
Number of anti-TB drugs 
(median, IQR) 
6.0 (5.0 – 7.0) 7.0 (6.0 – 7.3) 5.0 (4.0 – 6.0) 0.004
Group 1:
Ethambutol 26 (45%) 5 (28%) 21 (52%) 0.080
Pyrazinamide 14 (24%) 3 (17%) 11 (28%) 0.513*
Rifabutin  4 (7%) 0 (0%) 4 (10%) 0.300*
Group 2:
Aminoglycosides 52 (90%) 16 (89%) 36 (90%) 1.000*
Kanamycin  7 (12%) 0 (0%) 7 (18%) 0.087*
Amikacin 45 (78%) 16 (89%) 29 (73%) 0.307*
Capreomycin 1 (2%) 0 (0%) 1 (3%) 1.000*
Group 3:
Moxifloxacin 55 (95%) 17 (94%) 38 (95%) 1.000*
Levofloxacin 1 (2%) 0 (0%) 1 (3%) 1.000*
Group 4:
Ethionamide † 18 (31%) 4 (22%) 14 (35%) 0.330
Cycloserine 19 (33%) 17 (94%) 2 (5%) <0.001
PAS  10 (17%) 9 (50%) 1 (3%) <0.001*
Group 5:
Clofazimine 30 (52%) 8 (44%) 22 (55%) 0.457
Amoxicillin-clavulanic acid 17 (29%) 15 (83%) 2 (5%) <0.001
Thioacetazon 1 (2%) 0 (0%) 1 (3%) 1.000*
Clarithromycin 12 (21%) 0 (0%) 12 (30%) 0.011*
Other drugs
Meropenem 13 (22%) 13 (72%) 0 (0%) <0.001*
Cotrimoxazole 8 (14%) 0 (0%) 8 (20%) 0.048*
Mtb: Mycobacterium tuberculosis; IQR: interquartile range; TB: tuberculosis; † consists of data of both 
protionamide and ethionamide; *Fisher’s Exact Test. 
To test whether the drug susceptibility and number of drugs used at any time during treatment was the same 
in both hospitals the Independent Sample Mann Whitney U test was used. Frequency distribution of number 
drugs between Sondalo and Haren are calculated using the Pearson Chi-square test. When assumptions for 
the Pearson Chi-square test were not met, 2-sided Fisher’s Exact Test was used.  
DST revealed susceptibility to a median (interquartile range, IQR) number of 6.0 (4.0 – 8.0) 
drugs and resistance to 8.0 (7.0 – 10.0) drugs. Treatment regimens of 58 MDR/XDR-TB 
patients are displayed in Table 2. The median (IQR) number of different active drugs 
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administered at any one time point during treatment was 6.0 (5.0 – 7.0). Patients in Sondalo 
received more different drugs compared to Haren (p=0.004), with a median (IQR) of 7.0 
(6.0 – 7.3) drugs in Sondalo and 5.0 (4.0 – 6.0) drugs in Haren. DST revealed a median 
(IQR) MIC for linezolid of 0.5 (0.25 – 0.5) mg/L.
There were some notable differences in treatment regimens between the two centers: 
in Sondalo, patients received an aggressive treatment regimen including moxifloxacin, 
amikacin, linezolid, meropenem and/or amoxicillin/clavulanic acid if patients were very ill 
or DST revealed lack of active oral options. Two patients in Sondalo received bedaquiline 
as a part of a compassionate use program (22). In Sondalo, meropenem was administered 
to 13 (72.2%) patients, in contrast to none of the patients in Haren (p<0.001). Furthermore, 
WHO group 4 drug cycloserine was administered to almost all patients in Sondalo (94%), 
but was rarely (5%) administered to patients in Haren (p<0.001) due to differences in the 
availability of tuberculosis medication (23).
In Haren, identification of MDR-TB isolates by rapid molecular tests was followed by 
empirical treatment including kanamycin IV in doses adjusted using TDM, resulting in 
relatively low dosage of around 7 mg/kg. Usually, after 6 months treatment was switched 
to oral clofazimine; moxifloxacin (24); linezolid (12); and clarithromycin (12, 25). 
Cotrimoxazole was administered to 8 (20.0%) of the included patients in Haren based on 
DST (26, 27), compared to none (0.0%) in Sondalo (p=0.048). 
Efficacy
Of the 58 included patients, 29 (50.0%) patients were considered cured and 4 (6.9%) patients 
completed their treatment; 25 (43.1%) patients were still on treatment. All but one patient 
(98.3%), including those still on treatment, were culture and smear-microscopy negative at 
the time of data collection. Of the individuals with positive sputum smear and cultures at the 
beginning of the tuberculosis treatment, median (IQR) time to conversion was 47 (21 – 68) 
days for sputum smear and 47 (22 – 61) days for culture. There was no significant difference 
between time to microscopy or culture conversion between the two participating hospitals 
(p=0.062 and p=0.781, respectively). There was a low correlation between AUC/MIC ratio and 
parameters predictive of treatment outcome, i.e. days to sputum smear-microscopy (r2linear = 
0.364) or to culture conversion (r2linear = 0.169). The same lack of correlation applies for linezolid 
Cmin, Cmax, dose in mg/kg/day and days to culture or microscopy conversion with no linear r2linear 
higher than 0.138. When cases are categorized based AUC/MIC ratio using 100 as a cutoff, 
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Table 3 Hemoglobin (mmol/L) at day 0, day 30, day 60, and day 90 after the first administration of 
linezolid
Erythropoietin
Yes n No n p-value
Day 0 8.0 (7.1 – 8.6) 30 8.3 (7.1 – 9.5) 27 0.452
Day 30 7.8 (7.0 – 8.4) 29 7.9 (6.8 – 8.7) 27 0.863
Day 60 7.9 (7.1 – 8.9) 23 7.8 (6.9 – 8.8) 22 0.946
Day 90 7.5 (6.6 – 8.9) 15 7.7 (6.6 – 8.3) 15 0.967
Data presented as median (interquartile range) of hemoglobin (mmol/L). Erythropoietin was administered in a 
dose of 2000 IE two times a week. Data of day 120, day 150 and day 180 are not presented due to limited number 
of data. Mann Whitney U test (Wilcoxon rank sum) was used to test whether the distribution of hemoglobin 
concentrations were the same with or without erythropoietin at every time point.
which is a commonly used target based on other microorganisms, the distribution of days 
to microscopy (p=0.984) or culture conversion (p=0.241) was the same across both groups.
Adverse events
Linezolid and erythropoietin were co-administered for a median (IQR) of 88 (62 – 142) days. 
Baseline hemoglobin levels (median; IQR) of patients that did (8.0; 7.1 – 8.6 mmol/L) or 
did not receive erythropoietin at the start of linezolid therapy (8.3; 7.1 – 9.5 mmol/L) were 
similar (p=0.452) (Table 3). Furthermore, at all other time points up to 90 days there was no 
difference between hemoglobin of patients that did or did not receive erythropoietin, nor 
was there a difference in hemoglobin over time per patient between the two groups (Table 
3). There were too few patients with data on days 120 – 180 available to allow for adequate 
interpretation of these data. None of the patients in Haren received blood transfusions.
Table 4 describes the cumulative dose, days of exposure to linezolid, AUC0–24h, and Cmin 
of linezolid for patients with and without linezolid-related adverse events. Peripheral 
neuropathy was observed in 11 (19%) of the patients. The distribution of linezolid cumulative 
dosage in mg/kg (p=0.041) and days of exposure to linezolid (p=0.003) differed across 
patient groups with and without peripheral neuropathy. The cumulative linezolid dose 
was significantly higher in patients with peripheral neuropathy. They had a median (IQR) 
of 1,829 (1,414 – 2,255) mg/kg versus those without neuropathy that had a median (IQR) 
of 1,221 (742 – 1,994) mg/kg (p=0.041). A similar observation was made for the number 
of linezolid treatment days: median (IQR) 159 (120 – 196) days in patients with and 97 
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(66 – 147) days in patients without peripheral neuropathy (p=0.003). Nine percent (5/45; 8 
missing data) had leucopenia: no difference was identified in cumulative linezolid dose nor 
in days of exposure to linezolid (p=0.194 and 0.065, respectively). One patient had optical 
neuropathy.
The distribution of AUC0–24h was the same for patients with and without anemia (p=0.299), 
leucopenia (p=0.314), optical neuritis (p=0.612), and peripheral neuropathy (p=0.261). 
The distribution of Cmin of linezolid was the same across the categories anemia, leucopenia, 
optical neuritis, and peripheral neuropathy. Only two of 48 patients (2/48; 10 missing data) 
had diabetes type 2, rendering combined analysis of adverse events and diabetes impossible. 
Pharmacokinetic parameters
Patients had a mean (standard deviation, SD) Cmin of 3.1 (2.2) mg/L, a Cmax of 9.4 (3.1) mg/L, 
and an AUC0–12h of 70.1 (31.9) mg*h/L with all different dosages combined. Pharmacokinetic 
parameters for the different dose categories are displayed in Table 5. Due to the small number 
of patients receiving 400 mg, 900 mg, or 1,200 mg linezolid respectively, comparison of 
pharmacokinetic parameters of these groups was not possible.
There was no correlation between linezolid dose in mg/kg and AUC0–12h with or without 
excluding P-glycoprotein modulators (r2linear were 0.012 and 0.001, respectively). Patients 
that concomitantly received P-gp inhibitors did not display statistically significant different 
means for any of the pharmacokinetic parameters. Furthermore, ideal body weight did not 
correlate well with AUC0–12h.
Table 5 Pharmacokinetic parameters of linezolid
Linezolid daily dosage
400 mg (n=5) 600 mg (n=41) 900 mg (n=7) 1,200 mg (n=5) p-value
Cmin (mg/L) 3.7 (1.9) 2.8 (1.8) 3.0 (1.5) 4.6 (5.0) 0.405
Cmax (mg/L) 11.0 (3.8) 9.0 (3.1) 9.3 (2.5) 10.6 (3.1) 0.666
AUC0–12h (mg*h/L) 83.3 (33.9) 65.9 (30.8) 71.3 (19.7) 89.2 (49.3) 0.472
AUC/MIC ratio 499 (375) 357 (252)* 432 (135) 707 (499) 0.193
Data presented as mean (standard deviation). Pharmacokinetic parameters of patients that concomittantly 
received P-gp modulators are excluded.* n=37 due to 4 missing MICs. 
P-values calculated using Independent Samples Kruskal-Wallis Test displaying whether the distribution of 
pharmacokinetic parameters is the same across all linezolid dosage groups, i.e. 400 mg, 600 mg, 900 mg, and 
1,200 mg. A non-parametric test was used because of the small number of samples.
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DISCUSSION
This is the first study to investigate linezolid toxicity in relation to pharmacokinetic linezolid 
exposure. The efficacy of treatment regimens containing linezolid in this cohort was very 
good, with a large percentage of MDR-TB patients that was considered cured. The median 
times observed to microscopy and culture conversion (both 47 days) were similar to those of 
a recent meta-analysis; in that analysis, microscopy converted to negative after median 43.5 
days, and culture after 61 days (10). The proportion of adverse events in the retrospective 
cohort was lower than previously reported in a large meta-analysis (10). In our cohort, anemia 
occurred in 16%; peripheral neuropathy in 19%; and optical neuritis in 2% of all patients; 
anemia was seen in 38%, peripheral neuropathy in 47%, optic neuritis in 13% of patients in 
the meta-analysis (10). Comparison of dose related effects is difficult due to the multitude 
of the included studies in the meta-analysis, the non-fixed dose in our retrospective study 
and small overlap of data (10).
In Haren, 75% of the included patients received erythropoietin in a dose of 2,000 IUs twice a 
week. Erythropoietine was given in an attempt to prevent anemia which could otherwise lead 
to cessation of an effective drug in MDR-TB patients. Analysis of the Hb levels revealed no 
significant differences between patients that did or did not receive preventive erythropoietine. 
As no evidence for any benefit emerged from this analysis, we would now argue against 
routine use of erythropoietine in patients receiving linezolid.
Peripheral neuropathy was observed in 19% of the patients. The cumulative linezolid 
dosage and the number of days patients were exposed to linezolid were observed to be 
statistically significantly higher in patients who experienced peripheral neuropathy. A 
possible explanation that cumulative linezolid dosage and days of exposure to linezolid, in 
contrast to linezolid Cmin or AUC, are correlated to peripheral neuropathy might be that 
even the lower linezolid Cmin and AUCs are above mitochondrial toxicity threshold (28).
International collaboration in MDR/XDR-TB research is critically important to merge data 
and reach meaningful cohort sizes to explore important clinical questions. The toxicity 
data we found, e.g. for anemia and leucopenia in patients with higher Cmin  could only be 
detected by merging data of our two centers. The fact that in the same analysis, Cmin did not 
predict optical neuritis and peripheral neuropathy could be due to the limited sample size, 




Several methodological study limitations can be identified, particularly the limited 
sample size and the retrospective epidemiological nature of our study, and missing data. 
Unfortunately, 43 patients had to be excluded, because of lack of TDM data or due to 
recent admission to the hospital. Despite the fact that the inclusion and exclusion process 
has been transparently documented, this could have led to a selection bias. Furthermore, 
pharmacokinetic linezolid data were cross-sectionally computed at one or few moments in 
time. During the course of treatment, linezolid dosages or clinical parameters might have 
changed. The differences between the two study settings is another relevant limitation. 
Data were collected at two hospitals by two different researchers. We cannot exclude 
general differences in standard of care, treatment, and monitoring. The impact of observed 
differences in treatment regimens is expected to be limited since most differences are seen 
in drugs with a disputable place in therapy (6). Furthermore, differences were inherent to 
the individual character of treatment regimens.
Despite the retrospective nature of this study and the above mentioned limitations, our study 
supports the increasingly important position of linezolid in MDR-TB treatment regimens. 
Toxicity is more frequent with higher doses, i.e. 600 mg twice daily (15). However, with 
reduced dosages, adverse events appear manageable and infrequent. Our findings in this 
retrospective study justify confirmation in a prospective study.
One of the most important questions that remains to be answered is what pharmacokinetic / 
pharmacodynamic target should be aimed for in the treatment of MDR-TB? There are 
suggestive in vitro data for M. tuberculosis to support an AUC/MIC ratio of 100 which is 
adequate for gram-positive organisms (18). In addition, in vivo data showed promising results 
of linezolid added to other anti tubercular agents (29). Our study showed a weak association 
between AUC/MIC ratio and days to sputum smear-microscopy or to culture conversion 
in the presence of multi drug regimen limited by its retrospective nature. However, target 
AUC/MIC might be obtained in in vitro pharmacodynamic infection models that simulate 
human pharmacokinetics, such as hollow-fiber models. Next, prospective PK/PD studies 
should be designed to validate these targets in MDR-TB patients. Perhaps, linezolid dried 
blood spot and a limited sampling strategy could facilitate TDM in such studies (30). Being 
able to taper the dose to the lowest effective linezolid dosage with minimal toxicity based 
on TDM together with affordable, generic linezolid in safe and effective treatment regimen 
containing new agents, such as PA-824, bedaquiline, and delamanid, could help in the 
management of tuberculosis worldwide. 
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In conclusion, our retrospective study suggests that the treatment regimens containing 
linezolid were effective and well tolerated, with high sputum microscopy and culture 
conversion rates and low frequency of adverse events. Interestingly, peripheral neuropathy 
seems to be mediated by cumulative dose and days of exposure to linezolid. There was no 
relevant correlation between pharmacokinetic/pharmacodynamic parameters and patients 
characteristics.
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To the Editor: 
Approximately 3% of new tuberculosis (TB) cases worldwide represent multidrug-resistant 
tuberculosis (MDR-TB) (1). In these MDR-TB cases, resistance of Mycobacterium tuberculosis 
against the otherwise effective rifampicin and isoniazid forces clinicians to diverge to other 
antimicrobial agents. Such treatment options include World Health Organization (WHO) 
group 5 drugs linezolid and clarithromycin (1). Linezolid shows excellent efficacy in the 
treatment of MDR-TB, but its use is often troubled by adverse events (2-4). Linezolid has 
shown in vitro bacteriostatic activity against M. tuberculosis and is also effective at achieving 
culture conversion in drug resistant patients (5). In vitro testing revealed that clarithromycin 
is not very active against M. tuberculosis since the minimal inhibitory concentrations (MIC) 
are relatively high. Clinical efficacy seems questionable, since MICs, as reported in literature, 
are significantly higher than achievable serum peak levels in vivo (6). On the contrary, 
clarithromycin reaches adequate local concentrations in alveolar cells and in epithelial 
lining fluid, where most mycobacteria reside (7). Besides that lower clarithromycin MICs 
were observed by the Dutch National Mycobacteria Reference Laboratory (Bilthoven, the 
Netherlands; unpublished data). 
Due to the limited number of new treatment options, optimizing existing treatment 
regimens is a conceivable option. Exploring synergy between tuberculosis drugs might help 
in improving treatment regimens. A study that investigated several anti-TB drugs, such 
as isoniazide, rifampin, and/or ethambutol, but not linezolid, revealed in vitro synergistic 
activity with clarithromycin against M. tuberculosis (8). In this study, we aim to investigate the 
possible in vitro synergy between linezolid and clarithromycin in Mycobacterium tuberculosis 
isolates obtained from multidrug-resistant, resistant, and drug-susceptible TB patients.
We randomly selected a panel of 24 M. tuberculosis isolates from the strain collection of 
the Tuberculosis Reference Laboratory of the National Institute for Public Health and the 
Environment (RIVM, Bilthoven, the Netherlands). The selected collection consisted of 13 
multidrug-resistant, five drug-sensitive and six mono-resistant M. tuberculosis isolates. Drug 
susceptibility testing (DST) was performed using two methods: the absolute concentration 
method (ACM) and a Mycobacteria Growth indicator tube (MGIT) 960 system (9, 10). 
For the ACM, we used a sterilized Middlebrook 7H10 agar of pH 6.6 supplemented with 
oleic-acid-dextrose-catalase (both Becton Dickinson and Company, Sparks, MD) and varying 
concentrations of drugs (9). The plates were checked for mycobacterial growth after 4, 8, 
12, 14, 16, 19, and 21 days. The plates were analyzed when the growth in the control well 
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without anti-TB drugs was considered sufficient, i.e. when colonies were clearly visible 
and countable. At this point of time, all wells were checked for growth inhibition. Growth 
inhibition was defined as less than 90% of the colonies of the control well.
Next to the ACM, the MGIT 960 system with EpiCenter TB eXiST software was used (Becton 
Dickinson and Company, Sparks, MD) (10). Each tube contained 0.8 ml of Bactec MGIT 
drug susceptibility supplement and 100 μl of the appropriate drug solution. Growth was 
monitored hourly. The tubes were analyzed when growth unit (GU) value of the growth 
control tube, containing a 1:100 dilution of the inocula, reached 400. Growth inhibition 
was defined as GU value <100.
The checkerboard method was used to study in vitro synergy between linezolid and 
clarithromycin (both Sigma Aldrich, St.Louis, MO, USA). Linezolid was added in concentrations 
between 0 – 0.5 μg/mL and clarithromycin with a range of 0 – 8 μg/mL as is shown in Figure 
1. We calculated the lowest fractional inhibitory concentration (FIC) to determine synergy 
as follows: (MIClinezolid, combination / MIClinezolid, alone) + (MICclarithromycin, combination / MICclarithromycin, alone). 
Synergy was defined as a FIC ≤0.5, indifference as FIC >0.5 to 4, and antagonism as FIC 
>4 (11). 
Of the selected M. tuberculosis isolates (n=24), synergy between clarithromycin and linezolid 
was determined for 74% by using the MGIT method and in 59% by using the ACM. The 
median (interquartile range, IQR) FIC was 0.37 (0.31 – 0.47) using the MGIT and 0.50 
(0.38 – 0.75) using the ACM. The combination of drugs did not display antagonism in any 
of the isolates. A median checkerboard composed from all selected M. tuberculosis strains 
with clarithromycin and linezolid is shown in Figure 1. Synergy was observed in 77% of 
the MDR-TB isolates (n=13) using MGIT and in 46% in the ACM method. Combining 
clarithromycin and linezolid resulted in a median (IQR) FIC of 0.37 (0.32 – 0.37) using 
MGIT and 0.62 (0.375 – 1.0) using ACM in the MDR-TB isolates.
In conclusion, we observed synergy between clarithromycin and linezolid both with the 
MGIT and with the ACM method. This finding is in line with a previous observation 
that clarithromycin displayed synergy with isoniazide, rifampin, and/or ethambutol in M. 
tuberculosis (8).
Although the underlying mechanism is yet to be elucidated, it has been suggested that 
disorganization or disruption of the outer cell wall layer and the cytoplasmic membrane of 
the cell envelope by either clarithromycin or linezolid may play a role (8). This disruption 
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Figure 1 Schematic median checkerboard of Mycobacteria tuberculosis growth inhibition with varying 
concentrations of clarithromycin and/or linezolid using A. Mycobacteria Growth Indicator Tubes (MGIT, 
n=23) and B. Absolute Concentration Method (ACM, n=23).
Each cell represents the median result, i.e. growth or no-growth, of all tested isolates. Grey cells indicate 
growth, white cells indicate >90% less growth than controls. $ in order to calculate the fractional inhibitory 
concentrations (FIC) 4 μg/mL is used as the MICclarithromycin, alone. The lowest FIC cell is marked by ‘FIC’. For example: 
the FIC of Figure 1B is (MIClinezolid, combination / MIClinezolid, alone) + (MICclarithromycin, combination / MICclarithromycin, alone) = (0.125 / 
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might allow easier penetration by the other drug, resulting in the observed in vitro synergy. 
However, this hypothesis assumes that permeability is normally a limiting factor. Further 
research studying the underlying mechanism is needed and might also explain the fact 
that we observed in vitro synergy in the majority, but not all of the isolates. Although the 
majority of the isolates in this research displayed in vitro synergy when clarithromycin and 
linezolid were combined, it would be more interesting to determine or predict which isolates 
display synergy before applying these drugs in treatment regimens. Indeed, checkerboard 
experiments have not been validated or widely accepted for tailoring treatment in individual 
cases, and therefore cut-off values for FIC to deviate from the theoretical cut-off value of 1.0 
have been employed (11). Consequently, the number of isolates displaying synergy might 
be under- or overestimated.
Previously, we showed that clarithromycin increases linezolid exposure by 44% in MDR-TB 
patients (12). The implications were summarized as follows: clarithromycin might be used 
as a booster to increase linezolid exposure, comparable to low-dose ritonavir and protease 
inhibitors; and the relatively cheap clarithromycin might reduce costs of treatment of the 
relatively expensive linezolid (13). The in vitro synergy we observed in this study further 
strenghtens the case for adding clarithromycin as a secondary drug to MDR-TB treatment 
regimens. The increased drug susceptibility of linezolid and clarithromycin in combination 
with the increased linezolid exposure might allow for further reduction of linezolid dosage, 
further reducing costs and adverse events. A prospective evaluation of MDR-TB patients 
receiving both drugs as a part of their treatment regimen is warranted to investigate efficacy 
and tolerability in real life. Furthemore, synergy testing should be performed with both other 
second-line TB drugs, and new TB drugs in the pipeline. Especially since the number of 
new MDR-TB drugs emerging from the pipeline in the next years is expected to be limited, 
drug resistance should be avoided at all costs. Optimizing treatment regimens through use 
of combinations that show synergy could be one strategy to avoid over exended use of new 
drugs. This is particularly important when considering the new World Health Organization 
post-2015 Strategy, which is based on the concept of TB elimination (14, 15).
To conclude, clarithromycin and linezolid display in vitro synergy in multidrug-resistant 
M. tuberculosis isolates. Due to the boosting effect with linezolid, low incidence of adverse 
effects, low costs, observed higher concentrations in lung tissue, and the in vitro synergy 
with linezolid and other antimicrobial drugs, the role of clarithromycin might become more 
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In this thesis, we aimed to describe the clinical pharmacology of linezolid, with special focus 
on therapeutic drug monitoring (TDM) to optimize treatment of patients suffering from 
multidrug-resistant tuberculosis (MDR-TB). In order to attain our objectives, we studied the 
two main areas of pharmacology, i.e. the pharmacokinetics (PK) and pharmacodynamics 
(PD) of linezolid in MDR-TB. 
Pharmacokinetic drug-drug interactions
In Chapter 2, we performed a review of literature on drug-drug interactions of linezolid and 
other drugs from the oxazolidinone group. The multitude of PK drug-drug interactions that 
are presented in the review of literature (chapter 2) underline that drug-interactions are an 
important factor to take into account when designing a treatment regimen. In these PK drug-
drug interactions, the perpetrator changes PK parameters of the victim, possibly resulting in 
a clinically relevant increased or decreased exposure of the victim drug. Examples include 
the interaction between the perpetrator clarithromycin and the victim linezolid – studied in 
this thesis – resulting in a significant increase of linezolid exposure (1, 2). This interaction 
could potentially lead to an increased exposure of linezolid, a drug that is already infamous 
for its toxicity, forcing clinicians to temporarily cease treatment with linezolid. However, 
there are also examples of victim anti-TB drugs with a decreased exposure as a result of a PK 
drug-drug interaction. Lowered exposure to subtherapeutic levels could result in acquired 
resistance, limiting the number of effective drugs even further. Subtherapeutic exposure 
could also lead to treatment failure – possibly even resulting in death.
From the point of view of tuberculosis treatment, PK drug-drug interactions with the anti-TB 
drug as a victim might be perceived as being of most interest. However, drug interactions 
with anti-TB drugs as a perpetrator are potentially just as important. Suboptimal treatment 
of co-morbidities might delay or render adequate tuberculosis treatment impossible. Since 
delay of treatment does not only worsen outcomes of treatment of the individual patient, 
but also has a negative impact on transmission within a community (3), delay in the 
initiation of the intensive phase of treatment due to drug-drug interactions might also be 
unfavourable. 
Besides PK drug-drug interactions that are mentioned in summaries of product 
characteristics (SmPCs) or are known from literature, physicians must always be vigilant for 
new drug-interactions. For instance, the PK drug-drug interaction between linezolid and 
clarithromycin (2) is not yet described in the SmPC of linezolid (4). Moreover, the product 
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information explicitly states linezolid is not metabolised by humane CYP-isoforms (4). 
This underlines the importance of pharmacovigilance during the post-marketing phase. 
This is particularly important for drugs that are often used for the treatment of MDR-
TB. These anti-MDR-TB drugs are used off-label, such as linezolid and clarithromycin, 
or on-label but with an accelerated registration program followed by a confirmatory 
trial, such as bedaquiline (5). Perhaps, an intensive monitoring programme of new 
anti-TB drugs and new combinations could help to facilitate the gathering of real world 
clinical data. 
Designing treatment regimens
Clinicians often face a difficult challenge when designing treatment regimens consisting 
of at least four likely effective drugs for the treatment of MDR-TB, as recommended by the 
World Health Organisation guideline (6). In some low-resources countries, the challenge 
might be even greater due to lack of available drug susceptibility testing (DST) (7). In these 
cases, population-based data on DST and surveillance data determine the selection of likely 
effective drugs to design treatment regimens. However, besides drug susceptibility, there 
are other factors to take into account when designing a treatment regimen such as pattern 
of adverse events, drug-drug interactions, route of administration (e.g. intravenously versus 
orally), availability of the drug in the treatment setting, and even costs. 
Of these items that should be taken into account when designing a treatment regimen, 
adverse events deserve special attention. In cases where in vitro DST reveals sensitivity, the 
susceptible drug might not be suitable to add to treatment regimens due to adverse events 
that have occurred. Most clinical studies on diagnosis or treatment of tuberculosis present 
data on the in vitro drug susceptibility of the included patients. However, the number of 
feasible treatment options left might even be of greater relevance for clinicians than the 
number of resistant drugs. In order to allow comparison between clinical studies, it would 
be helpful to standardize the range of anti-tuberculosis drugs for which DST is performed 
together with the methods used. A recent study underlined the importance of DST. Perhaps, 
an addendum on the 2005 manuscript of Laserson et al. “Speaking the same language: 
treatment outcome definitions for MDR-TB” could help to propagate speaking the same 
language on the subject of DST as well (8).
Chapter 7
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Targets for Therapeutic Drug Monitoring 
Although PK / PD parameters are critically important, unfortunately, there are no clear PK 
/ PD targets yet that can be used for TDM for linezolid. However, several steps were made 
in defining these targets. For instance, in vitro studies revealed maximum killing rates at 
concentrations twice the MIC (9, 10). Linezolid also showed excellent activity at an AUC 
(area under the time concentration curve) / MPC90 (mutant prevention concentration of 
90% of the strains) ratio of 116 in isolates of drug-resistant M. tuberculosis (11). At the 
moment, a linezolid AUC / MIC ratio of at least 100 is strived for in MDR-TB. However, 
it should be noted that this target ratio is not based on in vitro analysis of M. tuberculosis 
isolates but on other microorganisms, such as Streptococcus pneumoniae and Streptococcus 
aureus (12). Although there are several arguments suggesting the PK/PD target of an AUC/
MIC ratio of 100 might be correct, an in vitro PD study is warranted, followed by a clinical 
validation in a prospective study.
In our retrospective study, in which almost all patients had an AUC/MIC ratio >100, we 
found no correlation between AUC/MIC ratio and sputum or culture conversion. This might 
suggest the AUC/MIC ratios were above target at a plateau on which further increasing the 
ratio does not have a clear effect on efficacy. Perhaps, doses could be lowered even further 
without loss of efficacy, whilst reducing toxicity.
Obviously, designing clinical PD studies by simply withholding treatment in one cohort 
is not ethically justified. Unfortunately, PD studies in animals are often not possible due 
to toxicity in animals at drug exposures that are relevant in humans (13). Because of these 
limitations, hollow fiber PD infection models of tuberculosis might provide a solution (13). 
These models take half-lives of drugs and clinically applied dosing schedules into account, 
mimicking in vitro exposure of M. tuberculosis in patients to anti-TB drugs as closely as 
possible. Previously, this method was used to determine the rifampicin PK/PD target in 
tuberculosis strains, i.e. a daily AUC0–24h/MIC of 24 (14). We propose to conduct a similar 
study to determine an appropriate PK/PD target for linezolid in MDR-TB strains. Once 
the PK/PD target is more clearly established for linezolid in MDR-TB, the target should be 
clinically validated. 
The identification of the linezolid AUC/MIC ratio for treatment of MDR-TB will possibly 
reveal a plethora of subjects to study, but more importantly it might improve MDR-TB 
treatment regimens containing an effective anti-tuberculosis drug. One of the positive effects 
on the research of the applicability of linezolid in the treatment of MDR-TB could be that 
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the identification of the linezolid PK/PD target might result in a more homogeneous dosing 
of linezolid in clinical studies. Results from different studies will be more easily comparable 
since the attained targets will be similar. This could rapidly increase the number of eligible 
patients in cohorts of whom TDM data are available, thereby revealing information that 
would had not have been discovered with small numbers of patients or when too high 
dosages are applied, a practice that is probably common today (chapter 5).
TDM using standard or alternative sampling techniques, such as DBS sampling or oral fluid 
sampling, could contribute to limiting adverse effects by tapering the linezolid dose to the 
lowest possible effective dose. This tapered linezolid dose could particularly be helpful in 
optimizing treatment regimens of extra vulnerable groups of patients, such a patients with 
multi-morbidity, pediatric, geriatric, and pregnant or lactating patients. In these patients, 
pharmacokinetics might be altered. Furthermore, these groups are often not included in 
studies because of safety reasons, resulting in a lack of and delay on information. Nevertheless, 
MDR-TB obviously also affects children, the elderly and pregnant women and thus these 
patients might need to be treated with linezolid as well.  In all of the above examples, 
development of PK models for specific populations is warranted. These PK models for 
specific patient groups could enable precise dose adjustments based on TDM, resulting in 
fast attainment of PK/PD targets. These data could also contribute to determining adequate 
standard dosages for these groups of patients.
As for adding linezolid to treatment regimens of pregnant or lactating patients with MDR-
TB, the lack of knowledge on in utero effects of linezolid on the pregnant patient and her 
(unborn) child, the possible efficacy of the drug, the risk of adverse effects and alternatives 
have to be deliberated by the physician. The fact that untreated MDR-TB is lethal to both 
the mother and the unborn child and the fact that multidrug-resistance severely limits the 
number of treatment options that are still feasible, will possibly force clinicians to prescribe 
linezolid. In these cases, tapering linezolid to the lowest still effective dose could possibly 
limit the chances of negative effects on the pregnant patients and their (unborn) child. 
Development of guidelines and increasing the number of peer-reviewed publications on 
the treatment of pregnant MDR-TB patients including short- and long-term follow-up of 
the child, would be very helpful for clinicians. This will allow pregnant MDR-TB patients 




Another subject that warrants future study, is the PK drug-drug interaction between linezolid 
and clarithromycin (chapter 3). After confirming the results in a new cohort, the next step 
should be to elucidate the underlying mechanism of the interaction. Although several studies 
refer to an interaction with linezolid as a victim and other drugs as a perpetrator, as being 
modified by P-gp (15, 16), this is merely based on one in vitro study combined with the 
summary of product characteristics (4, 17). Both the summary of product characteristics 
and Wynalda et al. state that linezolid is not metabolized through cytochrome P-450 iso-
enzymes (4, 17). Since the perpetrator drugs were P-glycoprotein and cytochrome P-450 
3A4 modulators, the hypothesis was postulated that the interaction with linezolid might 
be P-pg mediated (15, 16). However, there is one article – written by an employee of Pfizer, 
the manufacturer of linezolid – stating that the linezolid drug-interaction might not be 
P-gp mediated (18). This raises the question whether Pfizer might have unpublished data 
on file, contributing to the knowledge on the mechanism of the drug-drug interactions 
with linezolid as a victim. It would be interesting to elucidate the drug-drug interaction, 
preferably by publishing these data followed by a replication of the study to confirm 
the findings. 
Once the exact mechanism is elucidated, the effect of other perpetrator drugs using the same 
mechanism should be studied. If, for instance, the mechanism turns out to be CYP3A4 
mediated, it would be interesting to quantify the effect of other CYP3A4 modulators such 
as grapefruit juice, carbamazepine or ketoconazole. 
Another alluring sequel to the performed prospective PK drug-drug interaction study that 
we performed would be to quantify the effect of clarithromycin in a higher daily dose than 
the previously administered 500 mg of clarithromycin, such as a dose of 1000 mg extended 
release oral formulation once daily. This dose of 1000 mg clarithromycin daily is often 
administered for several indications without important adverse effects and this dosage is 
generally well tolerated. The concentration-enhancing effect on linezolid would possibly be 
more pronounced after administration of 1000 mg clarithromycin than what we observed 
after administration of 500 mg clarithromycin (2). 
The in vitro synergy between linezolid and clarithromycin that we described in chapter 
6 of this thesis should be followed by studies of other combinations of second line anti-
tuberculosis drugs. Investigating in vitro synergy could help in optimizing existing 
treatment regimens. Since the number of anti-TB drugs that emerges from the pipeline 
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is limited, it is critically important to protect these new drugs from acquiring resistance. 
Strategies to design and optimize new treatment regimens containing these drugs are 
warranted.
Elucidating the exact mechanism underlying the observed synergy would contribute to our 
knowledge of the disease and the mechanism of action of the drugs used. Furthermore, this 
would possibly answer the question whether the observed synergy is relevant in humans in 
clinical practice or is only limited to an in vitro setting. Detailed knowledge on synergy, but 
also on inhibition, could alter the way treatment regimens are designed. 
Generic linezolid: cheap linezolid for everyone?
In May 2015, the patent of linezolid will expire. As a result, cheaper generic versions of 
linezolid will become available within the following years. As a matter of fact, in India 
– where the patents of linezolid are not recognized by the authorities – cheaper versions 
of linezolid have been available for years (19). The lowered price of linezolid will make 
the drug affordable for a larger group of patients, including patients in low- and middle-
income countries. The affordability will possibly lead to an increased incorporation of 
linezolid in treatment regimens. This, in turn, might result in increased antimycobacterial 
pressure and the likelihood of emerging resistance increases (20). Clinicians should 
ensure addition of linezolid to adequate treatment regimens to protect this effective 
anti-tuberculosis drug. Attention should be paid to adherence, preferably administering 
linezolid under directly observed therapy (DOT) (21). Therapeutic drug monitoring 
should be applied to identify subtherapeutic drug exposure of linezolid, but also to identify 
subtherapeutic exposure of other drugs of the treatment regimen leaving linezolid as 
monotherapy. 
The long treatment duration is one of the great obstacles in treating MDR-TB. The impact 
on patients of being on treatment for at least 18 months is not to be underestimated. 
Possibly, the duration of treatment might also be one of the reasons of non-adherence 
or cessation of treatment. Shortening the treatment duration would have an enormous 
impact on the treatment of MDR-TB. Shortened treatment duration might not only 
increase the chances of treatment completion in an adequate manner, but it might also 
save the tuberculosis programs costs per treated patient. Recently, the shortened 9-months 
Bangladesh treatment regimen showed promising outcome in over 500 MDR-TB patients 
(22). In contrast with clofazimin (23) and pretomanid, previously known as PA-284 (24), 
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there is no clear evidence suggesting linezolid is effective in killing slowly replicating 
persistent microorganisms (25). However, the effective linezolid might play a future role in 
a comparable shortened treatment regimen: not as a killer of persisters but as an effective 
anti-MDR-TB drug in the intensive phase. When the saved resources would be used for 
research in the field of developing new anti-TB drugs, shortening the treatment duration 
might indirectly even help in reaching the WHO goal of eradicating TB by the year 
2050. 
However, perhaps in the following years the role of structure analogues of linezolid in treating 
MDR-TB will become greater than the role of linezolid. Preliminary results in a murine model 
of one of these analogues, suggest that sutezolid (PNU-100480) may have the potential to 
shorten TB regimens in both normal sensitive and MDR-TB (26). Another advantage of 
linezolid structure analogues might be that they display less toxicity than linezolid (10, 27). 
It will be interesting to study to what extent structure analogues will display less toxicity 
than linezolid in clinical practice and if findings from this thesis on linezolid, such as the 
PK drug-drug interaction and in vitro synergy with clarithromycin, will also be observed 
in the newer oxazolidinones.
Conclusion
In the General Introduction of this thesis, we referred to famous African musicians that fell 
victim to TB. Hopefully, the research in this thesis combined with the studies proposed in 
the future perspectives part of the General Discussion, will further contribute to the quality 
of treatment of MDR-TB. Perhaps, the research will contribute to improved treatment in 
both low- and high-income countries. It might even prevent a modern day African musician 
from falling victim to TB.
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In this thesis, the general aim was to describe the clinical pharmacology of linezolid in 
multidrug-resistant tuberculosis (MDR-TB). In order to do so, several aims were formulated 
to shed light on different pharmacokinetic (PK) and pharmacodynamic (PD) aspects of 
linezolid in MDR-TB. Since treatment regimens have to be composed of at least four anti-
TB drugs that are likely to be effective and since the number of new-drugs that emerge 
from the pipeline is limited, clinicians are forced to use drugs with limited knowledge 
about safety and efficacy to treat these patients. One of these drugs, the oxazolidinone 
linezolid, is used off-label in the treatment of MDR-TB. Linezolid holds promise to be 
highly effective in treatment regimens of MDR-TB, however linezolid is infamous for its 
adverse events, such as peripheral and optical neuropathy, anaemia, and myelosuppression. 
Because of these adverse events clinicians often feel forced to withdraw linezolid from 
MDR-TB treatment regimens. This is particularly important in patients that are infected 
with Mycobacterium tuberculosis, a microorganism that is only susceptible for few 
selected drugs. 
To reduce toxicity, dose reduction was studied and obviously, this helped to reduce adverse 
events. However, dose reduction should never compromise treatment efficacy, since reduced 
efficacy can result in failing treatment regimens, acquired resistance and even death. To 
help clinicians manoeuvre through the field of toxicity while retaining efficacy, we aim to 
contribute to the knowledge of PK and PD of linezolid in MDR-TB with special focus on 
TDM of linezolid to optimize treatment of patients suffering from MDR-TB.
Pharmacokinetics of linezolid
In order to attain our objectives, in Chapter 2, we performed a literature search on 
drug-drug and drug-food interactions of anti-microbial drugs, including those used 
in multidrug-resistant tuberculosis treatment regimens, such as clarithromycin and 
linezolid. The pharmacokinetic interactions, as described in Chapter 2, are a modified 
version of a published manuscript with a broader scope, studying other antimicrobial 
drugs as well. For each drug that was studied, including linezolid (oxazolidionones) and 
clarithromycin (macrolides), literature was searched using the Medical Subject Headings 
(MeSH) term ‘drug interaction’ combined with the drug name and group name. The search 
was confined by different limitations, with the goal of improving the quality of the search 
results. For oxazolidinones, the search also aimed to reveal drug-interactions of other, not 




posizolid (AZD2563), radezolid (RX-1741), and torezolid (TR-701). Due to the recent 
discovery of some of these drugs and due to the limited post-marketing knowledge of 
linezolid, the number of drug-interactions studies was very limited on linezolid, and even 
absent on the other oxazolidinones. 
The results revealed, that a fat meal decreased linezolid absorption and antacids had no 
clinical significant effect on absorption of linezolid. The metabolism of linezolid appeared 
not to be influence by CYP modulators, however literature suggests that linezolid might be 
a P-glycoprotein (P-gp) substrate. 
From this literature study, we concluded that there are drug-drug and drug-food PK 
interactions with linezolid, with variable relevance. The change in PK parameters of 
linezolid might influence therapy through increased toxicity or decreased efficacy. Finally, 
the sheer amount of pharmacokinetic drug interactions, with linezolid, but also other anti-
mycobacterial drugs, require multidisciplinary vigilance of physicians, pharmacists, and 
other health care professionals. 
Chapter 3 focuses on one of these pharmacokinetic drug-drug interactions. As a part 
of routine therapeutic drug monitoring (TDM) at the Tuberculosis Center Beatrixoord 
(Haren, the Netherlands), we discovered a drug-drug interaction between linezolid and 
clarithromycin in a 42-year-old male TB-patient. In this patient, the area under the time 
concentration curve (AUC0–12h) of linezolid was increased from 29 mg*h/L to 108 mg*h/L. 
Based on co-administrated medication, lack of significant changes in his liver or renal 
function, and coincidence with the start of co-administration of clarithromycin 1000 mg 
once daily, we hypothesised that there might be an interaction between linezolid and the 
potent P-gp pump inhibitor clarithromycin.  
Based on this observation, a prospective, single-arm, fixed-order study was designed to 
quantify the interaction. Male and female patients aged ≥18 years who were diagnosed with 
MDR-TB were eligible for inclusion in our study. Pregnant or lactating patients, subjects 
that had previously shown hypersensitivity to linezolid or macrolide antibiotics, patients 
that had hypokalaemia or concomitantly received P-glycoprotein modulators were excluded. 
All patients received linezolid 300 mg twice a day. The AUC was determined at three time 
points in the study: at baseline, after two weeks of co-administration of linezolid with 250 
mg clarithromycin once daily, and finally after two weeks of co-administration of linezolid 
with 500 mg clarithromycin. 
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In concordance with the calculated sample size, five of the seven included patients were 
suitable for evaluation. The median (interquartile range, IQR) of linezolid AUC was 36.3 
(33.2 – 46.3) mg*h/L without co-administration of clarithromycin. After co-administration 
with 250 mg clarithromycin once daily, the median (IQR) linezolid AUC increased to 61.0 
(34.6 – 63.9) mg*h/L (p=0.686) and after 500 mg clarithromycin to 67.2 (66.9 – 76.0) mg*h/L 
(p=0.043). In other words, linezolid exposure increased by a median (IQR) of 44% (23 – 
102%) after co-administration with 500 mg clarithromycin compared to baseline, whereas 
250 mg clarithromycin had no statistically significant effect. As for safety and tolerability, 
co-administration was well tolerated by most patients; none experienced severe adverse 
effects, one patient reported Common Toxicity Criteria grade 2 gastrointestinal adverse 
events. Based on this study, we concluded that further research in a larger cohort is needed 
to provide insight into the observed inter-patient variation, perhaps caused by genetic 
variability polymorphism. Furthermore, we concluded that TDM of linezolid is advisable 
when linezolid is co-administrated with clarithromycin until effect size of the PK interaction 
becomes predictable. 
Despite the advisable nature of TDM when administering linezolid with or without 
clarithromycin, in many parts of the world conventional sampling might be hindered by 
logistical problems. In order to facilitate easy analysis of the anti-TB drugs linezolid, we 
developed and clinically validated two new sampling methods using dried blood spot (DBS) 
and oral fluid analysis (Chapter 4). 
In order to clinically validate the DBS sampling, we recruited patients that were admitted 
to Tuberculosis Center Beatrixoord (Haren, the Netherlands) that were receiving linezolid 
as part of their treatment regimen for MDR-TB for whom routine TDM was scheduled. 
Sampling was performed at steady-state. Venous blood samples were obtained before drug 
intake, and at 1, 2, 3, 4, and 8 hours after drug intake. The venous blood samples were used 
as a control, but also to generate venous dried blood spots (vDBS) by dropping 50 μL onto 
Whatman 31 ET CHR paper. DBS samples were obtained at 2 and 8 hours after dosing 
by dropping blood from a finger prick, directly on DBS paper. Both the vDBS and DBS 
samples were dried at room temperature and stored in sealed plastic bags with desiccant 
sachets at -20°C until analysis. Just before analysis, an 8-mm-diameter disc was punched out 
of each (v)DBS after which extraction of these discs was performed. After further sample 
preparation, the samples were analysed using a validated liquid chromatography-tandem 
mass spectrometric (LC-MS/MS) method. The DBS analytical method was validated in 




validation tests, special tests were performed to evaluate the impact of haematocrit value 
(Hct) at 20, 25, 30, 35, 40, 45, and 50%, and blood spot volume set at 30, 50, 70, and 90 μL. 
Blood spot volume and Hct values were set at 50 μL and 35% during the validation of the 
analysis to represent tuberculosis patients.
The DBS assay showed linearity over the analytical concentration range (0.05 – 30 mg/L 
linezolid) with a pooled correlation coefficient, r2, of 0.9947. Reproducibility, presented as bias 
and coefficient of variation (CV) were less than 17.2% for the lower limit of quantification 
(0.05 mg/L linezolid), and less than 7.8% for other levels (0.25 – 30 mg/L linezolid). The 
method showed a high recovery of approximately 95% and a low matrix effect less than 8.7%. 
DBS samples proved to be stable for 2 months at 37°C. Bland-Altman analysis revealed that 
the ratio of the linezolid concentration in DBS to that in plasma was 1.2 (95% confidence 
interval [CI], 1.12 – 1.27). 
From this study, we concluded that DBS analysis of linezolid might be a useful tool for 
TDM of linezolid in the treatment of MDR-TB patients. The easy sampling procedure and 
high sample stability may be useful, especially in underdeveloped countries with limited 
resources and where conventional plasma sampling is not feasible.
In Chapter 4, we also developed and clinically validated an oral fluid sampling method. 
Patients that took part in the prospective study described in chapter 3 were included. All 
patients received 300 mg linezolid twice daily and 250 mg clarithromycin once daily when 
the steady state blood and oral fluid samples were obtained. The samples were collected 
simultaneously before and at 1, 2, 3, 4, 8, and 12 h after drug intake. Oral fluid samples 
were collected using a small cotton roll (Salivette; Sarstedt, Leicester, United Kingdom). 
Patients chewed on the Salivette for approximately two minutes after which the samples 
were centrifuged and then stored at -20°C until analysis. Linezolid and clarithromycin 
concentrations were analysed using validated LC-MS/MS analysis methods. 
Passing-Bablok regressions and Bland-Altman analysis revealed oral fluid analysis of linezolid 
to be suitable for TDM in MDR-TB patients as an alternative for conventional serum analysis. 
Since the ratio of the linezolid concentration in serum to that in oral fluid was calculated to 
be 0.97 (95% CI, 0.92 to 1.02) using Bland-Altman analysis, no correction factor is needed 
for the interpretation of linezolid oral fluid concentrations. However, the Bland-Altman 
analysis of clarithromycin concentration serum / oral fluid revealed a ratio of 3.07 (95% 
CI, 2.45 to 3.69). We observed a non-linear relationship between the concentrations of the 
metabolite of clarithromycin, hydroxyclarithromycin, in serum and in oral fluid. Based on 
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this study, we concluded that the analysis of linezolid and clarithromycin in oral fluid might 
be an easy, non-invasive alternative in MDR-TB patients when conventional sampling might 
not be possible or desirable.  
Previous chapters, but also studies on inter- and intra-patient variability of linezolid 
pharmacokinetics performed by other research groups, indicate that there might be an 
important role for TDM. Nevertheless, several recent studies did not incorporate TDM data 
in their research. Therefore, we advocated the use of TDM combined with drug susceptibility 
testing, among other things, in two letters to the editor (Chapter 5). Also, we pointed out 
the importance of directly observed therapy (DOT) in clinical trials, except perhaps in 
cases where compliance is highly probable. Furthermore, we suggested that a randomised 
controlled trial of linezolid versus a placebo should be designed and planned, in addition 
to an adequate background regimen that is designed using DST and TDM.
The suggestions that we made based on these recent studies, encouraged us to retrospectively 
study linezolid efficacy, safety, and tolerability in relation to linezolid pharmacokinetics in our 
Tuberculosis Center Beatrixoord (Haren, the Netherlands). In order to increase the sample 
size, an international collaboration was initiated allowing for inclusion of multidrug-resistant 
tuberculosis patients from the E. Morelli Hospital (Sondalo, Italy) as well. We selected MDR-
TB patients that received linezolid as a part of their treatment regimen, excluding patients 
younger than 18 years, patients lacking data due to recent admission to either reference 
hospital, and patients of whom no TDM data were available. Two researchers retrieved 
anonymous retrospective data, including patient characteristics, treatment information, 
pharmacokinetic data, and treatment outcome.
In both centers, a combined number of 58 MDR/XDR-TB patients that had received linezolid 
and underwent TDM were included. However, of 54 eligible patients in Sondalo, 36 had 
to be excluded, of whom 27 due to absence of pharmacokinetic data of linezolid. In the 
combined cohort, DST revealed a median (IQR) MIC for linezolid of 0.5 (0.25 – 0.5) mg/L. 
Of the 58 included patients, 29/58 (50.0%) patients were considered cured; 4/58 (6.9%) 
patients completed their treatment; and 25/58 (43.1%) patients were still on treatment at the 
moment of data collection. All but one patient (98.3%), including those still on treatment, 
were culture and smear-microscopy negative when data were collected. In this combined 
cohort, no correlation was observed between microscopy or culture conversion and the 
pharmacokinetic/pharmacodynamic parameters, the AUC/MIC ratio, which were above 




Retrospective analysis pointed out that patients with peripheral neuropathy had received 
a higher median (IQR) cumulative dose (1,829 (1,414 – 2,255) mg/kg versus 1,164 (755 – 
1,922) mg/kg (p=0.041)) or received linezolid for a longer median (IQR) period of time (159 
(120 – 196) versus 97 (66 – 147) days (p=0.003)) compared to patients without peripheral 
neuropathy. Another interesting finding from this study was that co-administration of 
erythropoietin with linezolid had no effect on preventing anaemia. At 0, 30, 60, and 90 days 
after starting linezolid, there was no difference between haemoglobin (Hb) of patients that 
did or did not receive erythropoietin, nor was there a difference in Hb over time per patient 
between the two groups.
From our retrospective study, we concluded that the treatment regimens containing linezolid 
were effective and well tolerated. High sputum microscopy and culture conversion rates and 
low frequency of adverse events were observed in our cohort. Furthermore, we concluded 
that peripheral neuropathy seemed to be mediated by cumulative dose and days of exposure 
to linezolid. We were not able to observe a relevant correlation between pharmacokinetic/
pharmacodynamic parameters, such as AUC/MIC ratio, and efficacy parameters. Perhaps 
this is due to the fact that in our cohort almost every patient had an AUC/MIC ratio 
of >100.
Pharmacodynamics of linezolid
Although in this thesis most emphasis is placed on pharmacokinetic of linezolid, in Chapter 
6 we focused on a pharmacodynamic interaction between linezolid and clarithromycin 
M. tuberculosis isolates. In collaboration with the Dutch National Mycobacteria Reference 
Laboratory (Bilthoven, the Netherlands), we performed an in vitro synergy test using the 
checkerboard method. A panel of 24 M. tuberculosis isolates were randomly selected from 
their collection. We used two previously described methods, i.e. the absolute concentration 
method (ACM) and the MGIT 960 system, with varying concentrations of drugs. Linezolid 
was added in concentrations between 0 – 0.5 mg/L and clarithromycin with a range of 
0 – 8 mg/L in a checkerboard fashion. After growth inhibition was determined for all 
combinations of isolates and concentrations, we calculated the lowest fractional inhibitory 
concentration (FIC) to determine synergy. The FIC was calculated as: (MIC of linezolid in 
combination / MIC of linezolid alone) + (MIC of clarithromycin in combination / MIC of 
clarithromycin alone), and defined synergy as an FIC ≤0.5, indifference as 0.5<FIC≤4, and 
antagonism as FIC >4.
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Of the 24 selected M. tuberculosis isolates, synergy between clarithromycin and linezolid 
was determined for 74% by using the MGIT method and in 59% by using the ACM. No 
antagonism was observed. Since the combination is most likely to be co-administered in 
MDR-TB patients, we also focused on MDR-TB isolates. In these MDR-TB isolates (n=13), 
synergy was observed in 77% using MGIT and in 46% using the ACM method with a median 
(IQR) FIC of 0.37 (0.32 – 0.37) and 0.62 (0.375 – 1.0) respectively. Based on these data, we 
concluded that clarithromycin and linezolid display in vitro synergy in multidrug-resistant 
M. tuberculosis isolates. The in vitro synergy that was observed in this study might play a 
role in designing future MDR-TB treatment.
In Chapter 7 we discussed whether the objectives of this thesis, as presented in the general 
introduction, were met. Furthermore, we placed the most important findings from this thesis 
in perspective of published literature and clinical practice. For instance, we explained the 
importance of pharmacokinetic drug-drug interaction studies of anti-TB drug as a victim, 
but also as a perpetrator.  Moreover, we explained the importance of individualized treatment 
regimens and defined targets for therapeutic drug monitoring. Finally, we discussed future 
perspectives following from the results of this thesis. These future perspectives include the 
possible impact of the patent of linezolid expiring in the following years and subjects that 





Wereldwijd overlijden jaarlijks meer dan één miljoen mensen aan de infectieziekte tubercu-
lose. Tuberculose wordt veroorzaakt door tuberkelbacillen die officieel worden aangeduid 
als Mycobacterium tuberculosis. Tuberculose wordt meestal overgedragen van mens tot mens 
via het inademen van tuberkelbacillen, die in wolken van fijne druppels – aërosolen – via de 
lucht worden verspreid door mensen met besmettelijke tuberculose. Door hoesten en niezen 
kunnen anderen besmet worden, vooral wanneer deze mensen langdurig met de besmettelijke 
tuberculosepatiënt in dezelfde ruimte verblijven, en als die ruimte weinig geventileerd wordt. 
Na het inademen van deze druppels met bacteriën zorgt het afweersysteem meestal dat de 
bacteriën opgeruimd worden. Bij ongeveer 10% van de mensen met een normale afweer is 
het afweersysteem niet in staat de bacterie voldoende te bestrijden. In deze gevallen nestelt 
de bacterie zich in het lichaam. Meestal ontstaat er vervolgens een latente, oftewel slapende, 
tuberculose-infectie waarbij de patiënt geen klachten en ziekteverschijnselen ontwikkelt. Als 
het afweersysteem te zwak is kan tuberculose ontstaan doordat de tuberkelbacil ‘wakker’ 
wordt en weer gaat delen. In de meeste gevallen gebeurt dit binnen enkele maanden of jaren 
na de besmetting, soms later. De besmette persoon krijgt dan klachten, meestal in de vorm 
van hoesten, nachtzweten en ongewild gewichtsverlies. De tuberkelbacil komt vrijwel altijd 
via de luchtwegen het lichaam binnen en veroorzaakt daar de meeste ziekteverschijnselen. 
De bacterie kan ook op andere plaatsen in het lichaam opduiken en daar bijna alle organen 
aantasten. Voorbeelden hiervan zijn de longvliezen, de lymfeklieren, de darmen, het 
buikvlies, de nieren, de geslachtsorganen, de lever, de hersenvliezen, de hersenen en de 
botten, vooral die van de wervelkolom. 
Multiresistente tuberculose
Bij iedere celdeling van de tuberkelbacil kan door toeval een fout, oftewel een mutatie, 
ontstaan. Af en toe ontstaat hierbij een mutant, oftewel een gemuteerde bacterie, die 
ongevoelig is voor een bepaald tuberculosemedicament. Het aantal bacteriën bij patiënten 
met tuberculose is enorm groot. Tussen al die bacteriën zijn er altijd enkele mutanten die 
tegen een of ander antibioticum resistent zijn. Deze mutanten zouden overleven wanneer de 
behandeling alleen met dit ene antibioticum, waartegen ze resistent zijn, zou plaatsvinden. 
Bij opeenvolgende fouten in de behandeling waarbij telkens maar één antibioticum wordt 
gebruikt, kan een patiënt uiteindelijk een infectie hebben met bacteriën die resistent zijn tegen 
meerdere middelen tegelijk. Om dit te voorkomen moet bij de behandeling van tuberculose 




Er kan een situatie ontstaan waarbij de bacterie niet meer gevoelig is voor de standaard-
behandeling met isoniazide, rifampicine, pyrazinamide en ethambutol, waarmee wereldwijd 
veel ervaring is opgedaan. Als de bacterie ongevoelig is voor de twee meest gebruikte en 
krachtigste middelen, namelijk rifampicine en isoniazide, spreekt men van multiresistente 
tuberculose (MDR-TB). Helaas komt MDR-TB vaak voor. Op basis van gegevens van 
de Wereldgezondheidsorganisatie (WHO) denken we dat 3,6 – 20% van de nieuwe 
tuberculosepatiënten besmet is met MDR-TB. 
Wanneer een patiënt besmet is met MDR-TB is de behandeling veel complexer dan die bij 
normaal gevoelige tuberculose, aangezien in het geval van MDR-TB de meest efficiënte 
middelen per definitie niet kunnen worden ingezet als onderdeel van de behandeling. 
Omdat deze middelen, rifampicine en isoniazide, niet gebruikt kunnen worden voor de 
behandeling van de tuberculose dient er uitgeweken te worden naar reserve-antibiotica. 
Volgens de behandelrichtlijn van de WHO behoort de medicamenteuze behandeling 
van MDR-TB te bestaan uit een combinatie van tenminste vier antibiotica waarvoor de 
bacterie hoogstwaarschijnlijk nog gevoelig is. Artsen hebben hierbij beschikking over vijf 
verschillende groepen reserve-antibiotica op basis van een indeling van de WHO. In de vijfde 
groep zitten de antibiotica linezolid en claritromycine. Op dit moment is er echter relatief 
weinig ervaring met de behandeling van MDR-TB met deze middelen en is er nog weinig 
bekend over de effectiviteit bij tuberculose. Hierdoor dient de patiënt geen zes maanden, 
maar soms tot 24 maanden te worden behandeld en is het onzeker of de patiënt überhaupt 
kan genezen. Wanneer de kennis over de effectiviteit, bijwerkingen en veiligheid van linezolid 
en claritromycine bij de behandeling van MDR-TB zou toenemen, zouden deze middelen 
mogelijk een grotere rol kunnen krijgen bij de behandeling.
Farmacologie
Om geneesmiddelen effectief in te kunnen zetten bij een medicamenteuze behandeling is 
kennis van de farmacologie van de toegepaste geneesmiddelen nodig. Farmacologie is de 
wetenschap die zich bezighoudt met de wisselwerking van het werkzame bestanddeel van 
een geneesmiddel met het aangrijpingspunt waar het middel moet werken. Bij infectieziekten 
zoals tuberculose dient het geneesmiddel aan te grijpen op levende tuberkelbacillen. 
De farmacologie bestaat uit twee onderdelen: farmacokinetiek en farmacodynamie. 
Farmacokinetiek beschrijft ruwweg wat het lichaam met het geneesmiddel doet en 
farmacodynamie hoe het geneesmiddel aangrijpt op het ziekteproces in het lichaam. Bij 
infectieziekten is dat vooral hoe het middel de ziektekiem aanpakt. 
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Het begrip farmacokinetiek beschrijft de reis van een geneesmiddel door het lichaam. Die 
reis begint bij opname of absorptie uit het maag-darmkanaal. Na inslikken moet het middel 
uit het darmkanaal opgenomen worden in het bloed. Vervolgens wordt het middel over het 
lichaam verdeeld (distributie), omgezet (metabolisme) en uitgescheiden (eliminatie). In 
combinatie met de dosering van het geneesmiddel hebben deze processen een concentratie 
van het geneesmiddel in het lichaam als gevolg. In algemene zin kan gezegd worden dat 
een te hoge concentratie in relatie tot farmacodynamische parameters giftige bijwerkingen 
kan veroorzaken. Daartegenover staat dat bij een te lage concentratie het geneesmiddel 
onwerkzaam is. Bij antibiotica kan een te lage concentratie de bacteriën met verminderde 
gevoeligheid selecteren waardoor uiteindelijk zelfs resistentie kan ontstaan. 
Onderzoek naar farmacokinetiek richt zich vaak op het meten van de concentratie van een 
geneesmiddel in het lichaam. Het liefst zouden we de concentratie meten op de plaats waar 
het geneesmiddel moet werken, maar dat lukt eigenlijk alleen als we een weefselmonster 
van een aangedaan lichaamsdeel zouden verwijderen voor onderzoek. We gaan er van uit 
dat het geneesmiddel via de bloedbaan bij de infectiehaard moet komen en dat in ontstoken 
weefsel de bloedvoorziening voldoende is, zodat de bloedconcentratie overeenkomt met 
de weefselconcentratie van het geneesmiddel. In de farmacokinetiek worden meestal 
bloedmonsters gemeten. Naast bloedmonsters kunnen echter ook urine- en speekselmonsters 
gebruikt worden of een gedroogde bloeddruppel uit een vingerprik op een papier, de 
zogeheten dried blood spot (DBS). Farmacodynamisch onderzoek bij tuberculose bestaat 
veelal uit laboratoriumonderzoek naar de gevoeligheid van bacteriën voor specifieke 
geneesmiddelen.
Beide bovenstaande begrippen kunnen gecombineerd worden: farmacokinetiek / farmaco-
dynamie (PK/PD). PK/PD relateert de gemeten concentratie van het geneesmiddel aan de 
benodigde concentratie, op basis van de gevoeligheid van de bacterie, op de plek van de 
infectiehaard. Het doseren op basis van PK/PD noemt men therapeutic drug monitoring 
(TDM). Met behulp van TDM zou onderzocht kunnen worden in hoeverre de concentratie van 
of blootstelling aan linezolid aansluit bij de gevoeligheid van de bacterie. Als de concentratie 
of blootstelling te hoog is, kunnen vermijdbare bijwerkingen of vergiftigingsverschijnselen 
optreden. De dosering van het geneesmiddel moet dan verlaagd worden. Wanneer de 
concentratie of blootstelling te laag is, zou de dosering van het geneesmiddel juist moeten 





Linezolid is een oxazolidinone-antibioticum dat geregistreerd is voor de behandeling 
van infecties van de huid en de longen met resistente stafylokokken. Linezolid wordt ook 
ingezet tegen MDR-TB, alhoewel het daarvoor niet geregistreerd is. Er zijn aanwijzingen 
dat linezolid een erg effectief geneesmiddel is in de behandeling van MDR-TB. Een nadeel 
is echter dat linezolid bekend staat om zijn bijwerkingen. De belangrijkste bijwerkingen 
zijn beschadiging van de oogzenuw, doofheid en prikkeling in de benen, voeten en handen 
door zenuwbeschadiging (perifere neuropathie), bloedarmoede en een onderdrukte 
bloedaanmaak in het beenmerg. Door deze bijwerkingen zien artsen zich vaak gedwongen 
te stoppen met toediening van linezolid als onderdeel van de tuberculosebehandeling. Voor 
de patiënt kan het moeten stoppen met linezolid zeer nadelige gevolgen hebben aangezien 
de multiresistente bacterie vaak slechts voor een paar geneesmiddelen gevoelig is.
Uit onderzoek is gebleken dat het verlagen van de dosering van linezolid het aantal bijwer-
kingen kan verminderen. Een gevaar van het verlagen van de linezoliddosering is echter 
dat dit de effectiviteit van linezolid in het gedrang kan brengen. Dit zou het falen van 
de behandeling, ontwikkelen van ongevoeligheid van de bacterie voor linezolid en zelfs 
overlijden van de patiënt tot gevolg kunnen hebben. 
Het doel van dit proefschrift is om zorgverleners te ondersteunen bij het manoeuvreren 
tussen enerzijds voldoende werkzaamheid en anderzijds bijwerkingen van linezolid door 
de klinische farmacologie van linezolid te onderzoeken wanneer het wordt ingezet bij de 
behandeling van MDR-TB. Hierbij wordt specifiek aandacht besteed aan de mogelijke rol 
van TDM bij het optimaliseren van de behandeling met linezolid. 
Een ander belangrijk probleem is dat linezolid nooit alleen, maar altijd in combinatie met 
andere geneesmiddelen moet worden gegeven, terwijl de patiënt misschien ook nog andere 
geneesmiddelen krijgt. Al die geneesmiddelen kunnen met elkaar botsen: het ene middel 
kan de concentratie van het andere beïnvloeden, bijvoorbeeld doordat beide middelen op 
dezelfde manier in de lever worden omgezet of doordat de uitscheiding wordt beïnvloed. 
In dit proefschrift is daarom een literatuuroverzicht van de verschillende farmacokinetische 
interacties tussen geneesmiddelen opgenomen. Een interactie tussen linezolid en 
claritromycine, die beide worden ingezet bij de behandeling van MDR-TB, hebben we 
daarom speciaal bestudeerd. Hiernaast hebben we een tweetal nieuwe methodes opgezet om 
linezolid te meten in speeksel en DBS. We hebben de meetmethode van speekselmonsters en 
de toepasbaarheid hiervan in de praktijk onderzocht. Ook hebben we de linezolidblootstelling 
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en bloedconcentratie onderzocht in eerder afgenomen monsters, waarbij we vooral aandacht 
hebben besteed aan de effectiviteit, veiligheid en verdraagbaarheid bij MDR-TB patiënten. 
Tenslotte is een van de doelen om in het laboratorium te onderzoeken in hoeverre er een 
farmacodynamische beïnvloeding is tussen linezolid en claritromycine in MDR-TB bacteriën. 
Door middel van bovenstaande doelen beogen we meer inzicht te krijgen in de farmacologie 
van linezolid bij de behandeling van MDR-TB, met bijzondere aandacht voor TDM. 
Resultaten
In hoofdstuk 2 beschrijven we een literatuuronderzoek naar interacties van enkele antibiotica 
met andere geneesmiddelen of voedsel. In het literatuuronderzoek is niet alleen gezocht 
naar interacties met het antibioticum linezolid, maar ook naar vele andere verschillende 
antibiotica. Voor een betere leesbaarheid hebben we ervoor gekozen om in hoofdstuk 2 alleen 
de resultaten van het onderzoek naar de oxazolidinone-antibiotica, inclusief linezolid, weer 
te geven. Hoofdstuk 2 is daarom een voor het onderwerp van dit proefschrift aangepaste 
versie van het oorspronkelijke onderzoek.
We hebben de literatuur op een systematische manier doorzocht op alle geneesmiddelen die 
binnen het bereik van het onderzoek vielen. We gebruikten de zoekterm ‘drug interaction’ 
(geneesmiddelinteractie) uit het gestructureerde trefwoordensysteem, de Medical Subject 
Headings (MeSH) database. Deze zoekterm combineerden we met de generieke geneesmid-
delnaam en de naam van de geneesmiddelgroep. Om het aantal resultaten te beperken en de 
kwaliteit van de resultaten te verhogen, hebben we vervolgens enkele filters toegepast. Zo 
werden bijvoorbeeld alleen Engelstalige wetenschappelijke artikelen geselecteerd voor het 
literatuuronderzoek. Uit de geneesmiddelgroep oxazolidinonen hebben we op de generieke 
geneesmiddelnaam linezolid en op de nog niet commercieel verkrijgbare geneesmiddelen 
uit de zelfde groep: sutezolid (PNU-100480), posizolid (AZD2563), radezolid (RX-1741) 
en torezolid (TR-701) gezocht. 
Het aantal onderzoeken dat geneesmiddelinteracties beschreef met linezolid of een van de 
andere oxazolidinone-antibiotica was beperkt. Mogelijk speelt het feit dat enkele van deze 
geneesmiddelen pas recent ontdekt zijn en dat er slechts beperkte ervaringsgegevens bij 
patiënten bekend zijn hierbij een rol. Een vette maaltijd bleek de opname van linezolid vanuit 
de darm te verminderen. De opname van linezolid vanuit de darm werd niet of nauwelijks 




Er zijn interacties van linezolid met enkele geneesmiddelen bekend die de concentratie 
van linezolid in het lichaam kunnen beïnvloeden. Er worden verschillende mechanismen 
geopperd om die interacties te verklaren. Zo zouden de geneesmiddelen de omzetting van 
linezolid beïnvloeden door verandering van het belangrijke ontgiftingssysteem in de lever, het 
zogenaamde cytochroom P450 enzymsysteem. Andere auteurs denken dat de waargenomen 
geneesmiddelinteracties veroorzaakt zouden kunnen worden door de beïnvloeding van de 
effluxpomp P-glycoproteïne.
Geconcludeerd kan dus worden dat er enkele interacties zijn tussen het antibioticum linezolid 
en andere geneesmiddelen, maar ook met voedsel. In de praktijk zijn deze interacties niet 
allemaal even belangrijk. De veranderde farmacokinetische parameters zouden de behan-
deling van MDR-TB direct kunnen beïnvloeden door middel van toxiciteit of verminderde 
effectiviteit van het antibioticum, maar ook indirect door beïnvloeding van middelen 
voor de behandeling van andere kwalen dan tuberculose. Tenslotte laat het grote aantal 
geneesmiddelinteracties nog eens zien aan artsen, apothekers en andere zorgverleners hoe 
belangrijk die geneesmiddelinteracties zijn voor de behandeling van patiënten.
In hoofdstuk 3 beschrijven we een nieuwe geneesmiddelinteractie van linezolid. Het meten 
van geneesmiddelconcentraties ten behoeve van TDM is een standaard onderdeel van de 
zorg die we verlenen aan MDR-TB patiënten binnen het Universitair Medisch Centrum 
Groningen, Centrum voor Revalidatie / Tuberculose Centrum Beatrixoord (Haren, 
Nederland; hierna: Tuberculose Centrum Beatrixoord). Tijdens een dergelijke routine-
analyse bij een 42-jarige mannelijke tuberculosepatiënt ontdekten we bij toeval een genees-
middelinteractie tussen linezolid en claritromycine. Bij deze patiënt bleek de blootstelling 
aan linezolid, weergegeven als de oppervlakte onder de concentratie-tijd curve (AUC) per 12 
uur, verhoogd van 29 mg*h/L naar 108 mg*h/L. We konden het verschil niet verklaren met 
behulp van bekende geneesmiddelinteracties. Ook boden leverproeven en nierfunctietesten 
geen aanknopingspunt om de verhoogde blootstelling te kunnen verklaren. Het ontstaan van 
de verhoogde blootstelling aan linezolid viel samen met het toevoegen van claritromycine in 
een dosering van eenmaal daags 1000 mg aan de behandeling. Op basis van het bovenstaande 
ontwikkelden we de hypothese dat er mogelijk een interactie zou kunnen zijn tussen linezolid 
en claritromycine.   
Dit heeft ons doen besluiten een open-label, prospectief, één arm, vaste volgorde onderzoek 
uit te voeren. Het doel van dit onderzoek was om een eventuele farmacokinetische interactie 
tussen linezolid en claritromycine in maat en getal weer te geven. Zowel volwassen mannen 
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als vrouwen, bij wie MDR-TB was vastgesteld, kwamen in aanmerking voor deelname aan dit 
onderzoek. Zwangeren, patiëntes die borstvoeding gaven, patiënten met eerder aangetoonde 
overgevoeligheid voor linezolid of een van de geneesmiddelen uit de claritromycine 
geneesmiddelgroep, patiënten met een kaliumtekort en patiënten die tegelijkertijd een 
geneesmiddel toegediend kregen dat de werking van het P-glycoproteïne beïnvloedde, 
kwamen niet in aanmerking voor deelname aan het onderzoek. Alle deelnemende patiënten 
kregen gedurende het gehele onderzoek tweemaal daags 300 mg linezolid toegediend. Bij 
alle patiënten werd de blootstelling gemeten op drie momenten gedurende het onderzoek: 
1. wanneer de patiënt alleen linezolid kreeg zonder claritromycine, 2. nadat dezelfde patiënt 
gedurende twee weken linezolid had ontvangen met eenmaal daags 250 mg claritromycine 
en 3. nadat deze gedurende twee weken linezolid had ontvangen met eenmaal daags 500 
mg claritromycine. 
Er hebben zeven patiënten deelgenomen aan het onderzoek en van vijf van deze patiënten 
konden we de gegevens gebruiken voor de uiteindelijke analyse. Van tevoren hadden we 
berekend dat dit aantal patiënten voldoende groot was om tot een duidelijk antwoord te 
komen.
De mediane blootstelling aan linezolid was 36,3 (33,2 – 46,3) mg*h/L zonder gelijktijdige 
toediening met claritromycine. Na gelijktijdige toediening met eenmaal daags 250 mg 
claritromycine bleek de mediane (interkwartielbereik, IQR) blootstelling aan linezolid 
verhoogd tot 61,0 (34,6 – 63,9) mg*h/L (p=0,686) en na gelijktijdige toediening met 500 
mg claritromycine tot 67,2 (66,9 – 76,0) mg*h/L (p=0,043). Met andere woorden: na 
toevoegen van eenmaal daags 500 mg claritromycine is de blootstelling aan linezolid met 
een mediaan (IQR) van 44% (23 – 102%) verhoogd ten opzichte van toediening zonder 
claritromycine. Toediening van 250 mg claritromycine had geen statistisch significant effect 
op de blootstelling van linezolid. 
Het gelijktijdig toedienen van claritromycine en linezolid kon door de meeste patiënten goed 
verdragen worden. Tijdens het onderzoek zijn geen ernstige bijwerkingen opgetreden. Bij 
één van de patiënten is een milde tot matig-ernstige (Groep 2, Common Toxicity Criteria, 
CTC) maag-darmbijwerking opgetreden. Op grond van de resultaten uit dit onderzoek 
concluderen we dat verder onderzoek in een grotere groep van patiënten wenselijk is. Er is 
vooral behoefte aan inzicht in de oorzaak van het verschil in effectmaat van de waargenomen 
farmacokinetische interactie tussen de individuele patiënten. Mogelijk was een van de 




te raden is indien linezolid tegelijkertijd wordt toegediend met claritromycine totdat het 
effect van de geobserveerde interactie beter te voorspellen is.
Ondanks het feit dat TDM van linezolid in sommige gevallen aangeraden wordt, is het op 
klassieke wijze afnemen van verschillende bloedmonsters in de tijd in grote delen van de 
wereld niet goed uitvoerbaar. Om het afnemen van monsters voor TDM van linezolid te 
vergemakkelijken, hebben we twee nieuwe methoden ontwikkeld om monsters af te nemen en 
er vervolgens de waarde van vastgesteld (gevalideerd) in hoofdstuk 4. We hebben methoden 
ontwikkeld om de linezolidconcentratie te kunnen meten in gedroogde druppels bloed op 
papier (Dried Blood Spot, DBS) en in speeksel (oral fluid). 
Om het meten van linezolid in DBS te valideren, hebben we patiënten uit het Tuberculose 
Centrum Beatrixoord die linezolid kregen als onderdeel van de MDR-TB behandeling 
opgenomen in het onderzoek. We hebben bloedmonsters verzameld in de plateaufase 
(steady state) vlak voor inname en 1, 2, 3, 4 en 8 uur na inname van linezolid. Met behulp 
van deze bloedmonsters hebben we ‘veneuze DBS’ (vDBS) monsters gemaakt door 50 μL 
aderlijk bloed te druppelen op geschikt Whatman 31 ET CHR DBS-papier. Ook hebben 
we DBS-monsters van patiënten verzameld op 2 en 8 uur na het toedienen van linezolid 
door een druppel bloed uit een vingerprik direct op DBS-papier te laten vallen. In beide 
gevallen hebben we de bloeddruppels laten drogen bij kamertemperatuur en opgeslagen 
in een afsluitbare plastic zak met droogpoeder. Hierna zijn de monsters in de vriezer bij 
-20°C bewaard totdat de monsters geanalyseerd werden. Vlak voor het analyseren hebben 
we een schijf met een diameter van 8 mm uit het papier met de gedroogde bloeddruppel 
geboord. Vervolgens hebben we de monsters onderzocht met behulp van een gevalideerde 
vloeistofchromatografie tandem massaspectrometrische (LC-MS/MS) methode. We 
hebben de nieuwe DBS-methode gevalideerd in overeenstemming met regelgeving van 
de Amerikaanse Food and Drug Administration (FDA). Naast het validatie-onderzoek op 
basis van deze regelgeving, zijn enkele aanvullende onderzoeken uitgevoerd specifiek voor 
DBS-analyse. 
Bij DBS wordt een ingedroogd bloedmonster in een schijfje filterpapier opnieuw in oplossing 
gebracht zodat een geneesmiddelconcentratie wordt gemeten. De hoeveelheid vloeistof 
wordt via een standaardmethode toegevoegd, waarbij wordt aangenomen dat bij iedereen de 
concentratie bloedcellen en hemoglobine (Hb) het zelfde is. Sommige mensen hebben echter 
bloedarmoede, anderen hebben juist een hoog Hb. De hoogte van het Hb, die recht evenredig 
is met de hematocrietwaarde, heeft invloed op de geneesmiddelconcentratie. Ook de grootte 
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van de bloeddruppels heeft invloed op de met DBS gemeten concentratie. Beide parameters 
zouden de resultaten van de DBS-analyse kunnen beïnvloeden. We hebben daarom de 
invloed van een hematocriet van 20, 25, 30, 35, 40, 45 en 50% en bloeddruppelvolumes van 
30, 50 70 en 90 μL onderzocht. Voor de validatie hebben we de hematocrietwaarde op 35% 
en het bloeddruppelvolume op 50 μL ingesteld.
De DBS-analyseresultaten waren recht evenredig met gemeten bloedwaarden over het 
bereik van de gehele analytische concentratie van 0.05 – 30 mg/L linezolid met een 
gepoolde correlatiecoëfficiënt van r2 = 0,9947. De reproduceerbaarheid was goed met 
een systematische fout (bias) en variatiecoëfficiënt (CV) kleiner dan 17,2% voor de laagst 
gevalideerde concentratie (0,05 mg/L linezolid). Voor de andere concentraties (0,25 – 30 mg/L 
linezolid) waren de waardes van de bias en CV kleiner dan 7,8%. Het effect van verschillen in 
hematocriet en bloeddruppelvolume was acceptabel. De methode heeft een goede recovery 
van ongeveer 95%. Er is een klein matrixeffect van minder dan 8,7% gemeten. De DBS-
monsters bleken stabiel te zijn nadat deze gedurende twee maanden bewaard waren bij 37°C. 
Een Bland-Altman-analyse liet zien dat de ratio van de linezolidconcentratie in DBS / plasma 
1,2 was (95% betrouwbaarheidsinterval, 1,12 – 1,27). Deze correctiefactor moet gebruikt 
worden om de concentratie gemeten in DBS om te rekenen naar de plasmaconcentratie 
van linezolid.
We concluderen dat de DBS-analyse van linezolid een gemakkelijke, bruikbare methode is 
om TDM van linezolid bij MDR-TB uit te voeren. De relatief simpele monsternameprocedure 
en de grote chemische stabiliteit van de monsters maken de analyse zeer gebruiksvriendelijk. 
Dit maakt de methode onder andere zeer geschikt voor ontwikkelingslanden. 
Tevens hebben we een speekselmonsteranalyse ontwikkeld en gevalideerd (hoofdstuk 4). 
Hiertoe hebben we gegevens van de patiënten gebruikt die deelnamen aan het onderzoek in 
hoofdstuk 3. Zoals in hoofdstuk 3 beschreven, kregen alle patiënten gedurende twee weken 
tweemaal daags 300 mg linezolid en eenmaal daags 250 mg claritromycine toegediend. Bloed- 
en speekselmonsters werden tegelijk afgenomen in de plateaufase. Monsters werden vlak 
voor toediening van de medicatie verzameld en op 1, 2, 3, 4, 8 en 12 uur na het toedienen 
van de medicatie. Speeksel werd verzameld met behulp van Salivettes (Sarstedt, Leicester, 
Engeland). Patiënten kauwden gedurende twee minuten op het katoenen watje van de 
Salivette. Vervolgens werden de monsters gecentrifugeerd en opgeslagen bij -20°C tot het 
moment van analyse. Linezolid en claritromycine concentraties zijn vervolgens gemeten 




Passing-Bablok regressie en Bland-Altman analyse hebben aangetoond dat analyse van 
linezolid in speeksel een geschikt alternatief is voor conventionele bloedmonsters van patiënten 
met MDR-TB. Er is geen correctiefactor nodig voor de interpretatie van speekselmonsters, 
aangezien de ratio tussen de linezolidconcentratie in serum en de concentratie in speeksel met 
behulp van Bland-Altman analyse berekend is op 0,97 (95% betrouwbaarheidsinterval: 0,92 – 
1,02). De Bland-Altman analyse van de claritromycineconcentratie liet echter een ratio tussen 
serum en speeksel zien van 3,07 (95% betrouwbaarheidsinterval: 2,45 – 3,69). We hebben 
een niet recht evenredige relatie waargenomen tussen de concentraties van het metaboliet 
hydroxyclaritromycine (in de lever gevormd omzettingsproduct van claritromycine) in serum 
en speeksel. We concluderen dat de analyse van linezolid en claritromycine in speeksel een 
makkelijke, non-invasieve methode is om monsters te verzamelen bij MDR-TB patiënten. 
Dit alternatief zou vooral kunnen worden overwogen wanneer het gebruikelijke verzamelen 
van bloedmonsters niet mogelijk of wenselijk is.
De mogelijke rol van TDM van linezolid bij MDR-TB bespraken wij in de eerdere hoofd-
stukken. Anderen hebben gewezen op verschillen in farmacokinetiek van linezolid tussen 
verschillende patiënten en in één patiënt in loop van de tijd. Het afnemen en analyseren van 
bloedmonsters ten behoeve van TDM wordt helaas niet altijd bij geneesmiddelonderzoeken 
uitgevoerd. Om het belang te onderstrepen dat we hieraan hechten, hebben we een tweetal 
brieven ingestuurd naar wetenschappelijke tijdschriften in reactie op een tweetal publicaties 
waarbij geen TDM was uitgevoerd (hoofdstuk 5). Naast het belang van TDM hebben we ook 
getracht aandacht te vestigen op het belang van het innemen van tuberculosemedicatie onder 
toezicht van zorgprofessionals (directly observed therapy, DOT). Alleen bij hoge uitzondering, 
wanneer therapietrouw hoogstwaarschijnlijk is, zou overwogen kunnen worden om van 
dit principe af te wijken. Tenslotte hebben we aangegeven dat er grote behoefte is aan het 
ontwerpen en uitvoeren van een dubbelblind gerandomiseerd onderzoek – een onderzoek 
waarbij noch de patiënt noch de dokter weet of de patiënt linezolid of een placebo krijgt – 
bovenop een standaard behandeling. Hierbij is het van belang om ook farmacokinetische 
gegevens en gegevens over de gevoeligheid van de betrokken bacterie voor de gekozen 
antibiotica te verzamelen.
De aanbevelingen die we deden in de twee ingestuurde brieven, hebben ons aangespoord 
om zelf ook het nut van TDM te bestuderen bij onze eigen patiënten die eerder linezolid 
hadden gebruikt. We hebben de veiligheid en verdraagbaarheid onderzocht in samenhang 
met de farmacokinetische en farmacodynamische gegevens de we terug hebben gezocht. Om 
de steekproef te vergroten hebben we niet alleen patiënten geïncludeerd uit het Tuberculose 
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Centrum Beatrixoord, maar ook uit het E. Morelli Ziekenhuis (Sondalo, Italië). We hebben 
patiënten geselecteerd die linezolid toegediend kregen als onderdeel van behandeling van 
MDR-TB. Patiënten jonger dan 18 jaar oud, patiënten waarvan onvoldoende gegevens 
beschikbaar waren door recente opname in een van beide ziekenhuizen en patiënten waarbij 
geen bloedmonsters zijn afgenomen voor TDM van linezolid, kwamen niet in aanmerking 
voor het onderzoek. Twee onderzoekers, één in Italië en één in Nederland, hebben van 
de geselecteerde patiënten alle belangrijke gegevens verzameld, met in elk geval ook de 
farmacokinetische gegevens en de behandelresultaten, waarbij we ervoor gezorgd hebben 
dat de privacy van patiënten niet werd geschonden.
In totaal konden we gegevens van 58 MDR-TB patiënten uit beide centra gebruiken. Van 
36 van de 54 patiënten uit Italië waren de gegevens onvolledig. Zo waren er bij 27 van 
de 36 geen bloedmonsters afgenomen ten behoeve van TDM van linezolid. De mediane 
(IQR) minimale groeiremmende concentratie (MIC) van de bacteriën voor linezolid was 
0,5 (0,25 – 0,5) mg/L. Terugkijkend bleek dat 50% (29/58) van de patiënten genezen was. 
Op het moment van het verzamelen van de gegevens had 6,9% (4/58) van de patiënten 
de behandeling afgerond, maar 43,1% (25/58) was nog bezig met de behandeling. Op één 
patiënt na waren alle patiënten kweeknegatief (‘geen groei’) op het moment van verzamelen 
van de data. We hebben in dit cohort geen samenhang kunnen ontdekken tussen omslag in 
de sputumkweek en PK/PD parameters. Mogelijk speelt het feit dat de AUC/MIC ratio in 
bijna alle patiënten boven het beoogde doel was een rol.
Terugkijkend zagen we dat patiënten met de bijwerking/vergiftiging perifere neuropathie 
een hogere mediane (IQR) totale linezoliddosering hadden gekregen. Zo kregen patiënten 
met perifere neuropathie 1829 (1414 – 2255) mg/kg ten opzichte van 1164 (755 – 1922) mg/
kg bij de patiënten zonder perifere neuropathie (p=0,041). Ook kregen de patiënten met 
perifere neuropathie gedurende een langere mediane (IQR) periode linezolid toegediend (159 
(120 – 196) dagen) ten opzichte van patiënten zonder perifere neuropathie (97 (66 – 147) 
dagen) (p=0,003). Een andere interessante bevinding uit dit onderzoek was dat het toevoegen 
van erythropoiëtine (“epo” voor het aanmaken van rode bloedcellen) aan behandelschema’s 
met linezolid om bloedarmoede voorkomen, geen toegevoegde waarde bleek te hebben 
bij het voorkomen daarvan. We hebben daarvoor het Hb op dag 0, 30, 60 en 90 na starten 
van linezolid onderzocht. Er was geen verschil tussen het Hb van patiënten die wel of geen 
erythropoiëtine toegediend kregen. Er was er ook geen verschil waar te nemen tussen het 




Terugkijkend leken de behandelregimes met linezolid effectief en waren er niet veel 
problemen met bijwerkingen. We zagen dat de sputumkweken van de meeste patiënten 
negatief werden en dat de bijwerkingen heel beperkt waren. 
Farmacodynamiek van linezolid
In hoofdstuk 6 beschrijven we een farmacodynamische interactie tussen linezolid en 
claritromycine in tuberculosebacteriën. Bij dit onderzoek hebben we samengewerkt met 
het Rijksinstituut voor Volksgezondheid en Milieu (RIVM, Bilthoven, Nederland) bij het 
uitvoeren van een laboratoriumtest. We hebben de zogeheten schaakbord methode gebruikt 
om eventuele synergie (versterkend effect: 2 plus 2 = 5) of juist antagonisme (verzwakkend 
effect: 2 plus 2 = 3) tussen linezolid en claritromycine te onderzoeken. We hebben hiertoe 
willekeurig 24 tuberkelbacilstammen geselecteerd uit de biobank van het RIVM bestaande 
uit bij patiënten geïsoleerde stammen. We gebruikten een tweetal al ontwikkelde methoden 
om groei/groeiremming vast te stellen, namelijk de absolute concentratie methode (ACM) 
en de Mycobacterium Growth Inhibition Tube (MGIT) 960 methode. Hierbij hebben we 
groei/groeiremming onderzocht na toevoeging van verschillende concentraties van beide 
geneesmiddelen op een schaakbord-achtige wijze. Linezolid hebben we toegevoegd in 
concentraties van 0 – 0,5 mg/L en claritromycine in concentraties van 0 – 8 mg/L. Nadat groei/
groeiremming geanalyseerd was bij alle mogelijke combinaties van concentraties van beide 
geneesmiddelen met de twee methoden hebben we de laagste fractionele groeiremmende 
concentratie (FIC) berekend. De FIC werd als volgt berekend: MIC van linezolid in 
combinatie met claritromycine gedeeld door de MIC van linezolid zonder claritromycine 
plus de MIC van claritromycine in combinatie met linezolid gedeeld door de MIC van 
claritromycine zonder linezolid. Synergie was gedefinieerd als een FIC≤0,5, geen invloed 
(indifference) als een 0,5<FIC≤4 en antagonisme als een FIC>4.
In 74% van de 24 willekeurig geselecteerde tuberculosebacteriën bleek er synergie te zijn 
tussen claritromycine en linezolid wanneer de MGIT methode gebruikt werd. Wanneer de 
ACM methode gebruikt werd was dit percentage 59%. Er werd in geen van de geselecteerde 
bacteriën antagonisme gezien. Aangezien de combinatie van linezolid en claritromycine in 
de praktijk vooral bij MDR-TB patiënten wordt toegepast, hebben we extra aandacht besteed 
aan de selecteerde bacteriën van MDR-TB patiënten. In deze MDR-TB bacteriën (n=13) bleek 
synergie te zijn in 77% van de gevallen gemeten met de MGIT methode en in 46% van de 
gevallen gemeten met de ACM methode. Ook hier werd in geen van de gevallen antagonisme 
Nederlandse samenvatting
144
waargenomen. De mediane (IQR) FIC die berekend werd bij de MDR-TB patiënten was 0,37 
(0,32 – 0,37) en 0,62 (0,375 – 1,0). We concluderen dan ook dat claritromycine en linezolid 
synergetisch werken in een deel van de laboratoriumtesten met MDR-TB bacteriën. Dit kan 
misschien helpen bij het ontwerpen van toekomstige MDR-TB behandelschema’s. 
In hoofdstuk 7 bespreken we de belangrijkste bevindingen van dit proefschrift: wat voegt 
het toe aan wat we al wisten, en hoe kunnen we de resultaten gebruiken voor patiënten met 
MDR-TB? We bespreken het belang van farmacokinetische geneesmiddelinteracties met 
antibiotica als slachtoffer, maar ook als veroorzaker van de interactie. Hiernaast besteden we 
aandacht aan het belang van geïndividualiseerde behandelschema’s en de noodzaak om PK/
PD streefwaarden voor TDM te onderzoeken. Tenslotte gaan we op het toekomstperspectief 
in: 1. Waar verwachten we dat de behandeling van MDR-TB naar toe zal gaan in de komende 
jaren; 2. Welke rol zou linezolid kunnen spelen bij de behandeling van (multiresistente) 
tuberculose; 3. Wat zou in de komende jaren de impact kunnen zijn van het verlopen van 
het patent van linezolid en 4. Wat zou (vervolg)onderzoek kunnen zijn waaraan op dit 
moment het meeste behoefte is.
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Het slotakkoord! Naast het feit dat onderzoek doen vooral leuk is, is het ook erg fijn om iets – 
al is het maar een klein beetje – bij te kunnen dragen aan de behandeling van de tuberculose. 
Zonder hulp van velen had ik dit punt nooit bereikt. Allereerst wil ik de patiënten, die zonder 
eigenbelang deelnamen aan het onderzoek, hartelijk bedanken. 
Ik ben vooral mijn promotores en copromotor ontzettend dankbaar. 
Prof. dr. T.S. van der Werf, beste Tjip. Ik heb ontzettend veel bewondering voor jou als arts, 
promotor en onderzoeker. Hartelijke dank voor je kritische blik op alle geschreven stukken. 
Vooral bij de eerste manuscripten had je veel op te merken (‘de METc maakte meer spelfouten 
dan jij’ en ‘kleine suggesties mijnerzijds’). Zonder je tekstuele, maar vooral ook inhoudelijke 
input zou het proefschrift nooit deze staat bereikt hebben. In het begin moest ik soms wat 
wennen aan je directe manier van communiceren. Maar ik kan me herinneren dat we elkaar 
tegenkwamen in een gang in het UMCG en dat je, zonder iets te zeggen, je hand opstak 
waarna we elkaar zwijgend een high five gaven. Toen wist ik dat de samenwerking goed zou 
komen. Ook heb ik erg veel gehad aan het samen peer-reviewen. Dit heeft geholpen bij het 
gestructureerd inhoudelijk en methodologisch kijken naar onderzoeken en kritisch kijken 
naar de nieuwswaarde. Tenslotte wil ik je graag hartelijk bedanken voor de benodigde uitleg 
en bovenal humor tijdens de TB-visites.
Prof. dr. J.G.W. Kosterink, beste Jos. Jij was niet alleen promotor, maar ook nog eens opleider 
tijdens een deel van dit promotietraject. Ik heb altijd ontzettend veel bewondering gehad 
voor het feit dat je je drukke baan als hoofd van de afdeling Klinische Farmacie en Apotheek 
– sinds januari 2014 Klinische Farmacie en Farmacologie – combineert met het opleiden 
van ziekenhuisapothekers, klinisch farmacologen, farmaciestudenten en promovendi. Toch 
was je altijd beschikbaar voor promotiebesprekingen, inhoudelijk overleg over op te zetten 
onderzoek, het reviseren van manuscripten, maar ook voor ad hoc overleg wanneer ik dat 
nodig had. Hartelijk dank daarvoor! Tenslotte wil ik je – ook hier nog eens – hartelijk danken 
voor het opleiden tot ziekenhuisapotheker. Ik heb ontzettend veel geleerd. 
Prof. dr. D.R.A. Uges, beste Donald. Zowel voor als tijdens je emeritaat speelde je een grote 
rol bij het onderzoek. Geweldig dat je nu nog steeds tijd vrij maakt voor het onderzoek. 
Niet alleen op afstand door het reviseren van stukken tekst, maar ook nu zit je altijd trouw 
bij de promotiebesprekingen. Dit geeft wel aan dat je een promotor in hart en nieren 
bent. In de eerste fase van het promotieonderzoek zat ik deels op het laboratorium als 
ziekenhuisapotheker in opleiding. Zonder een goed draaiend laboratorium, waar je het 




bereikt. Ook denk ik met veel dank terug aan de eerste periode als projectapotheker en 
later als ziekenhuisapotheker op het laboratorium waar je me altijd bij alle interessante cases 
betrok. Hier is misschien wel de basis gelegd voor mijn interesse in PK/PD en überhaupt 
in onderzoek.
Dr. J.W.C. Alffenaar, beste Jan-Willem. Ik heb er ontzettend veel bewondering voor hoe 
je binnen korte tijd na het afronden van je eigen promotie als co-promotor verschillende 
promovendi met succes begeleidt, een goed (inter)nationaal netwerk op hebt gebouwd en 
overal mogelijkheden ziet. Je ziet overal kansen en mogelijkheden. Een mooie eigenschap 
bij het opzetten van onderzoek. Ik wil je bedanken voor alle inhoudelijke gesprekken over 
het onderzoek en het mij betrekken bij verschillende ideeën en vooral voor het vertrouwen 
dat je in me had. Na het opschrijven van het case-report, ontstond bijna vanzelfsprekend 
de mogelijkheid om hier een promotieonderzoek van te maken, wat ik met beide handen 
aangreep. 
Graag zou ik de beoordelingscommissie, bestaande uit prof. dr. D.M. Burger, prof. dr. F.G.J. 
Cobelens en prof. dr. G. M. M. Groothuis, willen bedanken voor het beoordelen van het 
manuscript.
Er zijn veel mensen die een grote rol hebben gespeeld bij het totstandkomen van dit 
proefschrift. Ik zou dan ook allen willen bedanken die een directe bijdrage hebben geleverd 
aan de inhoud van dit proefschrift.
Allereerst de artsen van de TB-afdeling: drs. O.W. Akkerman, drs. R. van Altena en drs. 
W.C.M. de Lange. Zonder jullie hulp bij het opzetten van het onderzoek, bij het verzamelen 
van monsters en bij de inclusie van patiënten, was dit onderzoek nooit tot stand gekomen. 
We zeggen soms gekscherend dat alle tuberculosepatiënten op de locatie Beatrixoord op 
enig moment in een onderzoek terecht komen. Hoewel dat natuurlijk niet helemaal waar 
is, geeft dit wat mij betreft wel jullie onderzoeks-mindedness aan. Verder wil ik jullie, maar 
ook zeker dr. Y (Ymkje) Stienstra en Tjip, hartelijk danken voor de TB-visites. Dank voor 
het feit dat jullie mij als simpele apotheker meegenomen hebben in de wereld van de patiënt 
en de behandelaar, maar ook dank voor de humor tijdens deze besprekingen. Beste Onno, 
geweldig om met jou op OK monsters te verzamelen bij een wervel-TB operatie. Succes met 
het afronden van jouw boekje! Beste Richard, hartelijke dank, succes met je proefschrift en 
geniet van Myanmar. Wie weet ben ik ooit eens in de buurt. Beste Wiel, dank voor het mij 
op sleeptouw nemen bij de GGD en de mooie verhalen tijdens de visites. 
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Ook zijn er enkele apothekers die een directe, inhoudelijk bijdrage hebben geleverd aan dit 
proefschrift: drs. P.V. Nannan Panday, drs. A.D. Pranger en dr. D.H. Vu. Beste Prashant, 
hartelijk dank voor alle supervisie tijdens mijn opleiding tot ziekenhuisapotheker. Je 
hebt als consulent infectieziekten ontzettend veel kennis en expertise opgebouwd over 
medicamenteuze behandeling van infecties welke zeer van pas kwamen bij het opstellen 
van onze review naar geneesmiddelinteracties van antibiotica. Hiernaast waardeer ik je ook 
vooral als directe collega. Beste Arianna, vooral bij het prospectieve onderzoek heb je, met 
de ervaring die jij reeds had, me veel geholpen. Hiernaast denk ik met veel plezier terug aan 
de baseballwedstrijd die we samen keken: Let’s go Giants! Dear Hoa, I really enjoyed our 
cooperation on the analytical studies such as the linezolid in DBS study. 
Hiernaast zijn er twee laboratoria geweest die dit onderzoek mogelijk gemaakt hebben. 
Beide spelen niet alleen bij het onderzoek, maar ook bij de routinezorg een zeer grote 
rol voor de tuberculose. Allereerst dank aan alle analisten van het laboratorium van de 
ziekenhuisapotheek van het UMCG. Iedereen is wel op enig moment betrokken geweest 
bij het onderzoek. B. Greijdanus, beste Ben; R.A. Koster (binnenkort dr. Koster!), beste 
Remco; K. van Hateren, beste Kay. Hartelijke dank voor het bijdragen van jullie analytische 
expertise aan enkele van de artikelen in dit proefschrift. Hiernaast wil ik ook bioanalyse-
analisten, Albert-Jan, Erwin, Gerben, Hiltjo, Jan, en Mireille bedanken voor hun inzet: 
merci!
Het laboratorium van het RIVM speelde een belangrijke rol bij het uitvoeren van drug 
susceptibility testen, maar ook bij enkele onderzoeken. Prof. dr. D. van Soolingen, beste Dick 
en T. van der Laan, beste Tridia. Bedankt voor de prettige samenwerking.
I would like to thank the co-authors that contributed to the work in this thesis: Prof. dr. 
J.R.B.J. Brouwers (dank!), Simon Tiberi, Giovanni Sotgiu, Saverio De Lorenzo, Giovanni 
Battista Migliori. Mille Grazie! I hope we’re able to continue our international collaboration. 
Working together is the way forward.
Ook zou ik graag de verpleging van het Tuberculose Centrum Beatrixoord willen bedanken 
voor de rol die ze hebben gespeeld in dit onderzoek. Voor dit type onderzoek is het toedienen 
van het juiste geneesmiddel op het juiste moment van groot belang. Het is dan ook erg fijn 
dat jullie dit met zijn allen inzien en hier zo goed mee om gaan. Ook denk ik met plezier 





Hiernaast ben ik het secretariaat van de apotheek erg dankbaar voor de hulp die ze altijd 
bieden. Specifiek voor het onderzoek door middel van het versturen van brieven naar de 
METc en andere instanties en het inplannen van afspraken met mede-onderzoekers, maar 
ook in het algemeen in deze laatste fase van het onderzoek en tijdens het alledaagse werk 
in het UMCG. Annemiek, Jessica en Wianda: dank jullie wel!
Verder ben ik alle apothekersassistenten erg dankbaar voor de ondersteuning bij het onder-
zoek. Vooral dank aan de collega’s van de KGO, de balie, het magazijn, de voorraadbereidingen 
en satellietapotheek Beatrixoord. Jullie hulp maakte dat dit onderzoek te combineren was 
met andere taken binnen de apotheek. 
Tenslotte ben ik de staf, (ziekenhuis)apothekers en oud-collegae van de voormalige 
afdeling Klinische Farmacie en Apotheek erg dankbaar voor de feedback en de discussies: 
Anet, Annelies, Barbara, Bart, Bob, Daan, Derk, Eli, Esther, Eva, Frank-Jan, Gea, Hèlen, 
Hendrikus, Hilma, Iemke, Jan, Joke, Kim, Lisanne, Marian, Marieke, Marina, Marijn, 
Marjolijn, Marjolijn, Matthijs, Minke, Nour, Reinout Susan, Sylvia en Trea. Dank voor 
alles! Ik ben blij met jullie als collega’s. Ook hartelijk dank aan alle nieuwe collega’s van de 
voormalige Klinische Farmacologie van prof. Dick de Zeeuw. Ik verheug me op een intensieve 
samenwerking in de komende jaren.
Hiernaast zijn er natuurlijk ook velen die indirect hebben bijgedragen aan dit onderzoek. 
Ik wil daarom al mijn familie en vrienden bedanken voor de mooie tijden! 
Ik heb tijdens mijn studietijd met erg veel plezier wedstrijd geroeid bij de A.G.S.R. Gyas. De 
combinatie van feesten, sociaal leven, met zijn allen trainen voor een doel, nooit opgeven 
(‘pijn is tijdelijk, opgeven is voor eeuwig’) heeft bijgedragen aan hoe ik nu ben. Dank aan 
al mijn Gyas-vrienden en -kennissen, maar vooral aan mijn ploeggenoten, coaches en 
stuurtjes: Bram, Niels, Thijs, Janneke, Karijn, Alma, Maurice, Jan, Juliette, Nanne, Irma, 
Koen, Carolien en Sybolt. 
Dr. E.A.M. Festen, beste Noortje. Ik bewonder je gedrevenheid, je zelfvertrouwen, je 
eigenzinnigheid. Je hebt een grote rol gespeeld bij het feit dat ik promotieonderzoek ben 
gaan doen. 
Beste Djoelan, dank voor alle gezelligheid en theetjes op het terras ‘Chez Mathieu’ aan de 
Vismarkt. Je bent een van de meest sociale mensen die ik ken.
Dankwoord
154
Ook zou ik graag iedereen bedanken met wie ik schaats of fiets. Zonder regelmatig sporten 
zou ik gek worden. Is er iets lekkerder na een dag werken aan je onderzoek dan lekker 
schaatsen of een ‘rondje Zoutkamp’ doen? Rik en Anton, ik hoop dat we ooit nog een keer 
de echte Elfstedentocht mogen doen.
Beste Bas, Njord, Robbert, Peter en Tim. Ik ben ontzettend blij dat we elkaar hebben leren 
kennen via of op het Praedinius. We hebben de afgelopen jaren veel mooie dingen gedaan. 
Om maar een paar hoogtepunten te noemen: Lowlands, weekendje Boekarest, Pitch festival, 
maar ook op stand dineren bij ‘In de Molen’. Het plannen is soms lastig met alle volle agenda’s 
en de verschillende steden, landen, continenten waar we wonen. Het resultaat is echter altijd 
de moeite waard.
Ik ben blij met iedereen die ik via Mijntje heb leren kennen. Haar hele familie, maar vooral 
Wil, Ben, Margriet, Jeroen, Maartje en Phillip, en al haar vrienden. Fijn dat Mijntje zulke 
leuke vriendjes en vriendinnetjes heeft.  
Ook zou ik mijn hele familie – alle ooms, tantes, neven, nichten en andere familie – willen 
bedanken voor de steun en interesse. Lieve opa’s en oma, lieve Anna, Hein en Thies. mede 
dankzij jullie heb ik zulke mooie jeugdherinneringen. Ik hoop dat ik nog jaren van jullie 
mag genieten in goede gezondheid.
Ook zou ik mijn paranimfen, Jasper en Wouter, willen bedanken. Ik heb erg veel aan jullie 
beiden gehad tijdens mijn promotie. Jasper, geweldig dat je enige tijd geleden besloten hebt 
naar Groningen terug te komen. Hoewel het samen sporten er niet vaak genoeg van komt, 
hebben de avondjes in de stad, lekker eten met kookclub ‘Mathieu en Jasper’ en het samen 
rondhangen gezorgd voor de nodig ontspanning. Wie weet komt die marathon er ooit nog van. 
Wouter, mijn derde ‘broertje’, ik denk met veel plezier terug aan de avondjes Eurosonic, onze 
gezamelijke playlist, de BBQ’s bij jullie in de tuin, de echte koffie en onze werklunch bij een 
welbekend Schots etablissement. Geweldig om met jou te ouwehoeren in de apotheek. Jasper 
en Wouter, dank voor jullie praktische tips over het promoveren. Het wordt een mooie dag!
Lieve Jaap en Marielou. Bedankt voor alles. Dankzij jullie opvoeding ben ik zo geworden als 
ik nu ben. Op geen enkel vlak kan ik me een beter voorbeeld dan jullie wensen. Dank voor 
jullie steun. Lieve Oskar en Jules. Ik ben ontzettend blij met jullie als broers! Dank voor de 
mooie tripjes, leuke weekenden en de gezelligheid. Jules, dank voor de vakantie naar een 
van mijn droombestemmingen: Soedan. Het was onvergetelijk! Oskar en Tessa, geweldig 




Allerliefste Niamey, geachte Prop-Joe. Bedankt.
Liefste Mijntje. Wat kan een simpele treinreis toch veel veranderen. Ik ben ontzettend 
dankbaar dat ik toevallig tegenover jou kwam te zitten. Dank voor je steun en begrip voor 
het onderzoek. Maar bovenal dank dat de afgelopen jaren met jou zo geweldig waren: mooie 
feestjes, geweldige reizen (ooit nog Nigeria?), familie opzoeken in Madrid, serietjes kijken op 
de bank, stedentripjes, lekker koken, dansen door de woonkamer, theater en concertbezoek, 
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